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8Chapter 1
This thesis consists of research performed as part of the ‘Expert Center for Eczematous 
and Occupational Dermatoses’ at the department of Dermatology, University Medical 
Center Groningen, in the Netherlands. The focus of this thesis is on contact allergy and 
covers a broad range of topics, including immunology, diagnostics, and epidemiology.
The following introduction to this thesis functions as a general introduction to the field 
of contact allergy and related research, and introduces specific terms/concepts vital 
for a correct understanding and interpretation of the chapters which follow.
Dermatitis is inflammation of the skin, which presents with erythema, papules, 
vesicles (sometimes bullae in contact dermatitis), oozing, and excoriations in the acute 
phase, and with lichenification, squamae, and fissures in the chronic phase. Contact 
dermatitis is caused by contact of the skin with (mostly) harmful substances in our 
surroundings. Different etiological subtypes of contact dermatitis have been identified; 
irritant contact dermatitis (ICD), allergic contact dermatitis (ACD), and protein contact 
dermatitis.(1) The latter is a rare entity and will not be discussed any further, although 
it must be considered, for example, in occupations which involves food handling. The 
main difference between ICD and ACD is that ICD is caused by substances identified 
as ‘irritants’, and the resulting dermatitis is due to the toxic effects of said irritants, 
while ACD is caused by ‘contact allergens’, and is a T cell driven skin inflammation. 
Substances can be both an irritant and a contact allergen, and the latter most likely 
requires an irritant effect on the skin in order to activate the innate immune system 
(see below).(2-4) Because of this it is probably not uncommon in patients diagnosed 
with ACD for their dermatitis to be partially caused by exposure to irritants.(5) Irritants 
can range from the extremely harmful (e.g. a strong corrosive chemical), in which a 
short moment of contact results in ICD, to the relatively benign (e.g. water), to which 
frequent and prolonged exposure can ultimately result in ICD as well. Properties that 
make a chemical an ‘irritant’ include cytoxicity through pH disturbances, acting as a 
surfactant, and presence of alkylating properties, among others.(6, 7) The same is true 
for contact allergens, although allergenic potential (or rather, sensitising potential) is 
not defined as how much damage the contact allergen can do to the skin, but rather 
how sensitising it is, i.e. strong sensitisers can induce sensitisation at a lower dose (and 
shorter contact) than weak sensitisers. However, it is important to realise that the 
irritant effect of contact allergens is needed for sensitisation, and that therefore the 
sensitising potential is also dependant on the irritant properties.(6, 7) Management 
of both ICD and ACD are the avoidance of the causative exposure. Depending on the 
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severity and location of the contact dermatitis, topical corticosteroids of different 
potencies can be indicated.
ICD and ACD are among the major causes of occupational skin disease and therefore 
cause a high socio-economic burden, and can also greatly reduce quality of life in 
patients.(8) If the causative substance cannot be avoided at their current work, 
sometimes there is no choice but to change occupation.
GENERAL INTRODUCTION TO CONTACT ALLERGY AND AL-
LERGIC CONTACT DERMATITIS
In the simplest of terms, contact allergy is the immunological state in which re-
exposure to the causative contact allergen above a threshold dose results in dermatitis 
24 to 72 hours after re-exposure. Within the classification of hypersensitivity by Gell 
and Coombs, contact allergy is classified as a type IV delayed type hypersensitivity; 
a T cell mediated immune response.(9) An important distinction exists between 
contact allergy, an immunological state, and allergic contact dermatitis (ACD), the 
clinical consequence of a contact allergy in case of repeated exposure. Allergic contact 
dermatitis is always caused by a contact allergy, while individuals with a contact 
allergy might go their entire lives without ever experiencing skin complaints if they 
are never exposed again to the responsible contact allergen above the required dose 
for elicitation. Acquiring a contact allergy is called the sensitisation phase (also referred 
to as the induction of contact allergy), while ACD represents the elicitation phase. 
Contact hypersensitivity represents the mouse model of ACD.
Haptens, pro-haptens, and pre-haptens
In the field of contact allergy, contact allergens are also referred to as haptens, to 
avoid confusion with aeroallergens (causing immediate type allergic reactions, type 
I according to the Gell and Coombs classification). In order to function as a hapten, 
a molecule needs to have a specific molecular structure. Firstly, haptens have low 
molecular weight, meaning they are generally smaller than 500 daltons (Da, equivalent 
to g/mol), in order to allow for effective penetration of the stratum corneum.(10) 
To contextualize; a hydrogen atom is about 1 Da, and the hair dye allergen para-
phenylenediamine (PPD, CAS no. 106-50-3) is about 108 Da.(10) Secondly, haptens 
have to be protein reactive. The reason for this is twofold; to activate the innate 
immune system, and to either be recognized as a hapten-protein complex by DC 
receptors or react with surface proteins on dendritic cells (DCs), after which it can be 
1
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presented to naïve T cells.(11, 12) This process of binding to proteins in the human 
skin is called haptenization (or haptenation) and is vital, as the haptens themselves are 
too small to be recognized by the immune system. This concept of haptenization as a 
fundamental requirement of a molecule to act as a sensitiser was first proposed back in 
1936 by Landsteiner and Jacobs, and has been supported by many investigations since.
(11, 13) There are over 4000 chemicals and metal ions that can function as haptens; 
however, the majority of contact allergies are caused by a small fraction of all these 
possible haptens.(14)
It must be stated however, that sometimes the word ‘hapten’ is used to indicate the 
fragment bound to the protein after haptenization, which can be very different than 
the original chemical, as it can undergo transformation in the process of haptenization.
(15) In the current thesis the term ‘hapten’ refers to a chemical with the potential to 
induce contact allergy, i.e. before haptenization. In this introduction, the term ‘contact 
allergen’ will be used to denote haptens.
There is a group of molecules which do not initially possess a sensitising potential, but 
can become a contact allergen either through transformation by enzymatic processes 
in the skin or by transformation in the outside world by for example air oxidation 
or ultra-violet irradiation. These were initially collectively named ‘prohaptens’, but 
later the term ‘prehaptens’ was proposed for the latter category (not-enzymatic 
transformation).(16) However, this categorization has been argued against as there 
is not enough knowledge yet to completely distinguish between ‘prohaptens’ and 
‘prehaptens’, and some chemicals can be both.(15)
Pathogenesis
The immunological aspect of contact allergy and ACD has been investigated 
extensively over the previous decades, and advancements in technology has coincided 
with incremental steps taken in its understanding. The more we learn about the 
pathogenesis of ACD (or any disease for that matter), the more complex it becomes, 
and the task of understanding all facets can become daunting. Therefore, we should 
start with a bird-eye view of the whole process, step by step:
Sensitisation:
1) Skin exposure to a hapten with consequent penetration through the stratum 
corneum (henceforth referred to as the skin barrier).
2) Binding of hapten to epidermal proteins (haptenization).
3) Activation of the innate immune system creating an inflammatory environment 
(xenoinflammation).
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4) Binding of hapten-protein complex to DCs (or direct haptenization inside the MHC 
grove on DCs).
5) Migration of dendritic cells carrying the hapten-protein complex via afferent 
lymphatics to regional lymph nodes.
6) Recognition of the hapten-protein complex presented by the DC by naïve T cells.
7) Proliferation of hapten-specific memory, effector, and even regulatory T-cells in 
the lymph node and subsequent systemic dissemination by release of the proliferated 
T-cell progeny into the blood circulation.
Elicitation:
8) Re-exposure to the causative hapten, after which the hapten is again presented 
by DCs to memory/effector T cells present in the skin, causing them to secrete pro-
inflammatory cytokines and chemokines, causing local dermatitis.
Step 3, in which the innate immune system is activated, is thought to be caused by the 
irritant properties of a hapten, and the term xenoinflammation has been proposed.(4) 
The exact process has not yet been completely elucidated, although key players such as 
reactive oxygen species (ROS), Toll-like receptor 4 (TLR4), and the NOD-like receptor 
protein 3 (NLRP3) inflammasome have been identified.(2, 17, 18) The subsequent 
inflammatory environment that is created activates DCs and other epidermal cells.
(4) Besides activation of the innate immune system, irritants which have a solvent/
surfactant effects can disrupt the skin barrier, allowing for more efficient penetration 
by haptens.(19) Xenoinflammation also helps recruitment of effector T cells to the skin 
in the elicitation phase, and prior/concomitant exposure to other haptens/irritants can 
decrease the threshold for sensitisation and elicitation and/or increase the strength 
of elicitation response.(4, 20-22) More detail on how the innate immune system is 
activated is provided in chapter 2 of this thesis, with a focus on the cytokine tumor 
necrosis factor (TNF), and the role it plays in the pathogenesis of contact allergy and 
ACD.
Cross-reactivity and co-sensitisation
An important concept in contact allergy is cross-reactivity, in which an individual who 
is sensitised to hapten A develops an elicitation response when exposed to hapten B, 
to which there was no prior exposure. The explanation is that hapten B has the same 
chemical group and spatial geometry as hapten A and can therefore be recognized 
by the same hapten A-specific T cells.(23) Two haptens which are different from each 
other can still cross-react if one of the two is metabolized in the skin (or transformed 
non-enzymatically outside the skin due to for example oxidation) so that the resulting 
1
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molecule is similar to other hapten.(24) The pro- and prehapten concepts play an 
important role in understanding cross-reactions between initially chemically unrelated 
molecules. The reverse can also be true; two haptens which, although are of similar 
structure, do not cross-react as they are metabolized in the skin by two different 
pathways, an example being eugenol (CAS no. 97-53-0) and isoeugenol (CAS no. 97-
54-1).(25)
Individuals allergic to PPD can cross-react to another hair dye allergen 
2,5-toluenediamine (TDA, CAS no. 95-70-5, also known as para-toluenediamine, 
PTD), but also to benzocaine (CAS no. 94-09-7), a local anaesthetic which is 
ethyl ester of para-aminobenzoic acid, and to N-isopropyl-N’-phenyl-para-
phenylenediamine (IPPD, CAS no. 101-72-4), a stabilizer in rubber, among others.(26, 
27) Although the term cross-reactions is used in a clinical setting to denote elicitation 
reactions to two or more chemically similar haptens, it is almost impossible to ascertain 
whether these constitute true cross-reactions or if the patient has been co-sensitised, 
i.e. exposed to both haptens, especially if the two haptens are often found together 
in products (e.g. PPD and p-aminophenol, both ingredients present concomitantly in 
hair dyes) or separately but in similar products (PPD and TDA, both hair dyes). Only a 
limited number of cross-reacting haptens have been identified as true cross-reactions. 
A famous example are corticosteroids, in which four groups have been identified based 
on structure-activity relationship analyses (group A to D). It was hypothesized that 
cross-reactivity occur within corticosteroid groups, which was confirmed for groups 
A, B, and D by analysing patch test data.(28, 29)
Risk factors for sensitisation
Exposure
The largest determinant of whether a person becomes sensitised is exposure, as 
opposed to susceptibility. The area and concentration of the hapten in the substance 
to which the skin is exposed can be expressed as ‘dose per unit area’, and corresponds 
to the intensity of the sensitisation stimulus.(30) Exposure to specific contact allergens 
can be higher in specific occupations or in specific conditions, for example leg stasis 
dermatitis, in which there is high exposure to topical medicaments containing 
corticosteroids, preservatives, and fragrances as potential contact allergens.(31) 
Risk factors for having a contact allergy are being of the female sex and having old 
age; these can also both be explained more by exposure than by differences in innate 
susceptibility, although sex influences some aspects of the immune response. For 
example, the influence of the menstrual cycle on the elicitation phase has been 
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explored - often of nickel contact allergy - and results suggest an inhibitory effect 
during the ovulatory phase (high oestrogen) and an increased immune response during 
the progestinic phase (high progesterone).(32, 33) Increased exposure in females is 
due to more occupations with high exposure (health care workers, hairdressers) and 
habits and clothing (more fragrances, jewellery, etc.).(34) Although with age comes 
senescence of the immune system, i.e. it is theoretically more difficult to acquire a new 
contact allergy, this is countered by cumulative lifetime exposure.(34)
Additional risks other than susceptibility that influence sensitisation are exogenous 
factors which influence the penetration of the hapten through the skin barrier, for 
example the physiochemical properties of the chemical in question (e.g. the pH 
and the lipophilicity), the properties of the vehicle, and whether there is occlusion 
or not.(35, 36) Topical preparations that stay on the skin also transform over time, 
with evaporation of for example water leading to more concentrated preparations 
the longer it stays on the skin.(37) Depending on the hapten, higher or lower levels of 
exposure are required to reach the threshold for sensitisation or elicitation; a lower 
level of exposure is required for ‘strong’ sensitisers compared to ‘weak’ sensitisers.
Skin barrier
A second important determinant for sensitisation is the skin barrier; when 
compromised, it is easier for haptens to penetrate into the epidermis. There are 
inter- and intra-individual variations in the skin barrier. A method by which this was 
investigated was by measurements of the trans epidermal water loss (TEWL), an in 
vivo measurement in which passive water diffusion through the stratum corneum is 
measured.(38) Its most common use is to assess skin responses to irritants. TEWL has 
been found to be inversely correlated with the size of the flattened corneocytes and 
the number of cell layers of the stratum corneum in the respective skin area.(39) As 
most molecules penetrate in an intercellular fashion (through the lipid layer between 
the corneocytes), a higher TEWL implies higher permeability, i.e. TEWL is inversely 
correlated with barrier function. Some suggest that this might be true for hydrophilic 
chemicals, but that it is not known yet whether it is also true for lipophilic chemicals.(7)
There are no large sex- or race-dependent differences in TEWL.(40) A variation in 
TEWL between individuals has been observed as well, with a coefficient of variation 
ranging from 31% to 47% for the palm and from 35% to 57% for the forearm.(41) A 
possible explanation for these inter-individual differences might be mutations in the 
filaggrin gene (FLG), mainly found in populations of North-European descent and Asian 
populations.(42) Filaggrin (filament-aggregating protein) plays an important role in 
1
136610_Daan_Dittmar_BNW-def.indd   13 30-7-2019   10:16:58
14
Chapter 1
the formation of corneocytes and in the generation of intracellular metabolites, such 
as natural moisturizing factor, contributing to hydration and lowering the pH of the 
stratum corneum.(42) As a result, loss-of-function mutations in the filaggrin gene are 
associated with reduced hydration, increased TEWL, and an increased skin pH, which 
in turn leads to reduced resistance against pathogenic microorganisms and activation 
of pH-sensitive serine proteases.(43) The activated serine proteases can cause, among 
others, compromised intercellular connections and can activate the pro-inflammatory 
cytokines interleukin-1α (IL-1α) and IL-1β. Filaggrin has been argued to be at the centre 
of atopic dermatitis pathogenesis.(43) One study found that the R501X and 2282del4 
mutations in FLG were strongly associated with contact allergy in individuals with 
(atopic and/or hand) dermatitis, but not in individuals without dermatitis.(44) The 
most likely explanation for this is that active inflammation can cause down regulation 
of filaggrin. Prior or concomitant exposure to irritants during exposure to contact 
allergens can also negatively influence the skin barrier, as can psychological stress.
(22, 45)
Genetic predisposition
Besides the above mentioned FLG mutations, other genes have been investigated and 
specific mutations/genotypes have been found to contribute to a higher susceptibility 
for developing contact allergy. A more complete overview is provided in (46). There 
is evidence that mutations in the genes encoding for the pro-inflammatory cytokines 
IL-10, IL-16, and TNF pose a risk factor for sensitisation.(47-49) Many of these studies 
are however hampered by small sample sizes and other methodological flaws. Studies 
investigating TNF variants are discussed critically in chapter 2 of this thesis.
Another line of defence, besides the skin barrier, are drug-metabolizing/detoxifying 
enzymes present in the epidermis that metabolize and/or detoxify exogenous 
molecules.(50) Two well-known examples are glutathione-S-transferase (GST) and 
N-acetyltransferase 1 (NAT1), phase 2 enzymes of the cytochrome P450 superfamily. 
Specific genotypes for these enzymes may make an individual more or less susceptible 
to develop contact allergy to specific haptens, as has been suggested for GST and 
contact allergy to chromium and thiomersal.(51) N-acetyltransferases are enzymes 
with activity towards aromatic amines, and NAT1 had been shown to be able to detoxify 
unoxidized PPD into mono-acetyl-para-phenylenediamine (MAPPD) and di-acetyl-
para-phenylenediamine (DAPPD), which do not possess any sensitising potential.(52, 
53) Although in vitro studies have shown that NAT2 is also able to acetylate PPD, little 
to none NAT2 activity has been observed in the skin.(54) Variants in NAT1 can result 
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in rapid or slow acetylation phenotypes, the hypothesis being that slow acetylation 
phenotype results in a higher susceptibility to develop PPD contact allergy. Different 
studies investigating the role of NAT genotypes in contact allergy to PPD or para-
amino-substituted arylic compounds have produced contradictory results, however.
(53, 55, 56)
DIAGNOSING CONTACT ALLERGY: PATCH TESTING
Originally conceived by Joseph Jadassohn (and Jean-Henri Fabre) at the end of the 19th 
century and later expanded by Bruno Bloch (among others) in the early 20th century, 
patch testing is the golden standard diagnostic test to diagnose contact allergy.(57) 
Contact allergens dissolved or dispersed in a vehicle (often petrolatum or water) 
are applied to the skin under occlusion for a standard amount of time. In its essence 
patch testing is an attempt at recreating the elicitation phase of contact allergy in a 
controlled setting.
The main indication for patch testing is suspected ACD.(58) It can, however, also be 
indicated in patients with atopic dermatitis, especially if it is refractory to treatment 
and an underlying ACD is suspected.(59) Besides attempting to detect any contact 
allergies, patch testing is also used to investigate the safety of alternative products 
(topical medicaments, cosmetics, gloves, medical adhesives such as glucose monitors 
in diabetes patients or TENS (see chapter 8a)) in patients with suspected/proven 
contact allergies. This use of patch testing allows for adequate advice to be given to 
the patient on which products to avoid and which products are safe to use.
Patch test technique
The patch test is most often performed on the upper back of a patient for practical 
reasons, as it provides a large and relatively flat surface area. Sometimes a patch test 
can also be performed on the upper arms or thighs, for example if a large variety of 
contact allergens are suspected and the back is not large enough to test all preferred 
contact allergens, or if there is active dermatitis or other skin diseases on the back 
which make it impossible to perform the patch test (although postponing the patch 
test might be preferred in this situation; differences in skin barrier between anatomical 
sites make patch testing elsewhere less reliable (see above)).(58) Additional reasons 
for postponing a test are if topical corticosteroids are applied to the back - which 
implies active dermatitis on the back, another reason to postpone patch testing - or 
1
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if the patient is on immunosuppressive medication, as this can inhibit an elicitation 
reaction, with therefore a high risk of false negatives.(60)
Patch test materials and series
The contact allergens dissolved in a vehicle are applied to the back in patch test 
chambers; different test chambers exist and differ mostly in size (area ranging from 
0.5cm2 to 0.68cm2) and material (polyethylene foam in IQ Ultra™ chambers, aluminium 
in Finn Chambers®, polypropylene in Van der Bend chambers). Due to different 
sizes different amounts of contact allergen containing vehicle have to be applied 
so the ‘dose per unit area’ is equal.(61) These are loaded by the investigator with a 
standardized amount of contact allergen containing vehicle. For aqueous solutions 
it is recommended to load the chambers using a micro-pipette in order to minimize 
variation in dose between chambers; for petrolatum a syringe is often used, which is 
slightly more difficult and more dependent on the experience of the investigator.(62) 
An attempt to standardize patch testing, especially the dose applied, resulted in the 
true test, a preloaded, ready-to-apply, patch test in which the allergens are dissolved in 
a hydrophilic polymer vehicle that turns into a gel following contact with perspiration 
of the skin.(63)
In order to screen dermatitis patients for the most common and frequent contact 
allergens baseline series were developed, with variants for different continents and/or 
geographic regions. The most commonly applied in Europe is the European baseline 
series (EBS), consisting of contact allergens responsible for the most frequent contact 
allergies based on epidemiological data.(64) Inclusion in the EBS is warranted if a 
contact allergen shows more than 1% positive reactions in consecutively patch tested 
patients. A proposal for an update of the EBS was recently published, with inclusion 
of new allergens and exclusion of old allergens.(65) Besides the EBS country specific 
series have been developed as well (eg the Italian Group of Research in Environmental 
and Contact Dermatitis (GIRDCA) Series).(66) Most countries in Europe however opt 
to use the EBS supplemented with contact allergens relevant to exposures in that 
country. Besides these baseline series, additional series exist for patch testing in 
patients with specific (occupational) exposure to contact allergens not present in the 
EBS (or other baseline series). Examples of additional series containing a specific group 
of contact allergens include a cosmetic series, a fragrances series, and a corticosteroids 
series. Examples of additional series aimed at specific occupational exposures include 
a bakery series and a hairdressing series. Besides patch testing contact allergens at 
standardized concentrations, the clinician can also consider to patch test the patient’s 
136610_Daan_Dittmar_BNW-def.indd   16 30-7-2019   10:16:59
17
General Introduction
own material to which he/she has developed a skin reaction. It must be noted that 
this requires a lot of experience, and testing ‘as is’ can lead to active sensitisation or 
a strong irritant reaction (false positive), so often the substance has to be diluted, 
with the risk of obtaining a false negative result.(58) Testing the separate ingredients 
of a product can be very useful in diagnosing ACD, assuming this information can be 
obtained through an ingredient list or a material safety data sheet (MSDS).
Patch test method and interpretation
The optimal patch test technique as recommended by the European Society of 
Contact Dermatitis (ESCD) is to have an occlusion time of 48 hours with visual readings 
performed at day 2, day 3 or 4, and day 7.(58) Some patch test centres prefer to use 
an occlusion time of 24 hours for practical reasons. Studies have shown that for some 
contact allergens, for example nickel, more positive reactions are seen with 48 hours 
occlusion as compared to 24 hours occlusion.(67) A longer occlusion time might 
increase the chance of active sensitisation however, but this is rarely reported, and 
concentrations of contact allergens in the vehicle are chosen thusly to minimize this 
complication (but allowing for the maximum amount of elicitation reactions). Readings 
are often performed on two occasions instead of the optimal three, again because of 
logistical and practical considerations. Not performing a day 7 reading risks missing 
late positive reactions for some allergens, leading to a lower diagnostic sensitivity.(68)
As interpreting a patch test reaction is difficult and requires experience, in particular 
being able to differentiate between borderline positive reactions (termed doubtful) 
and irritant reactions, criteria were formulated by the ICDRG to facilitate interpretation 
and limit intra-observer variation (table 1).(58) Especially this latter issue is of large 
importance to increase validity of multicentre patch test studies (e.g. chapter 7)).(69) 
The reading criteria are based on morphology of the skin reaction and it is important 
for an assessor to avoid interpreting a skin reaction by what is expected based on the 
patients exposure patterns.
Besides assessing the morphology of a patch test reaction and distinguishing between 
true allergic reactions and non-allergic reactions, the clinical relevance of a positive 
patch test reaction has to be assessed. As stated earlier, a contact allergy does not 
necessarily imply that the dermatitis is caused by it; there has to be current exposure 
to the contact allergen, and the dermatitis has to be explainable with regard to 
localisation and course of the dermatitis relative to the exposure.(70) A contact allergy 
that is not of current clinical relevance might be of previous clinical relevance, i.e. there 
1
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has only been exposure in the past but not anymore, or it might not be relevant at all; 
the result of limited exposure only leading to sensitisation or a cross-reaction.
Table 1: reading criteria of the ICDRG (58)
Symbol Morphology Assessment
- No reaction Negative reaction
?+ Faint erythema only Doubtful reaction
+ Erythema, infiltration, possibly papules Weak positive reaction
++ Erythema, infiltration, papules, vesicles Strong positive reaction
+++ Intense erythema, infiltrate, coalescing vesicles Extreme positive reaction
IR Various morphologies, e.g. soap effect, bulla, 
necrosis
Irritant reaction
Additional diagnostic tests in detecting contact allergy
Patch testing is the golden standard in diagnosing a contact allergy, however, a 
few additional tests exist, to be viewed as complimenting patch testing rather than 
replacing it. The first is the repeated open application test, or ROAT, in which a test 
substance is applied twice daily to a small surface area of between 3x3 cm to 5x5 cm 
on the volar aspect of the forearm for about seven days, or longer if no dermatitis 
is seen yet but is expected to develop.(71) It is especially useful when patch-testing 
with a product or its ingredients is negative in spite of the suspicion that exposure to 
this product is the cause of the patient’s dermatitis. A scale for evaluating ROAT skin 
reaction was developed by Johansen et al, in which the area, erythema, infiltration, and 
number of vesicles are scored.(72) Besides the ROAT there are the semi-open test and 
open test, in which a small amount of product is applied to the skin and subsequently 
covered with permeable tape or left open, respectively.(58) The semi-open use test is 
suggested for products with a suspected irritant effect, and the open use test is useful 
to test whether it is safe to patch test a patient’s own material.
EPIDEMIOLOGY OF CONTACT ALLERGY
Contact allergy is a very common condition (or rather, immunological state), and 
in theory everybody is able to become sensitised to one or more contact allergens, 
if exposure is high enough.(73) Most epidemiological studies in the field of contact 
allergy provide us with prevalences of contact allergy overall and to specific contact 
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allergens; the number of people with a contact allery divided by the total population 
tested. Other important epidemiological outcomes are incidence and cumulative 
incidence; the number of new cases over a specified period of time in a population, 
and the proportion of new cases of a fixed, non-diseased, population per specified 
unit of time. It is important for both outcome measures that the source population 
is well defined in regard to size, time period, method of patch testing (consecutive 
testing or aimed testing), whether all individuals are tested with the same allergens 
in the same concentration, etc. The majority of epidemiological studies in the field 
of contact allergy focus on prevalence rather than incidence. For a cumulative 
incidence to be investigated a specific population has to be patch tested twice over 
a period of time, in order to reveal how many new cases of contact allergy have been 
developed over that time. One such example is the Copenhagen study, in which 12% 
of a randomly selected population developed one or more contact allergies over a 
period of 8 years.(74) Epidemiological studies with a focus on prevalence are mostly 
based on data from patch test clinics, and serve as an important surveillance method 
of observing trends in contact allergy to specific contact allergens, whether it be 
contact allergens with established high sensitisation rates, or rising sensitisation rates 
to new contact allergens, for example the preservative methylchloroisothiazolinone/
methylisothiazolinone (MI/MCI).(75) Another purpose in epidemiological studies is 
to determine whether there are specific risk factors, or specific groups with a high 
risk, for developing contact allergy. For example, as mentioned above, women and 
individuals of older age have a higher prevalence of contact allergies.(34) Most of the 
epidemiological data available on contact allergy are derived from research performed 
in patient populations, that is, patients suffering from dermatitis in which ACD is 
suspected. It is important to consider that these results cannot be extended to all 
dermatitis patients, as it more likely represents a subset of patients with more severe 
dermatitis, i.e. those referred to a dermatologist. More rare, and more difficult to 
perform, are prevalence studies focussing on contact allergy in the general population.
Reported prevalences are often age- and sex-standardized in order to allow for 
better comparability between studies.(76) Specific characteristics of the population 
which can influence the reported prevalences are covered by the MOAHLFA-index, 
in which the proportions of the following patient demographics are provided: male 
sex, occupational cause of dermatitis, (a history of) atopic dermatitis, hand, leg, and 
face, respectively, as primary sites of dermatitis, and age above 40 years old.(77) For 
example, in a population with a high proportion of leg dermatitis, a higher prevalence 
of contact allergy to ingredients of topical medicaments can be expected, or, in a 
1
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population with a high proportion of occupational dermatitis, higher prevalences of 
contact allergy to occupational contact allergens (e.g. epoxy resins) can be expected.
(31, 78) By reporting these characteristics the data can be correctly interpreted and 
correct comparisons between different studies is facilitated.
The prevalence of contact allergy is based on patch test results, and as with all 
diagnostic tests, patch testing carries the risk of false positives but more importantly 
the risk of false negatives.(79) Possible pitfalls of patch testing are important to keep 
in mind when interpreting the prevalence of contact allergy and ACD (see above). 
The majority of epidemiological studies concerning contact allergy are performed 
in Europe and North America. These results cannot be used to infer the prevalence 
of contact allergy overall and to specific contact allergens to other continents, as 
exposure to contact allergens differ between countries. Some examples of factors 
which influence the differences in exposure to contact allergens between countries are: 
products available on the consumer market, legislation which regulates presence and 
concentration of contact allergens in products, occupations with specific exposures 
(e.g. Batik industry in Indonesia), climate, culture (treatment of skin disease with 
natural products), etcetera.(80, 81)
As stated before, only a small fraction of all possible contact allergens are responsible 
for the majority of contact allergy. The allergen groups responsible for the majority of 
contact allergies are metals , fragrances, and preservatives.(82) The contact allergen 
with the highest reported sensitisation rate is nickel.(82, 83)
The most recent study investigating the prevalence of contact allergy in the general 
population in Europe (five countries participated: Sweden, the Netherlands, Germany, 
Italy and Portugal) found an overall contact allergy prevalence of about 27% 
(n=841/3119; 95% confidence interval 25.5–28.5) to one or more allergens from EBS.
(83) A recent meta-analysis on contact allergy prevalence in the general population 
found that about 20% have a contact allergy.(84) Although this number appears 
alarmingly high, the majority are caused by metals (mostly nickel), preservatives, and 
fragrances, and a large majority are most likely not of any real significance, i.e. have 
not resulted in actual morbidity (ACD). It should also be considered that the rate of 
false positive reactions is higher in a population with a lower disease prevalence.(85) 
A strength of this study is that the population which was patch tested has a similar 
age and sex distribution as the total European Standard Population. As expected, 
differences in contact allergy to specific contact allergens were seen between the 
countries. A clear example is the lower sensitisation rate of nickel in the general 
population in Sweden compared to for example Portugal. This is in all likelihood the 
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result of legislation implemented in 1990/1991 in Denmark, Germany and Sweden, 
prohibiting the sale of products containing high levels of nickel.(86)
Epidemiological studies in the field of contact allergy are of the upmost importance, and 
the data that is collected serves as surveillance of contact allergy epidemics, the most 
illustrative example being the methylchloroisothiazolinone/methylisothiazolinone (MI/
MCI) epidemic in the last decades.(75) New products are constantly introduced into 
the consumer market, and it is vital to remain vigilant as each new product carries the 
risk of causing contact allergy. Case reports are therefore also important in the contact 
allergy field, specifically for reporting new contact allergens or new exposures.
OUTLINE OF THIS THESIS
The field of contact allergy and ACD is constantly evolving and contains many facets, 
reflected in the outline of this thesis. The facets which were investigated were the 
immunology and genetics of contact allergy, the diagnostic patch test, and the 
epidemiology of contact allergy.
The first section concerns immunology and genetics of contact allergy. In chapter 2, 
attempts at finding a role of variants in TNF, specifically TNF – 308G>A in increased 
susceptibility to develop contact allergy either in general or to specific contact 
allergens, are reviewed. The role of TNF in the pathophysiology of contact allergy is 
explored to provide context, and suggestions for future studies are provided.
PPD is a common contact allergen, causing ACD in hair dying and henna tattoos, and 
by investigating the pathways in which it either is detoxified or causes sensitisation, 
prevention and/or safe alternatives can be explored. One such attempt at primary 
prevention of PPD contact allergy is the development of 2-methoxymethyl-para-
phenylenediamine (ME-PPD). Cross-elicitation patterns to ME-PPD in PPD allergic 
patients is investigated in chapter 3, by performing open use testing, and the dose-
response is investigated by patch testing with different concentrations.
The second section focusses on different aspects of patch testing; reliability and 
technique. Chapter 4 investigates whether a positive patch test reaction is persistent 
upon repeated testing, exploring not only whether a contact allergy is a permanent 
state or a transient one, but also how patch test results can change over time depending 
on exogenous and endogenous factors. The influence of vehicle and patch test system 
on a patch test outcome is by comparing MCI/MI tested in aqua versus MCI/MI as tested 
in the TRUE test in chapter 5.
1
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The third section is about the epidemiology of contact allergy, with chapter 6 
investigating prevalences of polysensitisation (≥3 positive patch test reactions to 
contact allergens in the EBS) throughout Europe based on data from the European 
Surveillance System on Contact Allergy (ESSCA). Furthermore, specific risk factors 
for becoming polysensitised are analysed. Chapter 7 reports prevalences of contact 
allergy to hydroperoxides of limonene and/or linalool in consecutively patch tested 
patients in our centre, and characterizes this group compared to individuals allergic 
to other fragrances and non-allergic individuals.
Chapter 8 reports two case studies; the first presents a patient who developed ACD 
to his transcutaneous electrical nervous stimulation (TENS), the second presents two 
patients with allergic contact dermatitis to ethylenediamine, both working at the same 
ethylene amines producing factory.
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During the sensitization phase of allergic contact dermatitis, the proinflammatory
cytokine tumour necrosis factor (TNF) plays an important role by promoting epidermal
Langerhans cell migration to draining lymph nodes. It also plays a role during the 
elicitation phase. The TNF gene (TNF) is located within the major histocompatibility 
complex region. Many single-nucleotide variants exist in the promoter region of TNF, 
and these may either increase or decrease RNA transcription and therefore lead to 
higher or lower levels of TNF. The most extensively studied single-nucleotide variant 
of TNF is a base pair substitution in the promoter region at location –308 relative to 
the transcription start site (rs1800629, TNF –308G>A), which is believed to increase 
transcription and lead to higher TNF levels. The role of TNF in allergic contact 
dermatitis and the functionality of TNF –308G>A are reviewed in this article. The 
association between genetic variants and disease can be studied in a case–control 
design. Only a few case–control studies investigating the association between TNF 
–308G>A and allergic contact dermatitis have been published, with contradictory 
results. These are reviewed critically, and suggestions for future case–control studies 
on this topic are made.
Allergic contact dermatitis (ACD) is a delayed-type hypersensitivity reaction caused 
by exposure of the skin to allergens (1). It starts with a sensitization phase, in which 
a person gains the potential to develop a cutaneous allergic reaction to a certain 
allergen, i.e., acquires contact allergy. Repeated exposure to this allergen (or a cross-
reacting allergen) in a sensitized person causes inflammation of the skin. This is 
called the elicitation phase. The level of exposure, determined by dose and time of 
exposure, is the most important exogenous factor determining whether an individual 
becomes sensitized. However, a certain amount of interindividual variability exists in 
the susceptibility to develop ACD independently from exposure (2), some examples 
being sex, ethnicity, and age (3, 4). There may, however, also be a genetic basis for this 
variability in susceptibility, as has been suggested by family and twin studies (5–8). 
Knowledge of the genetic factors that lead to an increased susceptibility to develop 
ACD could help in identifying individuals at risk. Genetic factors for the development 
of ACD that have been investigated so far have previously been reviewed by Schnuch 
et al. and Friedmann et al. (9, 10)
A large part of genetic research is focused on ‘candidate genes’, that is, genes that 
encode specific proteins relevant to the disease pathophysiology (11). One such 
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important protein is tumour necrosis factor (TNF) (sometimes still referred to as 
tumour necrosis factor alpha, or TNF-𝛼) (12). TNF is a proinflammatory cytokine 
with important roles in many inflammatory diseases, for example in psoriasis and 
rheumatoid arthritis (12). The role of TNF in ACD has been extensively investigated. 
The most important function seems to be to promote migration of the antigen- 
presenting Langerhans cells (LCs) to draining lymphnodes during the sensitization 
phase (13–15). TNF also has an important role during the elicitation phase of ACD 
(16). Genetic variants in the promoter region of the TNF gene (TNF) can lead to either 
an increase or a decrease in transcription of TNF, and can therefore influence TNF 
production (17). They can therefore theoretically lead to a higher or lower susceptibility 
to develop contact allergy and subsequent ACD. The role of these genetic variants of 
TNF in ACD has so far been studied in a few different clinical studies (18–24).
This review aims to elucidate the role of TNF in ACD, look at the different variants in 
the promoter region of TNF and their biological relevance, take a critical look at the 
clinical studies performed on TNF variants in ACD, and give suggestions for future 
research on variants in TNF.
2
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THE ROLE OF TNF IN CONTACT HYPERSENSITIVITY
TNF is an important player in the development of contact hypersensitivi-
ty by inducing LC migration
One of the essential steps in the sensitization phase of ACD is considered to be the 
migration of hapten-carrying LCs from the epidermis to draining lymph nodes. LCs 
belong to the dendritic cell (DC) family, and are the main antigen-presenting cell 
residents in the epidermis. When they arrive in the paracortical area of the lymph node, 
LCs present the hapten to naive T lymphocytes. The T lymphocytes then differentiate 
into antigen-specific type 1 T helper (Th) cells/type 1 cytotoxic T (Tc) cells and Th17/
Tc17 cells, and proliferate. More recent evidence suggests that dermal DCs are vital for 
hapten presentation to T cells and their differentiation into effector T cells, with LCs 
having a more tolerogenic tole (discussed in more detail below) (25, 26).
One of the essential steps in the sensitization phase of ACD is considered to be the 
migration of hapten-carrying LCs from the epidermis to draining lymph nodes. LCs 
belong to the dendritic cell (DC) family, and are the main antigen-presenting cell 
residents in the epidermis. When they arrive in the paracortical area of the lymph node, 
LCs present the hapten to naive T lymphocytes. The T lymphocytes then differentiate 
into antigen-specific type 1 T helper (Th) cells/type 1 cytotoxic T (Tc) cells and Th17/
Tc17 cells, and proliferate. More recent evidence suggests that dermal DCs are vital for 
hapten presentation to T cells and their differentiation into effector T cells,with LCs 
having a more tolerogenic tole (discussed in more detail below) (25, 26).
LC migration is initiated by altered expression of its surface adhesion molecules. 
This maturation process is induced by cytokines, among them TNF, released in the 
epidermis after penetration of a hapten into the epidermis. Experimental studies 
have shown the important role of TNF: intradermal injection of TNF induced DC 
accumulation in regional lymph nodes, and injection with anti-TNF inhibited LC 
migration (13–15). The following sections will examine the role of TNF in ACD more 
deeply, and discuss how TNF production in the epidermis is caused by exposure to 
haptens, how TNF induces LC migration, and the role of TNF in the elicitation phase.
TNF production and secretion occurs after activation of the innate 
immune system by the hapten
TNF secretion in the epidermis occurs early in the sensitization phase. Its secretion is a 
result of the activation of the innate immune system by haptens (27). Two concomitant 
pathways have been identified; one involving activation of the inflammasome, and 
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another involving activation of toll-like receptors (TLRs). These two pathways are 
illustrated in Fig. 1.
After a hapten penetrates into the epidermis, it induces keratinocytes to produce 
reactive oxygen species (ROS). One study showed that dose-dependent application 
of the chemical allergens 2,4,6-trinitrochlorobenzene (TNCB), 4-ethoxymethylene-
2-phenyloxazol-5-one (oxazolone, or OXA) and mercaptobenzothiazole induced ROS 
production both in vitro and in vivo (28). ROS cause cellular damage, resulting in the 
release of extracellular ATP,which, in turn, activates the NOD-like receptor protein 3 
(NLPR3) inflammasome. Inflammasomes are multiprotein complexes that are able to 
detect pathogens, irritants, and endogenous danger signals (29, 30). ATP can activate 
the NLPR3 inflammasome by binding to the transmembrane purinergic receptor P2X7, 
located on DCs (31). One study showed that nickel can directly activate the NLPR3 
inflammasome independently of ATP, although ROS were still required (32). Activation 
of the NLPR3 inflammasome activates caspase-1, an enzyme that is responsible for 
the maturation of the cytokines pro-interleukin (IL)-1𝛽 and pro-IL-18 (27, 31, 33). 
Keratinocytes produce both IL-1𝛽 and IL-18, and LCs produce only IL-1𝛽 (34, 35). 
Together, they activate keratinocytes to produce TNF and granulocyte–macrophage 
colony-stimulating factor (16, 36).
The second pathway involves the extracellular TLRs, which belong to the ‘pattern 
recognition receptor’ family. In the epidermis, they can be found on keratinocytes, DCs, 
fibroblasts, and mast cells. They are able to bind to pathogen-associated molecular 
patterns, for example lipopolysaccharide (LPS), a bacterial endotoxin, and provide a 
first line of defence against invading pathogenic microorganisms. Binding of ligands 
to TLR4 induces the production and secretion of Th1 and Th17 cytokines, among them 
TNF, IL-1𝛽, and IL-18 (37). In vivo experiments have shown the importance of TLRs in 
contact hypersensitivity (CHS) the mouse model of human ACD. One study showed 
that mice lacking both TLR2 and TLR4 did not develop CHS after repeated application 
of TNCB (38). The role of LPS as a ligand was investigated in germ-free mice (lacking 
a microbial skin flora) (38). These mice were still able to develop CHS. This led to the 
notion that the binding of endogenous ligands to TLR2 and TLR4 plays a vital role in 
the development of CHS. Both TLR2 and TLR4 are capable of binding to endogenous 
ligands, known as damage-associated molecular patterns (DAMPs). In CHS, both 
oxidative degradation (through ROS) and enzymatic degradation of hyaluronic acid 
(HA; also known as hyaluronan) contribute to the production of HA fragments (28, 
39). HA fragments are proinflammatory molecules, and can act as ligands for TLR2 
and TLR4 (40), causing maturation of DCs (41, 42). TNF secreted by keratinocytes 
2
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is required for HA fragment-induced maturation of DCs (41). The importance of HA 
fragments and TLR4 in DC migration, and in CHS overall, was further shown in mice 
overexpressing human hyaluronidase 1 (encoded by HYAL1), which showed increased 
HA degradation (43). Other examples of DAMPs that are TLR4 ligands in CHS are 
fi bronectin extra type III domain A, heparan sulfate, fi brinogen, and heat shock 
proteins (44). Besides activation of TLR4 by binding with DAMPs, it has been shown 
that both nickel and cobalt can bind directly to human, but not to mouse, TLR4 (45, 46).
Figure 1. 
Activation of the innate immune system after a hapten penetrates the skin. After haptens 
penetrate the epidermis, they, besides binding to Langerhans cells, activate the innate 
immune system through a series of steps. First, keratinocytes are induced to produce 
reactive oxygen species (ROS), which cause cellular damage that leads to the formation of 
damage-associated molecular patterns (DAMPs) and therelease of ATP. ATP activates the 
NOD-like receptor protein 3 infl ammasome by binding to, for example, the transmembrane 
purinergic receptor P2X7 on dendritic cells. The activated infl ammasome causes caspase-1 
activity. Caspase-1 is responsible for the maturation of pro-interleukin (IL)-1𝛽 and pro-IL-
18, and subsequently the cytokines IL-1𝛽 and IL-18 are released. At the same time, DAMPs, 
among them hyaluronic acid (HA) fragments, bind to toll-like receptors (TLR) 2 and 4, on 
either keratinocytes (as pictured here) or dendritic cells. Nickel and cobalt can bind directly 
to TLR4. Activation of TLR2 and TLR4 leads to secretion of IL-1𝛽, IL-18, and tumour necrosis 
factor (TNF). IL-1𝛽 and IL-18 stimulate keratinocytes to produce more TNF.
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Besides keratinocytes (the main producers of TNF in the epidermis), more recent 
evidence suggests that epidermal LCs may also be responsible for increased TNF 
secretion in CHS (47, 48). Experimental studies showed that CD34+ DCs (progenitors 
of both DCs and LCs) produced TNF when stimulated with certain chemicals (49–51). 
For example, nickel, oxazolone and hexyl cinnamal increased TNF production in CD34+ 
DCs (49, 50). Conversely, eugenol and 2,4,6-trinitrobenzene sulfonic acid decreased 
TNF production (50). Besides being hapten-dependent, TNF production by CD34+ DCs 
also showed individual variation (50). There is also evidence that mast cell-derived TNF 
plays a role in CD8+ DC maturation and migration in CHS (52).
Binding of TNF to TNF-R2 induces maturation of LCs and subsequent 
migration to draining lymph nodes
There are two TNF receptors: TNF-R1 (or p55TNFR) and TNF-R2 (or p75TNFR). LCs 
in the skin express TNF-R2 but not TNF-R1 (53). In accordance with this, one group 
showed that LC migration was normal in TNF-R1 knockout mice when they were 
challenged with fluorescein isothiocyanate (FITC), but abnormal in TNF-R2 knockout 
mice when they were injected with TNF (54, 55). When TNF-R2 knockout mice were 
challenged with oxazolone, they showed a decreased CHS response (54). Another 
study showed that TNF-R1 also plays an important role in CHS, as TNF-R1-deficient 
mice did not develop CHS in response to TNCB (56). Further investigation showed that 
TNF-R1 did not influence DC migration, but increased antigen uptake by DCs (56).
TNF influences LC migration in various ways through binding to TNF-R2. It induces a 
change in the expression of surface molecules of LCs in the maturation process. Among 
these changes are: decreased E-cadherin surface expression, and increased expression 
of CD44, major histocompatibility complex (MHC) II, intercellular adhesion molecule 
1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and chemokine receptor 
type 7 (CCR7) (57–60). LCs are positioned in the suprabasal layer of the epidermis, 
and are bound to the extracellular matrix and keratinocytes through E-cadherin. A 
decrease in E-cadherin surface expression therefore leads to separation of the LCs 
(60). CD44 plays an important role in the interaction between LCs and T lymphocytes 
(61, 62). CCR7-deficient mice show impaired LC migration upon skin painting with FITC 
(63). One study showed that, although CCR7 expression on maturing LCs is strongly 
dependent on TNF when they are stimulated with DNCB, it is mostly independent of 
TNF when they are stimulated with NiSO4 (64). One study showed that DC stimulation 
with TNF caused large changes in the actin-based cytoskeleton and highly increased 
motility (65). In order to reach the lymphatic vessels in the dermis, LCs have to move 
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through the basal membrane. TNF induces LCs to secrete matrix metallopeptidase 9 
(also known as gelatinase), which helps to degrade the basal membrane (66).
The role of TNF in the elicitation phase
The elicitation phase of ACD consists of the migration of circulating primed memory/
effector T lymphocytes into the (epi)dermis upon re-exposure to an allergen. The T 
cells are presented with the hapten by local DCs, and are subsequently reactivated and 
release proinflammatory cytokines, among them TNF. In order to show the relevance of 
TNF in the elicitation phase, one group treated sensitized mice with systemic anti-TNF 
antibodies immediately before challenge with TNCB; the CHS response was reduced 
significantly (16). Similarly, the CHS response decreased significantly in TNF–/– mice 
(although it was not absent), and an enhancing role of TNF was postulated (67).
Besides having a cytotoxic effect, TNF has other ways of influencing the elicitation 
phase. TNF causes increased expression of the adhesion molecules ICAM-1 and 
VCAM-1, and endothelial leukocyte adhesion molecule (also known as E-selectin), on 
endothelial cells, increased expression of ICAM-1 and VCAM-1 on DCs, and increased 
expression of ICAM-1 on keratinocytes (27, 68). These adhesion molecules help the 
recruitment of circulating effector/memory T lymphocytes into the epidermis. The 
expression of vascular endothelial growth factor, whose action contributes to oedema 
by way of increased vascular permeability, was shown to be reduced in TNF–/– mice as 
compared with wild-type mice (67). TNF also induces IL-33 production in keratinocytes. 
Blocking IL-33 in mice diminished the CHS response, showing its role in the elicitation 
phase (69).
Recent discoveries that challenge this model of CHS
Although ample evidence exists to support the role of TNF in inducing LC maturation 
and migration, more recent evidence suggests that certain allergens, for example 
2,4-dinitrochlorobenzene and 2,4-dinitrofluorobenzene (DNFB), can induce LC 
migration independently of TNF (70). Other investigated allergens, such as oxazolone 
and p-phenylenediamine (PPD), did require TNF, however (70).
The essential role of LCs in CHS was also questioned after studies performed in LC-
deficient mice. These studies showed both increased and decreased CHS responses 
in the absence of LCs (71–73).Despite this absence, the mice were still able to be 
sensitized, suggesting that dermal DCs are able tomediate a CHS response. The 
differences in CHS responses seen in these studies performed on LC-deficient mice 
might be explained by the use of different allergens. Decreased CHS responses were 
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seen in response to TNCB and oxazolone, whereas increased CHS responses were seen 
in response to DNFB, FITC, and oxazolone (71–73).
One study suggested a tolerogenic role for LCs through their secretion of IL-10 after 
interaction with CD4+ T cells (72). IL-10 influences LC migration negatively, inhibits 
effector/memory T cells, and induces the development of regulatory T (Treg) cells 
(74, 75). One group aimed to clarify this perhaps paradoxical role of LCs, in that 
they appear both to contribute to, and to counteract, CHS responses. It showed 
that, at steady state, human skin LCs induce the proliferation of skin-resident Treg 
cells, thereby mediating tolerance to endogenous antigens (76). However, when LCs 
were subjected in vitro to Candida albicans, an increase in the number of antigen-
specific memory/effector T cells was seen (76). Another recent study showed how LC 
migration in response to contact with a weak allergen (2,4-dinitrothiocyanobenzene) 
led to tolerization in vivo. LCs were able to present the hapten to both CD8+ and CD4+ 
Foxp3+ Tregs, leading to deletion or anergy of the former and activation of the latter 
(25). All in all, the role of LCs in CHS remains controversial (26).
THE SINGLE-NUCLEOTIDE VARIANTS (SNVS) IN THE PRO-
MOTER REGION OF TNF
The various SNVs in the promoter region of TNF
TNF is located on chromosome 6p21.3, in the MHC III region, situated between the 
MHC I and MHC II regions, which encode the human leukocyte antigen (HLA) surface 
molecules (17). Many SNVs1 of varying importance have been identified in the promoter 
region of TNF (17). SNVs in the promoter region can lead to either an increase or a 
decrease in TNF mRNA production and TNF release by different cell types (17, 78). 
Interestingly, one study investigated the genetic influence on individual variation in 
cytokine production, and found this to be ∼60% for TNF (79).
The SNV in the TNF promoter region at location –308 relative to the transcription start 
site (officially called rs1800629, but also referred to as –308G>A, 308.2, or TNF2), in 
which a guanine (G) is substituted by an adenine (A), was the first SNV to be discovered 
(80). Many others have since been found, including SNVs at the locations –1031, –863, 
–857, –575, –376, –238, –163, and –49 relative to the transcription start site (80–82). 
1 We have attempted to adhere to the most currently used genetic terminology and nomenclature 
in this review. Therefore, the term ‘single nucleotide variant’ or ‘SNV’ is used in this article, instead 
of single nucleotide polymorphism or ‘SNP’. An up-to-date source for genetic nomenclature can be 
accessed at: http://varnomen.hgvs.org/ (last accessed on 30-09-2016) (77).
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The SNVs at locations –308 and –238 (rs361525) are the most thoroughly investigated, 
concerning both function (or pathogenic effects) and their relevance in different 
diseases. Case–control studies of TNF promoter variants in ACD have focused almost 
solely on the SNV at the –308 location, which we will refer to as TNF –308G>A (18–23).
Is TNF –308G>A functional?
Whether or not TNF –308G>A has a functional effect has been investigated extensively. 
Investigations have focused on differences in transcriptional activity and/or TNF 
production. These studies have been previously reviewed by different groups, and 
these have, surprisingly, come to conflicting conclusions (78, 83, 84). We will discuss 
the different types of studies performed on this topic and the reasons why they might 
have come to contradictory conclusions.
Promoter activity can be measured in vitro by using reporter gene constructs. In this 
process, the promoter region of interest is attached to a reporter gene, so that it 
controls the expression of the reporter gene (85). Examples of reporter genes are those 
encoding chloramphenicol acetyltransferase and luciferase (86, 87). Luciferase is a 
firefly enzyme that generates light. The expression of the luciferase gene can therefore 
be quantified by measuring emitted light with a luminometer. By measurement of this 
light, the influence of SNVs on activity of the promoter region can be investigated. 
Transcription can be artificially amplified by challenging the reporter gene construct 
with a stimulant, for example phorbol myristate acetate, LPS, or TNF itself. Another in 
vitro method is to measure TNF mRNA with an enzyme-linked immunosorbent assay.
There are approximately as many in vitro gene reporter construct studies that report 
significantly increased transcription activity of TNF –308G>A as there are that do 
not show any significant increase or decrease (81, 88–98). A possible explanation 
for these discrepancies is that different methodologies are used. Some examples 
of factors that can influence the results of reporter gene assays investigating TNF 
–308G>A are the amount of DNA used, the amount of transfection control vector used, 
and the method of transfection (98). One group developed a new reporter system 
that circumvents these influences, and the results suggested that TNF –308G>A is 
functional (98). Another reason for diverging results might be that different cell lines 
are used to investigate the functionality of TNF –308G>A. The first study investigating 
the functionality of TNF –308G>A found a sixfold to sevenfold increase in transcription 
activity in Raji cells (B lymphocytes) that carry the SNV as compared with the wild 
type (88). Since then, studies investigating the effect of TNF –308G>A in Raji cells, 
Jurkat cells (T lymphocytes) and U937 cells (pre-monocytes) have found both increased 
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transcription activity and no change in transcription activity. This suggests that the 
functionality of this variant is perhaps more dependent on the context than on cell 
type. The choice of stimulant used to amplify transcription can also influence the 
results.
A second method of investigating the functionality of the TNF promoter region variants 
is to compare differences in TNF production between the different alleles/genotypes 
ex vivo or in vivo (79, 99–111). These studies have focused on both healthy populations 
and populations with specific illnesses, for example diabetes (99),multiple sclerosis 
(101), and sepsis (104, 105, 109). These studies also produced varying results, again 
most likely because of the varying methods that were used. Which type of study is able 
to draw more meaningful conclusions about whether TNF –308G>A is functional or 
not; in vitro or in vivo studies? One group found that in vitro quantification of mRNA 
was more accurate and sensitive than in vivo protein measurement (112). However, if 
a variant is shown to be functional in vitro, this does not necessarily mean that it will 
be functional in vivo (113), as expression of a gene in vivo might also be dependent on 
the tissue type, environmental context, and the genetic background of an individual.
Inheritance of variants in TNF
Different variants in the TNF promoter region are not inherited independently from 
each other, or independently of the rest of the MHC complex. Certain alleles within the 
MHC complex are inherited together as a haplotype. One example of such a haplotype 
is HLA-A1/HLA-B8/HLA-DR3 (114). An important concept in genetics is linkage 
disequilibrium. This is the association between a variant and a nearby marker at a 
population level (115). Alleles that are in close proximity to one another are more likely 
to be inherited together through linkage disequilibrium. As TNF is situated within the 
MHC III region, alleles in the promoter region are also associated with certain alleles in 
the MHC I and MHC II regions. The aforementioned haplotype HLA-A1/HLA-B8/HLA-
DR3 has been found to be associated with TNF –308G>A (114). Certain HLA alleles, for 
example HLA-DR1, HLA-DR3, and HLA-DR4, have been found to be associated with 
increased TNF secretion by monocytes. Others, however, for example HLA-DR2 and 
HLA-DR5, have been found to be associated with lower TNF secretion (99, 116–118). 
These findings might be explained by the presence or absence of linkage disequilibrium 
of HLA alleles with TNF –308G>A. Another option is that TNF –308G>A is a marker for 
increased TNF production through linkage disequilibrium with an as yet unidentified 
functional SNV. It is, however, important to keep in mind that linkage disequilibrium 
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is not always necessarily complete; certain alleles might be inherited together often, 
but not always (119).
The SNVs that have been identified so far in the promoter region of TNF have also 
been found to be associated with each other, to varying degrees. There are, however, 
differences between different ethnicities in how frequent the SNVs are and how 
strong the linkage between them is. One study found that TNF –238G>A is often 
found together with TNF –376G>A in people from Kenya, but not in people from 
Gambia (120). The same association has been found in Caucasians from New England, 
where the linkage was complete (121). A Dutch study looked at different combinations 
of TNF –238 and TNF –308 (together with two alleles in the lymphotoxin α gene) in the 
Dutch population, and found five different possible haplotypes. In this population, the 
combination of TNF –238G>A and TNF –308G>A did not occur (122). Because of these 
differences between different ethnic groups, it is important to focus on a well-defined 
homogeneous population when performing genetic association studies, in order to 
avoid confounding (123).
Investigating the relevance of TNF –308A in disease
An appropriate study design for investigating the relevance of an SNV in a specific 
disease is the case–control design. Some of the requirements for this study design are 
that the variant under investigation has to have a functional effect, and that the protein 
produced by its gene plays an important role in the pathophysiology of the disease. 
In other words, TNF –308A carriers have to have a significantly higher level of TNF at 
the site of the disease than TNF – 308G carriers. The SNV also has to be functional 
in the cell type responsible for TNF secretion in the disease under investigation. 
Differences can be assessed at either the allele level (comparing –308G carriers with 
–308A carriers), or at the genotype level, for example by comparing TNF –308A/A 
homozygotes with TNF –308G/A and TNF –308G/G carriers.
Case–control Studies of TNF –308G>A in ACD
There are, to the best of our knowledge, seven studies that have 
investigated TNF –308G>A in ACD (18-24). In the following section, we will take 
a critical look at these studies to learn from them and gain insights in how to 
improve future research on this topic. General limitations of these studies are then 
discussed. Table 1 gives an overview of the methodology of these seven studies, and 
Tables 2 and 3 show genotype and allele frequencies, respectively.
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Table 3. Overview of the allele frequencies in the case-control studies
Cases Control
Study A% G% A% G%
Westphal et al.(1) 126* 18.6 81.4 13.55a 86.45a
Wang et al.127* 17.65 82.35 7.82 92.17
Blömeke et al.47 22.1 77.9 12.42 87.58
Ertam et al.128 18 82 42 58
Khatri et al.129 17.5 82.5 13.33 86.67
Westphal et al.(2) 130 18.2 81.8 17.7 82.3
Colagiovanni et al.131 * 8.5 91.5 12.5 87.5
*Allele frequencies not mentioned in original article, therefore, allele frequencies were 
calculated using the genotype frequencies with the Hardy-Weinberg principle: p2 + 2pq 
+q2 = 1 (and p + q = 1), where p = G and q = A, and p2 = GG, 2pq = GA, and q2 = AA.
a Genotype frequencies within this control group deviated from the Hardy-Weinberg 
equilibrium and are therefore not representative of the whole population.
Westphal et al.1 (18)
This was the first case–control study to focus on genetic variants in ACD. Besides 
investigating genotype frequencies of TNF –308G>A and TNF –238G>A, the study also 
investigated genotype frequencies of variants in the genes encoding IL-1β, IL-1 receptor 
antagonist, and IL-6. Cases were subdivided into monosensitized and polysensitized 
individuals. Monosensitization was defined as having a positive patch test (PT) reaction 
to a p-substituted aryl compound (e.g. PPD), and polysensitization as having at least 
one additional positive PT reaction to a chemically unrelated allergen. Patch testing 
was performed with a ‘standard series’. Controls were subdivided into individuals with 
and without a history of eczema. No patch testing was performed in controls. The 
difference in TNF –308G>A genotype distribution between polysensitized cases and 
controls without eczema was significant (p = 0.038), but no significant differences were 
found in any of the other investigated variants, including TNF –238G>A.
The main strength of this study is that it investigated well-defined phenotypes. 
Polysensitized patients were compared with healthy controls without eczema, 
and these phenotypes represent subjects with high and low susceptibility, 
respectively (124). One limitation is that, in the control group, the TNF –308G>A 
genotype frequencies were not within the Hardy–Weinberg equilibrium, implying 
that the frequencies of the alleles are not in concordance with those in the general 
population, and are therefore not fully representative.
136610_Daan_Dittmar_BNW-def.indd   46 30-7-2019   10:17:00
47
TNF in allergic contact dermatitis
Wang et al. (19)
In contrast to the other studies discussed here, this cross-sectional study investigated 
risk factors for the development of ACD in response to chromate in Taiwanese cement 
workers. Variants of the TNF –308 allele and in the glutathione-S-transferase (GST)-
M1 and GST-T1 genes were analysed as risk factors. All subjects underwent patch 
testing with the European baseline series and construction-related substances. 
Carrying the TNF –308G/A genotype was found to be a significant risk factor for having 
a positive PT reaction to potassium dichromate [odds ratio (OR) 3.9, CI: 1.14–13.2]. 
None of the subjects carried the TNF –308A/A genotype.
Although this was not a case–control study, and therefore lacked a well-defined 
control group for comparison, a major strength of this study is that exposure to 
cement, and therefore to chromate, was equal in all subjects. Because of this, any 
difference between subjects with a positive PT reaction to chromate and those without 
can be explained by factors other than exposure, for example by variants in specific 
alleles. Besides those with allergy to chromate, there were also subjects with positive 
PT reactions to, for example, ammoniated mercury and nickel sulfate. It is unclear 
why TNF –308G>A was only assessed as a risk factor in chromate-allergic subjects, 
or what proportion of the chromate allergic-group also had positive PT reactions to 
other allergens.
Blömeke et al. (20)
This case–control study investigating the association between TNF –308G>A and 
ACD compared patients with a history of ACD and a positive PT reaction to PPD with 
age-matched and sex-matched controls. It is unclear whether a patient’s history of 
ACD had to be related to PPD exposure. The TNF –308A allele was significantly more 
frequent in cases than in controls (Fisher’s two-sided exact test, p = 0.0016; logistic 
regression, p = 0.0017), in agreement with the results found by Westphal et al. (18). 
Analysis of subgroups showed that the association was even stronger in females aged 
>45 years.
In contrast to the study by Westphal et al., this study did not subcategorize 
monosensitized and polysensitized subjects, owing to the small number of 
polysensitized subjects. In comparison, the majority of the population studied by 
Westphal et al. were polysensitized. Controls had no history of ACD or sensitization to 
PPD, although it is unclear whether this implies that controls underwent patch testing 
or not.
2
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Ertam et al. (21)
This Turkish case–control study looked at the association between TNF –308G>A 
and IL-1RA variants and ACD. Cases were defined as patients with ACD with a positive 
PT reaction to one or more allergens in TRUE Test®. More than half of the patients 
had a positive PT reaction to nickel sulphate. Controls consisted of individuals without 
a history of eczema and atopy. Interestingly, the frequency of the TNF –308G/G 
genotype was significantly higher in cases than in controls, which is in contradiction to 
the results found in the previous studies. The proportion of TNF –308A/A homozygotes 
in the control group (15%) is remarkable.
These results might be explained by the different genotype frequencies found in 
different ethnicities, although the reverse association of the A allele with ACD is still 
in contradiction to the current theory that the TNF –308G>A variant is functional and 
increases transcription of TNF mRNA. If TNF –308G>A is only a marker in linkage 
with the actual disease-causing gene, then the results can be explained by the study 
population being of a different ethnicity than in previous studies.
Khatri et al. (22)
A case–control study from India investigated the association between TNF –308G>A and 
airborne ACD to the plant Parthenium hysterophorus, in which the hapten parthenin, 
a sesquiterpene lactone, is the relevant allergen (125). The P. hysterophorus plant is 
common in India and Australia. Cases were defined as patients with ACD caused by P. 
hysterophorus, proven by a positive PT reaction. Cases were only included if they 
did not have any respiratory allergy and did not receive immunosuppressive drugs. 
Controls were healthy individuals, not further described. Perhaps surprisingly, no 
significant difference in genotype frequency between cases and controls was found. 
This might again be attributable to the difference in ethnicity studied as compared with 
previous studies in which a significant association with the TNF –308A allele was found.
Westphal et al.(2) (23)
The second case–control study by the group of Westphal et al. focused on multiple 
genetic variants in ACD, investigating a total of 15 variants on 13 genes. For 
the TNF gene, only the SNV at location –308 was investigated. Again, cases were 
subdivided into monosensitized and polysensitized individuals, but these were 
defined differently; monosensitization was defined as having one or two positive 
PT reactions, and polysensitization as having positive PT reactions to three or more 
unrelated allergens. Patch testing was performed with a baseline series and a cosmetic 
preservatives series. Within the polysensitized group, a ‘high-risk’ subgroup was 
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selected, which included patients with at least one strong or extremely positive (++ or 
+++) PT reaction. There was no significant difference in TNF –308 genotype distribution 
between either polysensitized or the ‘high-risk’ polysensitized cases and controls. The 
only significantly more frequent variant was the homozygous A/A variant of CXCL11, 
which encodes a chemokine ligand, although this difference was no longer significant 
after correction for multiple statistical testing.
Colagiovanni et al. (24)
The most recent study investigated the association between TNF –308G>A and ACD 
caused by nickel in 41 cases compared to 40 controls. Patch testing was performed with 
the European baseline series, and both cases and controls were limited to females aged 
between 18 and 40 years. Patients with severe chronic disease (including autoimmune 
diseases) were excluded. There was no significant difference in genotype distribution, 
except in a small subgroup of polysensitized patients (n = 4, with 3 carrying a variant). 
Polysensitization was, however, not defined, and the 1 patient carrying the rare TNF 
–308A/A genotype had positive PT reactions to nickel, cobalt, and chrome. These 
positive reactions are more likely to be attributable to either co-exposure or cross-
elicitation than to increased susceptibility.
Discussion of the genetic association studies in ACD
Although the studies described above had varying strengths in their design, there 
were some (common) limitations. One major limitation was that in none of the 
case–control studies patch testing was performed in the control group, although this 
might have been done in the study by Blömeke et al. Because of this, subjects with 
one or more undiagnosed contact allergies might have been included in the control 
group. Additionally, subjects in the control group might have been highly susceptible 
to develop sensitization but did not because of low exposure to allergens. None of 
the case–control studies attempted to assess the level of exposure in its population, 
because of the difficulty of this task. Exposure assessment would have increased the 
validity of the studies. Ideally, the level of exposure should be equal in both cases and 
controls. In general, description and selection of controls was lacking, with only a few 
inclusion or exclusion criteria being described. Meta-analyses show that the frequency 
of TNF –308G>A is increased in many autoimmune diseases (126, 127). Therefore, 
subjects with concomitant autoimmune diseases should be excluded, as this could 
be a confounding factor, and, in most studies, it was unclear whether these patients 
were excluded or not.
2
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Of the seven studies performed on TNF variants in ACD so far, three studies found an 
association between ACD and TNF -308G>A, three found no association, and one found 
an inverse association. The studies of Westphal et al.(1) and Blömeke et al. are the 
most similar in ethnicity studied and the allergen to which the cases were allergic to, 
and both found a positive association (18, 20). However, the second study by Westphal 
et al., which contained the largest cohort, found no association. Because of these 
varying results, no definitive conclusion can yet be drawn on whether TNF –308G>A is 
associated with increased susceptibility to develop ACD. Non-replication is a common 
phenomenon in genetic association studies, and can often be explained by reasons 
such as small sample sizes, genotyping errors, and population stratification, among 
others (123, 128).
FUTURE RESEARCH ON TNF VARIANTS IN ACD
Basic requirements for a good case–control study
Because of the large number of case–control studies with varying methodological 
weaknesses, the editors of Nature Genetics wrote an editorial about the basic 
requirements for genetic association studies (129). These include: large sample sizes, 
small p-values, high risk/ORs, associations that are biologically plausible, investigating 
alleles that have a relevant physiological function, initial studies accompanied by 
an independent replication study, and the association being reproducible in both 
population and family studies. Sample size is one of the most important determinants 
of quality in case–control studies investigating associations between genotype and 
disease. Hattersley and McCarthy calculated required sample sizes according to the 
frequency of the susceptibility allele in controls, and the desired power or OR (128). 
The frequency of the TNF –308A allele in the HapMap CEU population (Utah residents 
with northern and western European ancestry from the CEPH collection) is ∼17.56%, 
which is approximately the same percentage as was found in the control group in the 
study by Westphal et al. (2, 23, 130). Hattersley and McCarthy calculated that, for an 
allele frequency of ∼10% in controls, 3066 subjects are needed (or 1533 in each group) 
to achieve a power of 90% to obtain a p-value of 0.05 with an allelic OR of 1.3. For an 
allele frequency of 20%, the required sample size would be 1772 (or 886 subjects per 
group). To obtain smaller p-values, the sample size required increases even further. 
The genetic association studies with a focus on ACD performed so far all had relatively 
small sample sizes.
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Phenotype definition
Definition of the phenotype under investigation is another important factor for the 
quality of a case–control study. Here, we give a suggestion of which phenotype to 
investigate. There are several different types of selective case–control studies, 
which differ in the selection of cases and controls (131). One type of selective case–
control study is that of extreme discordance, and is especially suited to investigate an 
association between a specific allele or genotype and disease. In this type, ‘severely 
affected’ cases are compared with ‘extremely normal’ controls. One suggestion for 
defining ‘severely affected’ cases among patients with ACD would be polysensitization. 
The subject of polysensitization as a model of increased susceptibility has been 
reviewed by Schnuch et al. (124). Polysensitization is defined as being sensitized to 
more than one allergen. We propose that cases should be polysensitized, with at least 
three or more positive PT reaction to unrelated allergens in, for example, the European 
baseline series (132). For controls, we would propose healthy subjects with no history 
of eczema and negative PT results. Depending on which genes are being investigated, 
certain concomitant autoimmune diseases should be considered to constitute an 
exclusion criterion in both groups. Whether these phenotypes are feasible when one 
is trying to obtain a large sample size might be an issue, and there is no definitive 
answer to what is better: a small sample size of phenotypically homogeneous cases, 
or a large sample size of less well-characterized cases (128). A solution to increase 
statistical power could be to perform a meta-analysis of multiple studies that have 
been performed; however, these would need to be sufficiently homogeneous, for 
example similar phenotypes measured with the same criteria. Current studies differ 
too much with respect to the investigated ethnicity, the allergens to which the cases 
are allergic to, and possibly the levels of exposure, for a meta-analysis to be sensibly 
performed.
Which variant(s) to focus on
It is important that the variant under investigation be both functional and biologically 
relevant for the studied disease. The main cells believed to be responsible for TNF 
production and secretion in ACD are keratinocytes, together with epidermal LCs and 
mast cells (47-52). Studies investigating whether TNF –308G>A is functional have 
looked at pre-monocytes, T lymphocytes, and B lymphocytes, and have obtained 
conflicting results. It would appear to be important to investigate whether or not this 
variant is truly functional in keratinocytes and LCs, or in DCs in general.
2
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All studies investigating genetic variants of TNF in ACD focused solely on TNF –308G>A, 
except for the study by Westphal et al.(1), which also looked at TNF –238G>A (18). This 
is most likely because TNF –308G>A is the most extensively investigated variant in the 
promoter region of TNF. It has the most theoretical support for being functional, as it 
is located within a binding site for a transcription factor (133). Another option would 
be to focus on extended haplotypes, including multiple variants in the TNF promoter 
region, as seen in the study by Bouma et al. (122). However, an important drawback 
of this approach is that it causes an increase in degrees of freedom with an increasing 
number of haplotypes, leading to loss of power (115).
CONCLUSION
TNF plays an important role in the sensitization phase of ACD by inducing LC 
maturation and subsequent migration to draining lymph nodes. It also plays a role 
in the elicitation phase by exerting a cytotoxic effect and by promoting migration of 
circulating primed lymphocytes to the skin. There are many SNVs in the promoter 
region of TNF, of which some are believed to be functional. The most extensively 
investigated SNV is TNF –308G>A. There is no general consensus yet on whether 
it is functional, a marker for increased TNF production through genetic linkage 
disequilibrium, or neither. Despite this fact, it has been the focus of many case–control 
studies in many different diseases and conditions. Seven studies have investigated the 
association between TNF –308G>A and ACD, with varying results. For future studies 
on this subject, a consensus should be reached on which phenotype to investigate, in 
order to enable the performance of future meta-analyses, so meaningful conclusions 
can be drawn. We suggest that polysensitized subjects are compared with healthy 
controls with preferably comparable exposure, although the feasibility of such a design 
in terms of sample size remains an issue.
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Allergic contact dermatitis caused by p-phenylenediamine (PPD) is a health concern 
for hair dye users. Because of its lower sensitization potency, the PPD derivative 2-
methoxymethyl-p-phenylenediamine (ME-PPD) has been developed as an alternative 
hair dye for primary prevention. However, cross-elicitation responses can occur in 
PPD-allergic subjects.
Objectives
To compare cross-elicitation responses to ME-PPD in open use and diagnostic patch 
testing of PPD-allergic subjects with hair dye-related allergic contact dermatitis.
Methods
Reactions to ME-PPD were investigated in 25 PPD-allergic subjects by performing 
(1) 45-minute open use testing with a hair dye containing 2.0% of either ME-PPD or 
PPD, and (2) patch testing with increasing ME-PPD concentrations (0.1%–2.0% pet.).
Results
Of the 25 PPD-allergic subjects, 21 (84%) reacted to open use testing with a hair 
dye containing 2.0% PPD, and testing with 2.0% ME-PPD led to cross-elicitation 
in 12 (48%). When patch tested with increasing ME-PPD concentrations, 13 (52%) 
cross-reacted at 0.1% (lowest dose) and 21 (84%) at 2.0% (highest dose), indicating 
decreased reactivity as compared with published PPD dose-response data.
Conclusion
In line with the decreased cross-reactivity of ME-PPD in hair dye open use testing, 
PPD-allergic subjects show an attenuated cross-elicitation dose response to ME-PPD 
in patch testing.
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INTRODUCTION
p-Phenylenediamine (PPD, 1,4-diaminobenzene, CAS no. 106-50-3) is a hair dye 
molecule with good hair-colouring performance, but is also an important contact 
allergen associated with hair dye-related allergic contact dermatitis. Historically, 
attempts have been made to develop hair dye molecules that keep the balance between 
good hair-dyeing performance and sufficiently low skin sensitization potency to avoid 
induction under use conditions. The resulting PPD derivatives were toluene-2,5-diamine 
(TDA, 1,4-diamino-2-methylbenzene, CAS no. 95-70-5; synonym p-toluenediamine) 
and hydroxyethyl-p-phenylenediamine sulfate (HE-PPD, CAS no. 93841-25-9): TDA 
has good performance, but may lead to the induction of sensitization under use 
conditions, owing to its strong to extreme sensitization potency, as determined with 
the murine local lymph node assay (LLNA) and the guinea-pig maximization test. 
HE-PPD has limited performance and strong sensitization potency (as determined 
with the LLNA).(1-3)
More recently, 2-methoxymethyl-p-phenylenediamine (ME-PPD, CAS no. 
337906-36-2) has been developed by introducing a methoxymethyl side-chain into 
PPD, resulting in a hair-dyeing performance equivalent to that of PPD and TDA. 
Analysis of the skin sensitization potency of ME-PPD in in vitro studies indicated a 
lower skin sensitization potency than that of PPD and TDA. In vivo, the LLNA showed 
a moderate skin sensitization potency of ME-PPD. Therefore, induction of skin 
sensitization has been considered to be unlikely when ME-PPD is used to replace PPD 
or TDA in hair dyes.(3)
Accordingly, ME-PPD has been developed for the prevention of skin sensitization, and 
not for individuals who have already been sensitized to other hair dye precursors, such 
as PPD and TDA. However, it is known that many individuals who are allergic to PPD 
or TDA continue to dye their hair, and they may use hair dye products that contain 
ME-PPD instead of PPD or TDA. (4) Therefore, the current study investigated cross-
elicitation responses to an ME-PPD-containing hair dye under open use test conditions 
in PPD-allergic individuals with a history of hair dye-related allergic contact dermatitis. 
Furthermore, their cross-elicitation dose response to ME-PPD was determined under 
diagnostic patch test conditions, and compared with PPD elicitation dose-response 
data previously published by Søsted et al.(5)
3




Twenty-five adult individuals with a previously documented positive patch test reaction 
to PPD 90 μg/cm2 (TRUE Test; SmartPractice Europe, Reinbek, Germany) or PPD 
1% pet. (Chemotechnique Diagnostics, Vellinge, Sweden) and a history of allergic 
contact dermatitis caused by hair dye were included. The exclusion criteria were as 
follows: skin anomalies or active dermatitis on the volar aspects of the forearms or on 
the back, and the use of immunosuppressive medication (including, but not limited 
to, oral corticosteroids, cyclosporine, azathioprine, and methotrexate) during the 4 
weeks prior to inclusion. All tests were performed at the Department of Dermatology, 
University Medical Center Groningen, The Netherlands, and assessed according to 
ESCD guidelines on day (D) 2, D3, and D7.(6) Of the 25 subjects included in this present 
study, 8 had participated in a previous ME-PPD open use test study.(7) In the previous 
study, 6 of these 8 reacted positively to ME-PPD under hair dye conditions (open use 
test), and the other 2 did not. The study was approved by the local ethics committee 
of the University Medical Center Groningen.
Open use testing
Open use tests were performed on the volar aspects of both forearms. The patch test 
preparations, the vehicle (Koleston Perfect formula without fragrance) containing 
the hair dye precursors (PPD 4.0% or ME-PPD 4.0%, free base) and couplers (1.9% 
2-methyl-5-hydroxyethylaminophenol; 3.6% 2-methylresorcinol) and the hydrogen 
peroxide-based developer solution (6.0% wt/wt Welloxon) were provided by Procter 
& Gamble Service (now represented by Coty, Darmstadt, Germany). The couplers 
were selected on the basis of their negligible sensitization potency as determined 
with the LLNA, each with an EC3 greater than 50. (8, 9) The hair dye test product 
was always freshly prepared by mixing the tint (containing PPD or ME-PPD, and the 
couplers) with the hydrogen peroxide solution by use of a small wooden stick (1:1, 90 
μL each), resulting in solutions containing 2.0% PPD and 2.0% ME-PPD, respectively. 
A dye-free test product, also mixed with hydrogen peroxide as described above, was 
used as a negative control. A 100-μL aliquot of the final PPD-containing or ME-PPD-
containing product was applied directly to the volar forearm with a micropipette in a 
3.8-cm2 area marked by a round adhesive tape with a diameter of 22 mm. PPD was 
tested on the volar aspect of 1 arm, and ME-PPD and the negative control were tested 
on the other, so that an extreme positive reaction to PPD would have no influence on 
a possible elicitation response to ME-PPD. The contours of the round adhesive tape 
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were marked with a Chemo Skin Marker (Chemotechnique Diagnostics), in order to 
enable recognition of the test site at follow-up. The test areas were rinsed off  with 
water after 45 minutes of application to simulate hair-dyeing conditions.
Diagnostic patch testing
Patch testing was performed on the back with ME-PPD 0.1%, 0.25%, 0.5%, 1.0% and 
2.0% pet. in Van der Bend chambers (Van der Bend, Brielle, The Netherlands), fi xed 
with Fixomull Stretch (BSN Medical, Hamburg, Germany). In the fi rst 10 subjects, ME-
PPD was only patch tested in concentrations of 0.5%, 1.0% and 2.0% pet., after which 
the protocol was adapted to also include patch testing with ME-PPD 0.1% and 0.25% 
pet. The fi rst 10 subjects were recalled for testing with these 2 concentrations, and all 
except for 2 subjects were additionally tested.
Evaluation and statistics
Responses to the open use test were recorded at 60 minutes after application (15 
minutes after rinsing of the area), and, together with the patch test readings, on 
D2, D3, and D7, and graded according to ESCD guidelines.(6) For data analysis, the 
maximum open use test/patch test reactions were aggregated as the outcome.
Results are presented as the proportion of PPD-allergic patients who responded with 
a cross-elicitation response to ME-PPD as indicated by a positive patch test reaction 
for each dose. Binary logistic regression was performed, and a dose-response curve 
was plotted in order to investigate the threshold dose for cross-elicitation for diff erent 
proportions of the study population. The probability of a positive response P(x), 
where x represents the natural logarithm of the dose, for a given dose is as follows:
The eff ective dose (EDy), that is, the hypothetical dose at which a proportion y of the 
25 PPD-positive patients have a positive cross-elicitation response to ME-PPD, was 
calculated for 50%, 75% and 90% of the patients. For example, ED50 is the expected 
dose at which 50% of the 25 PPD-positive patients will have a positive response to 
ME-PPD. The confi dence interval (CI) for each EDy is given. The dose-response curve 
is presented for all 25 PPD-positive patients, and compared with the dose-response 
curve for PPD as reported by Søsted et al. (5) Dose-response curves were generated by 
3
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the use of graphpad prism 7.03, with non-linear regression with curve fitting (GraphPad 
Software, La Jolla, California).
RESULTS
Cross-elicitation response to ME-PPD-containing hair dye in open use 
testing
The strengths of the original patch test reactions to PPD were weak (+) positive (n = 
5), strong (++) positive (n = 12), and extreme (+++) positive (n = 8). The characteristics 
of the 25 subjects are shown in Table 1. A detailed overview of the individual open 
use and diagnostic patch test results obtained from the 25 PPD-allergic subjects is 
shown in Table 2. Twelve of the 25 subjects (48%, 95%CI: 28%-68%) showed cross-
elicitation reactions to the open use test with hair dye containing 2.0% ME-PPD 
(Table 2), whereas 13 of 25 (52%) showed no cross-elicitation response. In the 12 of 
25 subjects reacting to ME-PPD, the strengths of the reactions to the ME-PPD open 
use test were generally weaker than those to the 2.0% PPD open use test, with 6 of 
12 having weak positive reactions, 5 of 12 having strong positive reactions and 1 of 12 
having an extreme positive reaction to ME-PPD, as compared with 2 of 21 having weak 
positive reactions, 10 of 21 having strong positive reactions and 9 of 21 having extreme 
positive reactions to PPD. Correspondingly, 11 of 25 had reduced strengths of reaction 
to the ME-PPD open use test as compared with the PPD open use test, not counting 2 
subjects who showed doubtful reactions to PPD and did not react to ME-PPD.
Table 1. overview of subject included in the present study on cross-elicitation to 
ME-PPD in PPD positive individuals
Total n=25
Original PPD patch test reaction
 +  5 (20.0 %)
 ++ 12 (48.0%)
 +++  8 (32.0%)
Tested with all 5 ME-PPD patch test conc. 23
Only tested with ME-PPD 0.5%; 1.0%; 2.0% 2
Gender
 male/female  2/23
Age in years, mean (range) 50.2 yrs (18-71 yrs)
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Table 2. Individual results of all 25 PPD allergic individuals to 45 min open use test exposure 
to hair dyes containing 2.0% of either PPD or ME-PPD and patch test results with increasing 








2.0% 2.0% 0.1% 0.25% 0.5% 1.0% 2.0%
1 + +++ ++ ++ +++ +++ +++ +++
2 + ?+ ?+ - - + ++ ++
3 + + - ?+ ?+ - - -
4 + +++ - - - - + ++
5 + ?+ - - - ?+ ?+ ?+
6 ++ ++ + + + + + +
7 ++ ++ + ++ ++ ++ +++ ++
8 ++ +++ + NT NT ++ ++ +++
9 ++ ++ - ++ +++ ++ +++ +++
10 ++ ++ + ++ ++ ++ ++ +++
11 ++ ++ + ? + + ++ +++
12 ++ ++ - - - - - +
13 ++ ?+ - - - - - -
14 ++ + - ?+ ?+ ?+ + ++
15 ++ ++ + + ++ ++ ++ ++
16 ++ ++ ?+ - - + + +
17 ++ - - - - - - -
18 +++ +++ +++  NT NT +++ +++ +++
19 +++ ++ - - ?+ + + +
20 +++ +++ ++ +++ +++ +++ +++ +++
21 +++ ++ - + ++ ++ ++ ++
22 +++ +++ - + ++ ++ +++ +++
23 +++ +++ ++ ++ +++ +++ +++ +++
24 +++ +++ ++ +++ +++ +++ +++ +++
25 +++ +++ ++ ++ ++ +++ +++ +++
‘-‘, negative patch test reaction; ‘?+’, doubtful patch test reaction, considered negative in 
statistical analyses; ‘NT’, not tested.
3
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Figure 1A shows the distribution of the non-responsive subjects and cross-reacting 
subjects in ME-PPD open use testing against the strengths of the original diagnostic 
patch test reactions to PPD. The percentage of subjects cross-reacting to the ME-PPD 
open use test increased with the strength of the original PPD patch test reaction: 
20% (1/5) with +, 50% (6/12) with ++, and 62.5% (5/8) with +++. In contrast, elicitation 
responses to identical open use tests with 2.0% PPD hair dye were as follows: 60% (3/5) 
with +, 83.3% (10/12) with ++, and 100% (8/8) with +++ (Figure 1B), giving an elicitation 
response rate of 84% (21/25) PPD-allergic subjects.
Furthermore, the reaction strength of the cross-elicitation response was reduced in 11 
of the 12 PPD-allergic subjects who reacted to both PPD and ME-PPD open use tests; 
when plotted against their PPD patch test reaction strengths, reduced cross-elicitation 
reaction strengths occurred in all subgroups: 1 of 1 with +, 6 of 6 with ++, and 4 of 5 
with +++ (Table 2).
None of the subjects showed immediate reactivity to either ME-PPD or PPD hair 
dye open use tests, as no positive reactions were seen 60 minutes after application. 
No positive reactions to the open use test with the vehicle (negative control) were 
seen. Eight of the 25 subjects had previously undergone an open use test with ME-
PPD.7 None of these 8 subjects had been exposed to ME-PPD hair dye in any other 
manner prior to participation in the present study. The 2 who did not react to the 
ME-PPD open use test in the previous study did not react to ME-PPD in the present 
study, suggesting that they were not actively sensitized in the previous study.
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Figure 1.
(A), Percentages of p-phenylenediamine (PPD)-sensitized subjects with either negative or 
positive reactions to 2.0% 2-methoxymethyl-p-phenylenediamine (ME-PPD) following 45 
minutes of exposure in hair dye open use testing, plotted against the strengths of their patch 
test reactions to PPD. (B), Percentages of PPD-sensitized subjects with either negative or 
positive reactions to 2.0% PPD following 45 minutes of exposure in hair dye open use testing, 
plotted against the strengths of their patch test reactions to PPD
3
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Dose-dependent cross-elicitation reactions to ME-PPD in diagnostic 
patch testing
Figure 2 provides a summary of the relative frequencies of cross-elicitation reactions to 
increasing ME-PPD doses in diagnostic patch testing as compared with the rate of open 
use cross-elicitation reactions to 2.0% ME-PPD and the rate of open use elicitation 
reactions to 2.0% PPD. Cross-elicitation responsiveness to increasing concentrations of 
ME-PPD (from 0.1% to 2.0% pet.) was tested in PPD-allergic subjects by patch testing 
(23 were tested with all concentrations, and 2 were only available for the 3 highest 
concentrations). The percentage of subjects who showed a positive cross-elicitation 
reaction to ME-PPD 0.1% pet. was 52% (12/23, 95%CI: 32%-72%), and increased to 84% 
(21/25, 95%CI: 70%-98%) when they were exposed to ME-PPD 2.0% pet. A percentage 
of 84% also reacted to the open use tests with 2.0% PPD, although these were not 
exactly the same subjects; of the 21 subjects with an elicitation response to 2.0% 
ME-PPD, 20 showed a reaction to the open use test with 2.0% PPD, and vice versa 
(Table 2). No irritant patch test reactions were seen.
Figure 2.
Proportions of response of p-phenylenediamine (PPD)-sensitized subjects (n = 25) to 45 
minutes of open use test exposure to hair dye containing 2% of either PPD (green bar) or 2-
methoxymethyl-p-phenylenediamine (ME-PPD) (dark violet bar), and to 48 hours of patch 
test exposure to increasing ME-PPD concentrations (violet bars)
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Figure 3 shows the distribution of the PPD-allergic subjects with positive cross-
elicitation reactions to the increasing concentrations of ME-PPD against the strength 
of the original PPD diagnostic patch test reactions. The data indicate a clear correlation 
of increasing cross-reactivity to ME-PPD and increasing strength of PPD reactivity; 
that is, all subjects with an extreme (+++) positive reaction to PPD had a positive cross-
elicitation reaction to ME-PPD at a concentration of 0.5% and above.
Figure 3.
Cross-elicitation reactions of p-phenylenediamine (PPD)-allergic subjects to patch testing 
with increasing 2-methoxymethyl-p-phenylenediamine (ME-PPD) concentrations plotted 
against the strengths of their patch test reactions to PPD
On the basis of the patch test results with ME-PPD, a cross-elicitation dose-response 
curve was plotted for the 25 PPD-allergic subjects (Figure 4, blue dashed line) and 
compared with a previously published elicitation dose-response curve for PPD in 15 
PPD-allergic patients (Figure 4, grey line) from Søsted et al.5 The curve for ME-PPD 
was shifted further towards higher concentrations, indicating that, over the entire 
concentration range, higher doses are needed to generate a response rate comparable 
to that of PPD. The expected patch test doses (EDy values) at which 50%, 75% and 
90% of PPD-allergic subjects are estimated to develop a positive cross-reaction to 
3
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ME-PPD are shown in Table 3. The ED50 for ME-PPD was calculated to be ∼0.11%. 
When we used the data from Søsted et al in our calculation, the ED50 was 0.03% for 
PPD, in line with the ED50 value reported by Søsted et al.(5)
Figure 4.
Cross-elicitation dose-response curve for 2-methoxymethyl-p-phenylenediamine (ME-
PPD) patch testing. The blue line and circles represent the dose response to ME-PPD in 
25 p-phenylenediamine (PPD)-allergic patients; the grey line and squares represent the 
dose response to PPD in the 15 PPD-allergic patients (taken from Søsted et al (5)). Each 
symbol corresponds to the number of subjects with a positive reaction at the concentration 
indicated
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Table 3: Calculated values of Effective Dose (ED)y for ME-PPD cross-elicitation reactions 
observed in PPD allergic subjects (n=25) with 95% confidence intervals compared to PPD 
elicitation dose response














ED50 0.11 0.03 1.49 0.03 0.01 0.10
ED75 0.72 0.32 1.63 0.10 0.04 0.51
ED90 4.94 0.75 32.36 0.28 0.10 3.40
1 Values for EDy for PPD 2.0% pet. patch test were taken from Sosted et al, 2006. Values 
were transferred from ppm to %.
DISCUSSION
In this study, we have analysed cross-elicitation responses to ME-PPD in 25 PPD-
allergic individuals by comparing their responses to open use tests simulating hair 
dyeing, and to diagnostic patch tests with increasing ME-PPD concentrations.
Open use testing with 2.0% ME-PPD in a hair dye showed cross-elicitation in 12 of the 
25 PPD-allergic subjects, that is, in 48% (Figure 1A). In contrast, open use testing with 
2.0% PPD (Figure 1B) showed an elicitation response in 84% (21/25). Furthermore, the 
reaction strength of the cross-elicitation response was reduced in 11 of the 12 (92%) 
PPD-allergic subjects who reacted to both PPD and ME-PPD open use tests (Table 2). 
This is in line with data from previous cross-elicitation studies,(7, 10) indicating partial 
cross-reactivity to ME-PPD under hair dye use conditions. In those previous studies, 
the response was ∼30% with an exposure time of 30 minutes. The observed higher 
response of 48% to the 45-minute ME-PPD hair dye open use test in the present study 
confirms previous findings with PPD showing that an increase in the exposure time 
from 30 to 60 minutes increased the amount available for (cross-)elicitation by >2-fold.
(11)
We also investigated whether non-responsiveness to ME-PPD open use tests in PPD-
allergic subjects is dependent on the limited 45-minute exposure time. Exposure to 
increasing ME-PPD patch test doses for 48 hours under occlusion showed a dose-
3
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dependent increase in the cross-elicitation response: at the lowest patch test dose of 
0.1%, the response of 52% was similar to that with hair dye open use testing with 2.0% 
ME-PPD (48%), indicating that a comparable immune stimulus can be provided with 
either short high-dose exposure or longer low-dose exposure. This interpretation is 
further supported by similar cross-elicitation reaction strengths in 5 of the 9 subjects 
(55.0%) who showed elicitation reactions to both 0.1% patch tests and 2.0% open 
use tests.(12)
With increasing patch test doses up to 2.0%, an increasing number of PPD-allergic 
subjects cross-reacted to ME-PPD, with 84% showing positive reactions at the 
maximum tested dose of 2.0% (Figure 1). These findings indicate that the majority of 
PPD-allergic patients are probably able to cross-react to ME-PPD, provided that the 
dose is high enough and/or the exposure time is long enough. In line with the responses 
to open use testing (Figure 1A), a higher percentage of the extreme PPD responders 
than of the weaker PPD responders cross-reacted at lower ME-PPD patch test doses. 
A possible explanation might be a higher number of PPD-specific memory T cells being 
present in the extreme PPD responders.
On comparison of the ME-PPD cross-elicitation patch test dose response obtained in 
the present study with the patch test dose response to PPD obtained in 15 PPD-allergic 
subjects,(5) the curve for ME-PPD is shifted further towards higher concentrations 
(Figure 3). In other words, over the entire dose range, higher ME-PPD concentrations 
are needed to generate a response rate comparable to that seen with PPD. This is also 
indicated by the 4-fold increased ED50 value for ME-PPD vs PPD, and is in line with 
the hypothesis that ME-PPD is a less potent allergen.(3, 5)
The measured exposure level (MEL) (representing the concentration that is available 
to the skin) of the applied PPD patch dose of 1.0% for 48 hours is 200 μg/cm2. This is 
an order of magnitude higher than the MEL for PPD in hair dye open use conditions 
for 30 minutes, which ranges from 6.8 to 21 μg/cm².(11) This PPD concentration was 
found to be sufficient to elicit a reaction in 84% of PPD-allergic patients. For ME-PPD, 
the MELs for 1.8% applied under hair dye use conditions were 8.75 and 10.21 μg/cm2 for 
30 minutes and 60 minutes, respectively,(3) and were thus similar to the MEL for PPD. 
Consequently, it is reasonable to assume that the MEL for patch test conditions with 
exposure to 2% ME-PPD is at least >10 fold higher and in line with the higher response 
observed in patch testing than in open use testing.
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In agreement with the present results, a study from Kock et al investigating cross-
elicitation reactions to repeated hair dyeing with ME-PPD in PPD-allergic and/or TDA-
allergic individuals showed that 29 of 43 were able to tolerate repeated hair colouring 
with an average of 9 treatments per year.(13) In that study, 9 subjects did not react to 
the initial 45-minute open use test on the forearm, and 7 of them developed allergic 
contact dermatitis symptoms during the first hair colouration with ME-PPD. Together 
with our findings, these data suggest that an individual threshold for cross-elicitation 
to ME-PPD exists in PPD-allergic subjects. We assume that the skin site-specific 
occurrence of the cross-elicitation responses to ME-PPD between forearm and back (in 
the present study) or scalp (in the study from Kock et al (13)) is related to the presence 
of (sufficient) residual memory T cells. Similar findings have been reported for patients 
with allergy to nickel: a rapid response to nickel only occurred after re-exposure to 
nickel on the exact body site that had been previously exposed, and the magnitude 
of the elicitation responses correlated with local recruitment of epidermal CD8+ T 
cells.(14)
In line with previous studies on ME-PPD, our hair dye open use and patch test data 
further support the recommendation for hair dye-allergic individuals to avoid hair 
colouring, because cross-elicitation responses to ME-PPD cannot be excluded.
(7, 10, 13)
Despite intensive investigations, the precise hapten responsible for PPD allergy has 
not been identified.(15) Considering that induction of sensitization with PPD has been 
shown to be dependent on duration of exposure,(16) PPD oxidation to protein reactive 
auto-oxidation products such as Bandrowski’s base may be involved in elicitation.
(17) Furthermore, PPD undergoes N-acetylation when entering the epidermis, and thus 
becomes deactivated.(18) In line with the findings for PPD, both oxidative activation 
of ME-PPD and deactivation by N-acetylation have been described in vitro, and 
human skin has been shown to actively N-acetylate ME-PPD.(3) Correspondingly, the 
structural similarity to PPD and the consistent activation and deactivation mechanisms 
suggest that, in PPD-allergic individuals, the concentration-dependent immune 
response to ME-PPD is based on the partial inability of T cells to differentiate between 
PPD-derived and ME-PPD-derived haptens.(10)
3




Cross-elicitation analysis in PPD-allergic individuals indicates that ME-PPD is a less 
potent allergen than PPD under simulated hair dye use conditions and under diagnostic 
patch test conditions. The cross-reactivity shows a clear dose dependency, with 
increasing cross-reactivity to ME-PPD being seen at higher patch test doses. ME-
PPD can only be considered to be an alternative hair dye for primary prevention of 
sensitization.
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Persistence of contact allergy: a 
retrospective analysis
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CHAPTER 4





Studies have shown that not all positive patch test reactions are reproducible upon 
retesting, that is, persistent. Non-persistent reactions might represent initial false-
positive reactions, meaning that patients might unnecessarily avoid allergens.
Objectives
To investigate the occurrence of both persistent and non-persistent patch test 
reactions, to explore possible explanations, and to investigate whether allergen-
specific differences exist.
Methods
A retrospective analysis was performed on patients who were patch tested at least 
twice between 1 January 1995 and 31 October 2016, with at least one positive patch 
test reaction to an allergen that had been retested. Both univariable and multivariable 
analyses were performed to investigate the influence of several factors on persistence.
Results
Of 274 retested positive reactions in 119 patients, 183 (66.8%) reactions remained 
positive. The strongest predictor for non-persistence in both univariable and 
multivariable analyses was strength of the first patch test, with weak positive reactions 
being significantly less persistent. Regarding allergen groups, metals and fragrances 
were less persistent than other allergens.
Conclusion
Weak positive reactions have a low persistence rate, and the dermatologist should 
be conservative in advising the patient on avoidance of these allergens, especially if 
clinical relevance is uncertain.
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There is an ongoing debate within the contact dermatitis research community on 
whether contact allergy, once acquired, is persistent or can be lost. Multiple studies 
spanning decades have investigated the persistence of positive patch test reactions and 
the loss of sensitization, and still no conclusion has been reached (1–11). Diagnosing 
a patient with allergic contact dermatitis is based on patch testing, which is the gold 
standard for diagnosing contact allergy. The most common methods with which patch 
test reactions are evaluated are according to the criteria of the ICDRG and those of the 
ESCD, respectively (12). Every positive patch test reaction has to be evaluated with 
regard to whether it is currently relevant, that is, the patient has current exposure to 
the allergen at the site of the dermatitis, or of past relevance. Patients receive oral 
information regarding their positive patch test reactions and what to avoid, and are 
given written information. Studies have shown that patients’ ability to remember 
the patch test results is mediocre at best, and that they might be inclined to avoid 
every allergen to which they had a positive patch test reaction, which can have a 
major impact on a patient’s job or lifestyle (13, 14). A positive patch test reaction can 
therefore have substantial consequences, and it is important to know (i) the odds of 
a positive reaction being either a false positive or not clinically relevant, (ii) whether 
a patient with a contact allergy can become tolerant, and (iii) whether any allergen-
specific differences exist. To explore the issue of non-persistent patch test reactions, 
we investigated patients who have been patch tested twice or more at our department.
METHODS
We performed a retrospective search on our patch test database from 1 January 1995 
to 31 October 2016 for patients who underwent patch testing at least twice, with at 
least one positive patch test reaction to an allergen that had been retested in the same 
concentration and the same vehicle, with no restriction on patch test series/allergen 
or age. If a patient had been patch tested more than twice, only the results of the last 
two patch tests were evaluated. All patients were tested with at least a baseline series, 
consisting of TRUE Test® (SmartPractice Europe, Reinbek, Germany) with additional 
investigator-loaded allergens (Chemotechnique, Vellinge, Sweden), tested in Van der 
Bend square chambers (Van der Bend, Brielle, The Netherlands). The composition of 
this baseline series has changed over time, having been adjusted to trends detected 
in epidemiological data. All patch tests were read by experienced dermatologists 
according to the ICDRG/ESCD criteria, with the possible outcomes being: negative, 
irritant, doubtful (?+), weak positive (+), strong positive (++), and extreme positive (+++). 
4
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Readings were performed on day (D) 3 and D7 by one of two trained dermatologists. 
For the present analysis, the maximum patch test reactions of these two readings were 
aggregated as the patch test outcome. Furthermore, no distinction was made between 
doubtful and irritant reactions, and these were counted as negative when persistence 
of contact allergy was calculated. As a general rule, patch testing is not performed at 
our department in patients receiving oral immunosuppressive therapy, and a wash-
out period of at least five half-lives is adhered to before patch testing is performed. 
Besides patch test reactions, other variables that were analysed were: age at second 
patch test, sex, history of atopic dermatitis, season in which the patient was patch 
tested (‘warm season’, ranging from April to September; and ‘cold season’, from 
October to March), years elapsed between the two patch tests, and the patch test 
system (TRUE Test® or investigator-loaded). Persistence is reported for the 12 most 
frequently tested allergens and for groups of allergens as reported in Table 1.
Table 1. Overview of the allergen groups used for logistic regression analysis, and 
composition of each group.
Allergen group
Metals Cobalt chloride, mercury, nickel sulfate, and potassium dichromate
Preservatives Bronopol, Bioban P1487, MCI/MI, diazolidinyl urea,dichlorophene, 
formaldehyde, imidiazolidinyl urea, MDBGN, n-methylol 
chloroacetamide, quaternium 15, and sodium omadine
Fragrances FM 1, FM 2, myroxylon pereirae (Balsam of Peru), lemon grass oil, HICC, 
orange oil (citrus dulcis)
Rubbers Black rubber mix, carba mix, MBTS, dipentamethylenethiuram disulfide, 
mercapto mix, MBT, MOR,
N-Cyclohexyl-2-benzothiazolesulfenamide, TMTD, TMTM, thiuram mix
Dyes/colours 4-Aminoazobenzene, disperse blue 124, disperse orange 3, PPD, TDA
Topical 
medicaments
Amerchol L 101, caine mix, compositae mix, oleamidopropyl 
dimethylamine, neomycin sulfate, parthenolide, propylene glycol, 
quinoline mix, sesquiterpene lactone mix
Corticosteroids Budesonide, hydrocortisone-17-butyrate, methyl prednisolone, 
tixocortol-pivalate, triamcinolone acetonide
MCI/MI, methylchloroisothiazolinone/methylisothiazolinone; MDBGN, methyldibromo 
glutaronitrile; FM 1, fragrance mix 1; FM 2, fragrance mix 2; HICC, hydroxyisohexyl 3-cyclohexene 
carboxaldehyde (lyral); MBTS, dibenzothiazyl disulfide; MBT, mercaptobenzothiazole; 
MOR, morpholinyl mercaptobenzothiazole; TMTD, tetramethylthiuram disulfide; TMTM, 
tetramethylthiuram monosulfide; PPD, para-phenylenediamine; TDA, 2,5-toluenediamine
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Statistics
Persistence is given as relative frequencies together with their 95% confidence 
interval. The chi²-test or Fisher’s exact test was used to analyse differences between 
persistence proportions. Logistic regression was performed to analyse the influence 
of the documented independent variables on the persistence of a positive patch test 
reaction. Both univariable and multivariable backward regression analyses were 
performed. The influence of type of allergen was also included in these analyses, and 
allergens were grouped on the basis of chemical structure, cross-reactivity, and co-
sensitization, resulting in seven groups: metals, preservatives, fragrances, rubbers, 
dyes/colours, topical medicaments, and corticosteroids (Table 1). Statistical analyses 
were performed with SPSS v.23 (IBM) and Excel 2013 (Microsoft).
RESULTS
Overall, 119 patients (66.4% female)were included in the analysis, with 274 initial 
positive reactions to an allergen that was retested in a second patch test. The mean 
age at the first patch test was 38.9±13.7 years, and that at the second patch test was 
46.2±14.6 years. Of the 274 positive reactions, 183 (66.8%) remained positive upon 
retesting, 14 (5.1%) became doubtful, 1 irritant, and 76 (27.7%) became negative (Table 
2). Of these 76 initially positive reactions that became negative, 64 (84.2%) were weak 
positive (+) reactions, 10 (13.2%) were strong positive (++) reactions [3 to nickel sulfate, 
3 to p-phenylenediamine (PPD), and 1 each to mercaptobenzothiazole, neomycin 
sulfate, cobalt chloride, and Disperse Orange 3], and 2 (2.6%) were extreme positive 
(+++) reactions (to zinc dimethyl dithiocarbamate 1% pet. and tixocortol 21-pivalate 
0.1% pet., resp.). All 15 reactions that became either doubtful or irritant reactions upon 
retesting were initially weak positive (+) reactions. Conversely, of the 199 initially weak 
positive reactions (+), 120 (60.3%) remained positive, of the 56 initially strong positive 
reactions (++), 46 (82.1%) remained positive, and of the 19 initially extreme positive 
reactions (+++), 17 (89.5%) remained positive. 
4
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Table 2. Reaction pattern of the second patch test stratified by strength of the original 
patch test.
Patch test 2 Total
negative + ++ +++ doubtful irritant
Patch test 1 + 64 70 48 2 14 1 199
++ 10 16 23 7 0 0 56
+++ 2 1 7 9 0 0 19
Total 76 87 78 18 14 1 274
The persistence rates for the different variables that were analysed are shown in Table 
3. Some of the findings are highlighted here. Of the 274 retested positive reactions, 
195 were to allergens in TRUE Test®, and the remaining 79 were to investigator-loaded 
allergens. The persistence rates were 69.2% for TRUE Test® allergens and 60.8% for 
investigator-loaded allergens (p=0.18). Of the 119 patients, 83 (69.7%) had (a history 
of) atopic dermatitis. Of the 274 retested reactions, 195 (71.2%) were in patients with 
past or current atopic dermatitis. The persistence rate of positive patch test reactions 
in atopic dermatitis patients was 64.6%, as compared with 72.2% in patients without 
(a history of) atopic dermatitis (p=0.26). The influence of time elapsed between the 
two patch tests was also assessed, and three groups of patients were compared: retest 
within 3 years, retest between 3 and 8 years, and retest after >8 years. Persistence 
rates for these three groups were, respectively, 64.4%, 73.3%, and 61.5% (p=0.20). 
Moreover, seasonal influence on persistence was examined. The highest persistence 
rate was found in patients who were tested both times in a warm season (71.9%), and 
the second highest was found in patients tested both times in a cold season (67.5%). 
Patients who were tested in a different season had lower persistence rates: 64.5% for 
warm to cold, and 63.9% for cold to warm. The influence on persistence of the season 
during which patch testing took place was, however, not significant (p=0.77).
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Table 3. Persistence rates for all analyzed variables
Persistent reactions
Total (n) N (%) 95% CI (%)
Total 274 183 (66.8) 60.9-72.3
Sex male 69 45 (65.2) 52.8-76.3
Female 205 138 (67.3) 60.4-73.7
Age at second 
patch test
<40 years 95 59 (62.1) 51.6-71.9
≥40 years 179 124 (69.3) 62.0-75.9
TRUE Test® vs 
Chamber Loaded
TT 195 135 (69.2) 62.2-75.6
CL 79 48 (60.8) 49.1-71.6
Atopic dermatitis non atopic 79 57 (72.2) 60.9-81.7
Atopic 195 126 (64.6) 57.5-71.3
Strength of the 
first patch test
+ 199 120 (60.3) 53.1-67.2
++ 56 46 (82.1) 69.6-91.1
+++ 19 17 (89.5) 66.9-98.7
Metals other allergens 201 138 (68.7) 61.8-75.0
Metals 73 45 (61.6) 49.5-72.8
Preservatives other allergens 233 151 (64.8) 58.3-70.9
Preservatives 41 32 (78.0) 62.4-89.4
Fragrances other allergens 246 168 (68.3) 62.1-74.1
Fragrance 28 15 (53.6) 33.9-72.5
Rubbers other allergens 230 149 (64.8) 58.2-70.9
Rubbers 44 34 (77.3) 62.2-88.5
Dyes other allergens 241 161 (66.8) 60.5-72.7
Dyes 33 22 (66.7) 48.2-82.0
Topicals other allergens 252 169 (67.1) 60.9-72.8
Topicals 22 14 (63.6) 40.7-82.8
Corticosteroids other allergens 265 179 (67.5) 61.5-73.1
Corticosteroids 9 4 (44.4) 13.7-78.8
Years between 
patch test
retest within 3 years 82 53 (64.6) 53.3-74.9
restest >3 years up to 8 years 101 74 (73.3) 63.5-81.6
retest >8 years 91 56 (61.5) 50.8-71.6
Season warm to warm 57 41 (71.9) 58.5-83.0
cold to cold 83 56 (67.5) 56.3-77.4
warm to cold 62 40 (64.5) 51.3-76.3
cold to warm 72 46 (63.9) 51.7-74.9
4
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To assess whether there was variation between allergens, persistence was calculated 
for individual allergens and for grouped allergens (Tables 3 and 4). Corticosteroids had 
the lowest persistence rate (44.4%; n=9), and preservatives had the highest persistence 
rate (78.0%, n=41). Fragrances also had a relatively low persistence rate (53.6%; n=28). 
The persistence rate for individual allergens ranged from 0.0% to 100.0%, although 
this was mostly a consequence of many allergens having been retested only once. 
However, large variation was seen in the top 12 most frequently retested allergens 
(Table 4), ranging from 35.3% for cobalt (n=17) to 100.0% for potassium dichromate 
(n=11), also indicating strong variation within allergen groups (in this case, metals). 
Table 4. Top 12 of allergens most frequently re-tested
Persistent reactions
Total N (%) 95% CI (%)
Nickel sulfate 200 µg/cm2 44 27 (61.4) 45.5-75.6
Cobalt chloride 20 µg/cm2 17 6 (35.3) 14.2-61.7
Fragrance mix I 430 µg/cm2 14 9 (64.3) 35.1-87.2
p-Phenylene diamine (free base) µg/cm2 13 9 (69.2) 38.6-90.9
Quaternium-15 100 µg/cm2 12 11 (91.7) 61.5-99.8
Potassium dichromate 23 µg/cm2 11 11 (100.0) 71.5-100.0
Carba mix 250 µg/cm2 10 8 (80.0) 44.4-97.5
Colophony 850 (Rosin) µg/cm2 9 7 (77.8) 40.0-97.1
Mercaptobenzothiazole(MBT) 75 µg/cm2 9 5 (55.6) 21.2-86.3
Balsam of peru 800 µg/cm2 8 5 (62.5) 24.5-91.5
Formaldehyde 180 µg/cm2 8 7 (87.5) 47.3-99.7
Thiuram mix 25 µg/cm2 8 7 (87.5) 47.3-99.7
In the univariable logistic regression analysis, only the strength of the first patch test 
reaction reached significance, confirming that strong (++) and extreme (+++) positive 
patch test reactions have higher persistence rates than weak (+) positive patch test 
reactions, with odds ratios (ORs) of, respectively, 3.03 and 5.60. A multivariable model 
was built with all variables included, with backwards elimination, resulting in model 1 
(Table 5). In this model, the strongest significant positive predictor for persistence of a 
positive patch test reaction remained strength of the patch test reaction (++ reaction, 
OR 3.09; +++ reaction, OR 6.55). Atopic dermatitis, metals and the investigator-loaded 
patch test technique were negative predictors, with ORs of, respectively, 0.6, 0.55, 
and 0.53 (significant). Because we were interested in the predictive power of specific 
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allergen groups, a second model was built with the same technique but excluding 
strength of the patch test reaction, as this might overpower the influence of allergen 
groups on persistence. This resulted in a model with three significant negative 
predictors for persistence: the investigator-loaded technique (OR 0.5), metals (OR 
0.48), and fragrances (OR 0.40).
4
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A retrospective analysis of our contact allergy database showed that, when positive 
patch test reactions were later retested, 66.8% remained positive, meaning that >30% 
became negative. This is in line with previous literature (4, 5, 7, 8). As expected, the 
large majority (almost 85%) of these non-persistent reactions were initially weak 
positive (+). One might argue that many or most of these had been false positives, as 
many allergens also have an irritant potential, even though the concentration in which 
allergens are tested is such that the risk of an irritant reaction should be minimal. 
Other possibilities must be considered; the patient could have become tolerant, or the 
threshold for elicitation could have changed. One study by Katsarou et al. investigated 
differences in T cell subsets expressed in persistent reactions as compared with 
diminished or lost reactions, and found that, in persistent reactions, a proliferation 
of CD45RO+/memory cells was seen, whereas in non-persistent reactions CD45RA+/
suppressor-inducer cell proliferation was observed (15). These results support the 
theory that certain patients can be become tolerant. 
Another explanation for a non-persistent positive patch test reaction could be that 
the skin was momentarily more (or less) reactive. One known example of this is the 
excited skin syndrome or angry back (16, 17); however, when this is observed in our 
department, we report these reactions as negative. Experimental studies have also 
shown that the area of skin around a strong or extreme positive reaction has higher 
reactivity, possibly explaining false-positive reactions (18). Neither the amount of 
positive reactions that a patient had during a patch test nor the proximity of reactions 
to other strong/extreme positive reactions were taken into account in the current 
analysis.
There are known factors that can explain variation in individual skin reactivity during 
patch testing, for example hormones and ultraviolet radiation (19–22). Although there 
have been conflicting reports, in general it is believed that the immune response of the 
skin diminishes with ageing (23). Our data, however, show that the persistence rate is 
higher in patients aged≥40 years at the second patch test than in patients aged <40 
years (69.3% versus 62.1%). This might result from chance, as patients aged≥40 years 
are over-represented. Age at second patch test was not significant in the univariable 
regression analysis. The effect of age might be overshadowed by the fact that the most 
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likely reason for retesting is persistent dermatitis, suggesting that senescence of the 
immune system is not evident in these patients.
The persistence rate in patients with atopic dermatitis was lower than that in patients 
without (a history of) atopic dermatitis. Atopic dermatitis was also included in the first 
multivariable regression model, but it was not significant. It is interesting to note that 
atopic dermatitis was no longer included in the second model, in which strength of the 
first patch test reaction was not entered, suggesting that patients with (a history) of 
atopic dermatitis have more stronger patch test reactions that are not persistent than 
patients without atopic dermatitis. Of the 12 initially strong/extreme positive (++/+++) 
reactions that became negative, 11 were in patients with atopic dermatitis (data not 
shown). It has been suggested that strong inflammatory activity of atopic dermatitis 
can decrease the elicitation response in patch testing, leading to a higher chance of 
false-negative reactions (24).
Persistence of a patch test reaction can also depend on the patch test technique used. 
A previous retrospective study focusing solely on patients tested with TRUE Test® 
found a persistence of 66%,which is similar to our results, in which 69.2% of positive 
TRUE Test® reactions were persistent, as compared with 60.8% of investigator-
loaded reactions (7). Reactions to investigator-loaded allergens were significantly 
less persistent in the first multivariable regression model than reactions to TRUE 
Test® allergens, meaning that this difference was independent of the strength 
of patch test reaction. Gollhausen et al. investigated the reproducibility of TRUE 
Test® as compared with allergens tested in Finn Chambers®, and found that, in Finn 
Chambers®, reproducibility was half that in TRUE Test® (25). Ale and Maibach tested 
491 patients with TRUE Test® on both sides of the back, and found a concordance of 
95% (26). This is most likely a direct consequence of the fact that TRUE Test® is more 
standardized, whereas the investigator-loaded technique depends on the investigator, 
and the amount of vehicle containing allergen applied to each chamber might vary, 
except when a micropipette is used for aqueous solutions.
It has been suggested by previous studies that the chance of an irritant or doubtful 
reaction increases in cold and dry weather conditions, therefore increasing the risk of a 
false-positive reading (27, 28). This is more likely for allergens that are also marginally 
irritant, for example formaldehyde, for which the most evidence exists of increased 
odds of questionable and irritant reactions in cold/dry weather (28, 29). Other 
allergens for which this effect might exist are methylchloroisothiazolinone (MCI)/
4
136610_Daan_Dittmar_BNW-def.indd   97 30-7-2019   10:17:04
98
Chapter 4
methylisothiazolinone (MI) and PPD (29). The effect of weather conditions on patch 
test outcome might be stronger for hydrophilic allergens tested in aq. as the vehicle, 
as is the case for formaldehyde and MCI/MI (29). In our results, no influence of season 
on persistence was seen, and the persistence rates for formaldehyde, MCI/MI and PPD 
were all relatively high for cold to warm (81.8%, n=9/11) and relatively low for warm 
to cold (62.5%, n=5/8), which is in contrast to what one would expect on the basis of 
previous studies (28, 29). One possible explanation might be that formaldehyde and 
MCI/MI were tested in a povidone gel instead of aq. A more likely explanation is that, 
for all three allergens, only a few of the reactions were initially tested in a cold season 
and subsequently retested in the summer. It must also be considered that weather 
conditions in central Europe vary, and that the dichotomous distribution of ‘cold’ and 
‘warm’ seasons is a very crude and possibly inaccurate approximation of actual weather 
conditions (28). This is, to our best knowledge, the first time that separate allergen 
groups have been compared with respect to the persistence of positive patch test 
reactions. In the second multivariable regression model, excluding strength of the 
first patch test reaction, metals and fragrances were significantly less persistent than 
other allergens. For metals, this effect appears to be mostly determined by nickel 
(persistence rate of 61.4%), as this gave the majority (60.3%) of all metal reactions. 
In previous studies, the persistence rate of nickel allergy ranged from 54% to 87% (1, 
5, 30, 31). Cobalt had a very low persistence rate (35.3%), which is lower than seen in 
previous reports, in which the persistence rate was also on the low side, ranging from 
47% to 57% (15, 31). Potassium dichromate, on the other hand, had a 100% persistence 
rate (n=11), as compared with a previously reported persistence rate of 63–79%(15, 32). 
An easy explanation for the low persistence rate of cobalt would be the high proportion 
of weak positive reactions (15/17): however, 7 of the 11 retested reactions to potassium 
dichromate were also weak positive (data not shown). There is no obvious explanation 
for why metals would have a low persistence rate as compared with other allergens. 
A possible explanation could be tolerization through oral exposure, which has been 
observed in both experimental animal studies and retrospectively in humans, especially 
for nickel (33, 34). One caveat, however, was that oral exposure had to take place prior 
to cutaneous exposure, although it could still be possible that oral exposure (at an 
appropriate dose) after cutaneous exposure might result in suppression of contact 
allergy (35).
The persistence rate of fragrances was mostly determined by fragrance mix (FM) I and 
Myroxylon pereirae (balsam of Peru), which have the highest sensitization prevalence in 
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Europe of all fragrance markers (36). The persistence rate of FM I (64.3%) was similar 
to that in a previous report, that is, 62% (7). The low persistence rate of fragrances 
as a group might be merely an artefact resulting from the small sample size. As a 
retrospective database study, the current study had some inherent limitations. In order 
to achieve an as large as possible sample size, we enforced no limitation with regard 
to which allergen was retested, which led to a heterogeneous sample consisting of a 
wide range of allergens. To assess whether there was any variability in persistence rates 
between allergen groups, they were pooled together. However, even larger sample 
sizes are required for any statements to be made on differences in persistence rates 
between allergens. Another limitation was that, for most patch test readings, data 
on the relevance of a patch test reaction were lacking. This could help to differentiate 
false-positive reactions from true-positive reactions.
In conclusion, our study once again confirms that the persistence of a patch test 
reaction is not 100%, and that non-persistence is particularly an issue for weak positive 
reactions. It is therefore important to be conservative in advising a patient in the case of 
a weak positive reaction, especially if the clinical relevance of the reaction is uncertain, 
as future avoidance of the specific allergen might be unnecessary. A repeated open 
application test might help to assess clinical relevance. Differences in the results of 
two consecutive patch tests in a patient might be explained by changing reactivity of 
a patient’s skin, owing to both internal factors (atopic dermatitis activity and age) and 
external factors (meteorological conditions and ultraviolet radiation). Differences in 
persistence rates between specific allergens and allergen groups appear to exist, but 
further investigation is required.
4
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Methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI), a widely used 
preservative/biocide, was included in the European baseline series in 1988 at a 
concentration of 100 ppm (0.01%) in a ratio of 3:1 (1). Although recently it has been 
recommended to be tested at 200 ppm (0.02%), many centres still test it at 100 ppm 
(2). MCI/MI is also included in the TRUE Test®, offering an alternative patch test 
technique. The objective of the current investigation was to compare the diagnostic 
performance of MCI/MI 0.01% aq. with MCI/MI in the TRUE Test®.
METHODS
 Between April 2013 and August 2016, a total of 1122 consecutive patients were patch 
tested with our departmental baseline series, of whom 1115 (99.4%) were tested 
simultaneously with both MCI/MI 4 𝜇g/cm² (TRUE Test®; Mekos, Hillerod, Denmark) 
and MCI/MI 0.01% aq. (Trolab; Almirall Hermal, Reinbek, Germany), corresponding 
to a dose per unit area of 3 𝜇g/cm², in Van der Bend® square chambers (van der Bend, 
Brielle, The Netherlands), attached to the back with Fixomull stretch® (BSN Medical, 
Hamburg, Germany). Twenty microlitres of the aqueous solution of MCI/MI was applied 
to the chambers with a micropipette. The patch tests were applied on the back for 48 h 
under occlusion, and readings were performed on day (D) 3 and D7 according to ESCD 
guidelines (3). The maximum patch test reactions were aggregated as the patch test 
outcome. In case of a positive reaction (+, ++, or +++), clinical relevance was determined 
on basis of patient history, clinical examination, and exposure patterns, with possible 
outcomes being unlikely/not, possible, probable, and certain. Statistical analyses 
were performed with SPSS (version 23.0; SPSS, Chicago, IL, USA), and guidelines for 
contact allergy data were followed (4). The McNemar test was used to compare the 
strength of reactions of both patch test preparations.
RESULTS
The MOAHLFA index for the investigated patient group was as follows: male, 32.6%; 
occupational dermatitis, 24.1%; atopic dermatitis, 40.9%; hand, 34.0%; leg, 22.4%; 
face, 3.7%; and age ≥40 years, 57.5%. A total of 14.4% (n=161) of patients had a 
positive reaction to one of the MCI/MI preparations; 13.6% (95%CI: 11.6–15.6%) had 
positive reactions to MCI/MI TRUE Test®, and 7.2% (95%CI: 5.7–8.7%) had positive 
reactions to MCI/MI 3 𝜇g/cm² aq. The patch test reactions to MCI/MI TRUE Test® were 
significantly stronger (p<0.001). Table 1 shows the patterns of reactions to both patch 
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test preparations in greater detail. Of all patients with positive reactions to MCI/MI 
TRUE Test® (n=152), 81 (53.3%) did not have positive reactions to MCI/MI 3 𝜇g/cm² 
aq. Furthermore, 35 of these 81 reactions were strong to extreme positive reactions. 
Conversely, of the 80 patients who had positive reactions to MCI/MI 3 𝜇g/cm² aq., 9 
(11.3%) did not react to MCI/MI TRUE Test ®.
Table 1. Relationship between patch test reactions of MCI/MI TRUE Test® and MCI/MI 0.01% 
aq.
MCI/MI 0.01% aq.
TotalNegative Irritant Doubtful + ++ +++
MCI/MI TRUE 
Test
Negative 931 2 14 8 1 0 956
Irritant 1 0 0 0 0 0 1
Doubtful 5 0 1 0 0 0 6
+ 37 0 9 15 1 0 62
++ 27 0 2 29 16 0 74
+++ 6 0 0 4 5 1 16
 Total 1007 2 26 56 23 1 1115
The clinical relevance of all positive reactions was determined, and is shown in Table 2. 
Of all positive reactions to MCI/MI TRUE Test®, 88.8% (135/152) had some degree of 
clinical relevance (ranging from possible to certain), as compared with 87.5% (70/80) 
of positive reactions toMCI/MI 3 𝜇g/cm² aq. For the 9 patients with positive reactions 
to MCI/MI 3 𝜇g/cm² aq. but without positive reactions to MCI/MI TRUE Test®, six 
reactions were considered to be of possible clinical relevance, two of probable clinical 
relevance, and one of no clinical relevance. Conversely, for the 81 patients with positive 
reactions to MCI/MI TRUE Test® but without positive reactions to MCI/MI 3 𝜇g/cm² 
aq., 90.1% (n=73) of reactions had some degree of clinical relevance (39 possible, 24 
probable, and 10 certain), three reactions were of unknown clinical relevance, and 
the remaining five were of no clinical relevance. This means that, if this cohort had 
been patch tested solely with MCI/MI 3 𝜇g/cm² aq., there would have been 73 missed 
reactions, constituting 6.5% of all consecutively patch tested patients.
5
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Table 2. The clinical relevance of all positive reactions to either MCI/MI TRUE Test or MCI/
MI 0.01% aq.
Clinical relevance % (n) of patients with a 
positive reaction to MCI/MI 
TRUE Test (n=152)
% (n) of patients with a positive 
reaction to MCI/MI 0.01% aq. 
(n=80)
Unlikely/not  7.2 (11)  11.3 (9)
Unknown 4.0 (6) 1.3 (1)
Possible  38.8 (59)  32.5 (26)
Probable  27.0 (41)  23.8 (19)
Certain  23.0 (35)  31.3 (25)
DISCUSSION
Although the prevalence of MCI/MI contact allergy in patch test populations remained 
relatively stable at 2.5% for a long period of time, recent publications have shown it 
to be rapidly rising (5–8). The most recent publication of the European Surveillance 
System on Contact Allergies (ESSCA) showed a standardized prevalence of 7.3% for 
contact allergy to MCI/MI 0.01% in 2013–2014, which is similar to our results (9). More 
surprising in the current results is the high proportion of positive reactions to the TRUE 
Test® preparation, which was almost twice as high, at 13.6%. A large majority of these 
positive reactions were deemed to have at least some degree of clinical relevance, 
making the possibility of false positives less likely. The concentration of MCI/MI in 
the TRUE Test®, at 4𝜇g/cm², is slightly higher than the 3 𝜇g/cm² of MCI/MI 0.01% aq., 
which explains part of this discrepancy, as MCI/MI has a steep dose–response curve 
(7). This also illustrates that, besides dose, other factors, such as vehicle, also affect 
elicitation responses, as MCI/MI is tested in povidone in the TRUE Test® (10). A major 
limitation of the current study is that MCI/MI was not tested at a concentration of 
0.02% (200 ppm or 6 𝜇g/cm²), which would have allowed an even better comparison 
of the different patch test techniques, but this might be addressed by future studies.
136610_Daan_Dittmar_BNW-def.indd   108 30-7-2019   10:17:04
109
MCI/MI tested with both TRUE Test and in investigator-loaded chambers
REFERENCES
1.  Andersen K E, Burrows D, Cronin E et al. Recommended changes to standard series. Contact 
Dermatitis 1988: 19: 389–390.
2.  Bruze M, Goossens A, Isaksson M. Recommendation to increase the test concentration 
of methylchloroisothiazolinone/methylisothiazolinone in the European baseline patch 
test series – on behalf of the European Society of Contact Dermatitis and the European 
Environmental and Contact Dermatitis Research Group. Contact Dermatitis 2014: 71: 35–40.
3.  Johansen J D, Aalto-Korte K, Agner T et al. European Society of Contact Dermatitis guideline 
for diagnostic patch testing – recommendations on best practice. Contact Dermatitis 2015: 
73: 195–221.
4.  Uter W, Schnuch A, Gefeller O. Guidelines for the descriptive presentation and statistical 
analysis of contact sllergy data. Contact Dermatitis 2004: 51: 47–56.
5.  Geier J, Lessmann H, Schnuch A, Uter W. Recent increase in allergic reactions to 
methylchloroisothiazolinone/methylisothiazolinone: is methylisothiazolinone the culprit? 
Contact Dermatitis 2012: 67: 334–341.
6.  Schwensen J F, UterW, Bruze M et al. The epidemic of methylisothiazolinone: a European 
prospective study. Contact Dermatitis 2017: 76: 272–279.
7.  Engfeldt M, Ale I, Andersen K E et al. Multicenter patch testing with methylchloroisothizoline/
methylisothiazolinone in 100 and 200 ppm within the International Contact Dermatitis 
Research Group. Dermatitis 2017: 28: 215–218.
8.  Methylisothiazolinone, quo vadis? Contact Dermatitis 2016: 75: 263–264. 
9.  Uter W, Balato A, Ballmer-Weber B et al. European Surveillance System on Contact Allergies 
(ESSCA): results with the European baseline series, 2013/2014. J Eur Acad Dermatol Venereol 
2017: https://doi.org/10.1111/jdv.14423 (e-pub ahead of print).
10.  Marzulli F N, Maibach H J. Effects of vehicles and elicitation concentration in contact 
dermatitis testing I. experimental contact sensitization in humans. Contact Dermatitis 1976: 
2: 325–329.
5
136610_Daan_Dittmar_BNW-def.indd   109 30-7-2019   10:17:04
1University of Groningen, University Medical Center Groningen, Department of 
Dermatology, 9700 RB Groningen, The Netherlands, 
2Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen/
Nürnberg, 91054 Erlangen, Germany, 
3Department of Dermatology, University Allergy Centre, University Hospital Carl Gustav 
Carus, Technical University of Dresden, 01307 Dresden, Germany, 
4Dermatology Unit, Department of Paediatrics, University of Padova, 35137 Padova, Italy,
5Allergy Unit, Department of Dermatology, University Hospital, 4031 Basel, Switzerland, 
6Dermatology Department, University of Medical Sciences, 60-355 Poznan, Poland, 
7Department of Dermatology, University Medical Centre Maribor, 2000 Maribor, Slovenia, 
8Department of Dermatology, University Hospital Jena, 07743, Jena, Germany, 
9Section of Dermatology, DISSAL – Department of Health Sciences, University of Genoa, 
16132 Genoa, Italy, 
10Department of Dermatology, Ninewells Hospital and Medical School, Dundee DD1 9SY, 
UK, 
11Department of Dermatology, Hospital del Mar. Universitat Autònoma and Pompeu 
Fabra, 08003 Barcelona, Spain,
12Department of Dermatology, Leicester Royal Infirmary, Leicester, LE1 5WW, UK, 
13Faculty of Medicine and Health Science, The Jan Kochanowski University, 25-317 Kielce, 
Poland, 
14Unit of Occupational Medicine, University of Trieste, 34129 Trieste, Italy, 
15Department of Dermatology, Free University of Amsterdam, 1081 HV Amsterdam, The 
Netherlands, 
16Dermatology Department, Hospital Universitario de la Princesa, Instituto de 
Investigación Sanitaria la Princesa (IIS-IP), 28006 Madrid, Spain, 
17Information Network of Departments of Dermatology at the University of Göttingen, 
37075 Göttingen, Germany, 18Department of Dermatology, Inselspital, Bern University 
Hospital, University of Bern, 3010 Bern, Switzerland, 19Department of Experimental 
Dermatology and Cosmetology, Jagiellonian University Medical College, 30-688 Krakow, 
Poland, 
20Department of Dermatology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, 
Switzerland, 
21Department of Dermatology, Hospital of Pordenone, 33170 Pordenone, Italy, 
22Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, 
44307 Kaunas, Lithuania,
23Lithuanian University of Health Sciences Hospital, 50009 Kaunas, Lithuania, 
24Dermatovenerološka ambulanta, 6310 Izola, Slovenia, 
25Department of Clinical Social Medicine, Occupational and Environmental Dermatology, 
University Hospital Heidelberg, 69117 Germany and 
26Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds LS7 4SA, UK
136610_Daan_Dittmar_BNW-def.indd   110 30-7-2019   10:17:05
European Surveillance System on 
Contact Allergies (ESSCA):
polysensitization, 2009–2014
Daan Dittmar1 , Wolfgang Uter2 , Andrea 
Bauer3, Anna B. Fortina4, Andreas J. 
Bircher5, Magdalena Czarnecka-Operacz6, 
Aleksandra Dugonik7, Peter Elsner8, 
Rosella Gallo9, Sharizan A. Ghaffar10, 
Anna Giménez-Arnau11, Graham A. 
Johnston12, Beata Krecisz13, Francesca 
L. Filon14, Thomas Rustemeyer15, Anna 
Sadowska-Przytocka6, Javier Sánchez-
Pérez16, Axel Schnuch17, Dagmar Simon18 
, Radoslaw Spiewak19, Philipp Spring20, 
Maria T. Corradin21, Skaidra Valiukeviciene˙ 
22,23, Marko Vok24, Elke Weisshaar25, Mark 
Wilkinson26, Marie L. Schuttelaar1 for the 
ESSCA Network
CHAPTER 6
Published in Contact Dermatitis, 78.6 (2018): 373-385.





Polysensitization, defined as being allergic to three or more haptens from the European 
baseline series, is considered to reflect increased susceptibility to developing a contact 
allergy, and is likely to be associated with an impaired quality of life.
Objectives
To evaluate the prevalences of polysensitization across Europe and to analyse factors 
associated with polysensitization.
Methods
Patch test data collected by the European Surveillance System on Contact Allergies 
(ESSCA; www.essca-dc.org) in consecutively patch tested patients from January 2009 
to December 2014, comprising 11 countries and 57 departments, were retrospectively 
analysed. 
Results
A total of 86 416 patients were available for analysis, showing a standardized 
prevalence of polysensitization of 7.02%, ranging from 12.7% (Austria) to 4.6% (Italy). 
Allergen pairs with the strongest association are reported for the total population, for 
South Europe, and for North/Central Europe. Overall, polysensitized patients showed 
a higher percentage of extreme (+++) positive patch test reactions than oligosensitized 
patients. Female sex, occupational dermatitis and age > 40 years were risk factors for 
polysensitization.
Conclusions
The varying prevalences of polysensitization across Europe most likely reflect differences 
in patient characteristics and referral patterns between departments. Known risk 
factors for polysensitization are confirmed in a European dermatitis population. 
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Polysensitization, in terms of multiple contact allergies, is currently defined as 
sensitization to three or more non-related allergens of the European baseline series 
(EBS) (1). Although arbitrarily defined, this concept is used both to investigate 
risk factors for developing multiple contact allergies, and to address the topic of 
increased susceptibility, for example caused by genetic variants (2). For example, 
polysensitization was shown to be associated with certain genetic markers with links 
to pathogenetic steps of allergic contact dermatitis (ACD) (3, 4), reflecting increased 
susceptibility independently from actual haptens 5, which implies that allergen-
specific susceptibilities should be considered as well (5, 6). Polysensitization has been 
extensively reviewed by Carlsen et al. and Schnuch et al. (7, 8). The main cause of 
acquiring multiple sensitivities is apparently high exposure to environmental allergens, 
for example by occupational exposure, or pre-existing inflammatory dermatoses 
conveying ‘danger signals’ [e.g. in patients with leg (stasis) dermatitis or leg ulcers] 
(9). Studies have shown, however, that polysensitized individuals, when sensitized in 
an experimental setting, have a lower elicitation threshold and generally show stronger 
elicitation reactions than single/double-sensitized individuals, providing arguments 
for different susceptibilities between these groups (10, 11). 
Although quality of life has not been thoroughly investigated in polysensitized 
patients, one case–control study investigating quality of life in fragrance-allergic 
dermatitis patients as compared with dermatitis patients with no fragrance allergy 
found an increase in impairment in quality of life with an increasing number of positive 
patch test reactions to fragrance allergens (12, 13). Polysensitized individuals have a 
higher probability of relevant exposure, and therefore it is not difficult to imagine that 
they suffer more from persistent dermatitis and frequent relapses of their dermatitis. 
The reported prevalences of polysensitization in patch test populations depends 
greatly on the tested population and the length of the tested baseline series, yielding 
prevalences ranging from 5.0% to almost 20.0% (this last result was based on a baseline 
series consisting of 73–80 allergens) (1, 11, 14). The prevalence of polysensitization 
in the largest reported group, that of the Information Network of Departments of 
Dermatology (IVDK) in Germany, has been found to be stable around 10.0% (15, 16). 
In one study, the prevalence of polysensitization found in a small general population 
sample was 0.7% (17). 
6
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The objective of this study was to evaluate prevalences of polysensitization in 
different European countries. We also aimed to evaluate factors associated with 
polysensitization in patients who were patch tested at departments of the European 
Surveillance System on Contact Allergies (ESSCA) network in the period from 2009 
to 2014.
METHODS
The analysis is based on clinical data collected by the ESSCA network, as described 
in previous publications (18, 19). Briefly, clinical and demographic data, along with 
patch test results, of all patients patch tested in the departments participating in the 
ESSCA for suspected ACD caused by various potential exposures are documented 
electronically in the local departments. These use diverse data capture software 
and, partly, the multilingual software winalldat/essca provided by the ESSCA 
(20). Standardized patch testing follows international recommendations (21). The 
anonymized data delivered by the participants are pooled in the ESSCA data centre 
in Erlangen for further analysis, (22) with r (version 3.2.3) software (www.r-project.
org, last accessed 22 March 2017). Pertinent guidelines for the statistical analysis of 
patch test data were considered (23, 24). 
For analysis, the maximum patch test reactions between day (D) 3 and D5 (inclusive) 
were aggregated as the patch test outcome. Reactions designated as either +, ++ or 
+++ were classified as positive (allergic), and the remainder were classified as non-
allergic. The study period was January 2009 to December 2014, and included, for the 
present analysis, 11 European countries and, in total, 57 departments.
Test results obtained with the EBS valid in the study period, during which 
methylisothiazolinone (MI) 2000 ppm aq. had been added, and the recommended 
test concentration of methylchloroisothiazolinone (MCI)/MI had been increased from 
100 to 200 ppm aq., and that of formaldehyde had been increased from 1% to 2% 
aq., were analysed (25). Altogether, 86 416 patients were registered who were tested 
with the EBS and whose tests were read at least between D3 and D5. The TRUE Test® 
employing a hydrocellulose matrix for the haptens instead of pet. or aq. was used in 
a relatively small number of consultations, namely 3649, with the vast majority of 
patients being tested with pet.-based and aq.-based haptens and investigator-loaded 
chamber systems, respectively. Moreover, two German departments used a 1-day 
patch test exposure, applied to 2870 patients. As in previous analyses, the impact of 
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these variations of the standard technique was found to be limited, so the results have 
all been pooled (26). 
Concerning the allergens of the EBS, which form the basis of the present analysis 
of polysensitization, the following rules were applied for counting of the number of 
individual positive patch test reactions: 
• Positive reactions to fragrance mix II and hydroxyisohexyl 3-cyclohexene 
carboxaldehyde (HICC) were pooled, that is, counted as one reaction if one or 
the other, or both, were positive.
• The same rule was applied to reactions to mercapto mix 1% and 2% pet. (which 
were never both tested in one patient) and reactions to 2-mercaptobenzothiazole 
tested additionally.
• As a marker concerning local anaesthetics, benzocaine is tested in the current 
EBS, whereas caine mix III is tested by a large number of ESSCA members because 
of its better diagnostic yield; the positive reaction(s) were counted as one.
• Likewise, sesquiterpene lactone mix is included in the current EBS, but (partly 
differing versions of) Compositae mix were considered to be equivalent, and 
positive reaction(s) were counted as one.
• Partly, the mixture of methyldibromo glutaronitrile (MDBGN) and 2-
phenoxyethanol 1:4, for example Euxyl® K 400, was tested instead of, or in 
addition to, MDBGN. All positive reactions were pooled into one.
• In view of corresponding dithiocarbamates and thiurams being redox pairs 
(27), positive reactions both to zinc diethyldithiocarbamate (ZDEC) or carba 
mix – which were never both tested in one patient – and thiuram mix were counted 
as one. 
• Although it could be debated whether positive reactions to formaldehyde and 
various formaldehyde releasers are truly equivalent, as isolated reactions to a 
releaser might be attributable to the donor molecule, these were also pooled, 
which concerned quaternium-15, which is presently the only formaldehyde 
releaser contained in the EBS.
Besides polysensitization, prevalences are also provided for oligosensitization, defined 
as having one or two positive patch test reactions, but not more, and for ‘at least one 
positive’, also known as the ‘P’ measure (28). For the polysensitized group and for 
all patients with no positive patch test reactions to the EBS, the MOAHLFA (Male, 
6
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Occupational dermatitis, Atopic dermatitis, Hand dermatitis, Face dermatitis, Leg 
dermatitis, Age ≥ 40 years) index is given (29). 
To evaluate regional differences for concomitant reactions, that is, pairs of positive 
reactions contributing to polysensitization (30), or ‘oligosensitization’, countries were 
classified into two regions, as previously done by Schuttelaar et al. (31). Two regions 
were defined: North/Central Europe, comprising Finland, Lithuania, Poland, Germany, 
Austria, Switzerland, The Netherlands, and the United Kingdom; and South Europe, 
comprising Spain, Italy, and Slovenia. 
Besides descriptive statistics, adjusted multifactorial analyses were employed to 
quantify the independent association of potentially relevant explanatory factors 
and oligosensitization and polysensitization, respectively. To this end, log-binomial 
regression analysis was utilized, which quantifies the association by means of a 
prevalence ratio (PR), which can be interpreted as a representation of relative risk. 
Point estimates were accompanied by 95% confidence intervals (CIs) obtained with 
the profile likelihood method. The set of explanatory variables considered included the 
country, sex, age (dichotomized as < 40 years versus ≥ 40 years), occupational aetiology 
of contact dermatitis (‘yes’ or ‘partly’ versus ‘no’ or ‘unknown’), atopic dermatitis, past 
or present, versus no atopic dermatitis, and the anatomical sites hand, leg, face, trunk 
(as reference), and ‘other’. Moreover, the number of allergens in the baseline series 
tested was used as an adjustment factor, as the likelihood of one (or more) positive 
reactions depends also on the number of allergens tested (32). 
RESULTS
In the years 2009–2014, altogether 86 416 patients were patch tested in the 57 
European departments. The characteristics of the patients, and univariate results 
obtained with the EBS allergens, have been published in a number of publications 
covering the 2009–2012 study period and the 2013–2014 study period, respectively. 
For further information, the reader is referred to these (26, 33-38). 
Prevalences of polysensitization across Europe
Crude and age- and sex-standardized prevalences for polysensitization and 
oligosensitization, stratified per country, are presented together with 95%CIs in 
Table 1. In order to put these results into perspective, prevalences for at least one 
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positive reaction (‘P’ measure) and for negative patch test results are also given 
(28). No large differences were seen between crude and standardized prevalences. 
Overall, the standardized prevalence of polysensitization was 7.05%, with the highest 
standardized prevalences being seen in Austria (12.7%) and The Netherlands (12.4%), 
and the lowest in Italy (4.6%) and Lithuania (5.2%). The standardized ‘P’ measure, 
presented as ‘at least one positive reaction’ to the EBS allergens, was 43.0% for the 
total population, with considerable variation between countries; from 52.9% in The 
Netherlands to 38.6% in the United Kingdom. 
6
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Of the total polysensitized population, the proportion of males aged < 40 years 
was 6.5%, and the proportion of females aged < 40 years was 24.3% (Table 2). The 
proportion aged ≥ 40 years and male was 19.9%, and the majority were female and 
aged ≥ 40 years (49.3%). These proportions were largely similar in the oligosensitized 
population, except that this population was younger. The MOAHLFA index of the 
polysensitized population is shown in Table 3, together with the total patch tested 
population as a reference 29. For most of the categories of the MOAHLFA index, the 
polysensitized group was similar to the total patch tested population, except that 
the percentage of females was slightly higher for the polysensitized group, and a 
higher percentage were aged ≥ 40 years. This difference in age distribution was most 
pronounced in the United Kingdom, whereas, in Spain and Poland, the percentages 
were almost the same for the polysensitized and the total patch tested population. 
The distribution of individuals with (a history of) atopic dermatitis was equal between 
the totals of both groups; however, country-specific differences could be seen. The 
primary site of dermatitis seemed to be distributed similarly in both groups overall, 
as well as for all of the individual countries.
6
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The most common allergen pairs in polysensitized individuals and the 
strengths of patch test reactions
Within the polysensitized group, odds ratios (ORs) were calculated for all possible 
allergen pairs to evaluate concomitant positive patch test reactions. This was 
performed for the total population, and separately for South Europe and North/Central 
Europe as defined above, in order to observe any differences based on geographical 
location. The top 10 allergen pairs per region ranked by the highest OR are shown 
in Table 4. Overall, associations were stronger in South Europe than in North/
Central Europe. For both regions, the top two concomitant reactions were those to 
quaternium-15/formaldehyde and carba mix/thiuram mix. The most probable reason 
for the concomitant reactions is also suggested in the footnotes to Table 4. 
6
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The most commonly positive EBS allergens in polysensitized patients are shown and 
compared with those in oligosensitized patients in Table S1. There were no large 
differences regarding which allergens were the most commonly positive between 
the two groups. 
The distribution of grades of positive reactions, from weak positive to extreme 
positive, in oligosensitized and polysensitized individuals stratified per country is 
shown in Table 5. Overall, for almost all countries, the polysensitized population had a 
slightly higher percentage of extreme positive (+++) reactions than the oligosensitized 
population. The percentage of strong positive (++) reactions was comparable between 
both populations, except for Finland, where the oligosensitized population had a higher 
percentage of strong positive reactions than the polysensitized population. Large 
differences between countries can also be observed; for example, the percentage 
of weak positive reactions in the polysensitized population in The Netherlands was 
81.6%, as compared with only 21.0% in Spain. 
Table 5. The distribution of grades of positive reactions (+, ++ vs. +++) in oligo- and 
polysensitised patients in the European Surveillance System on Contact Allergies (ESSCA) 
database between January 2009 to December 2014, respectively, stratified for country. 
In this analysis, Slovenia is not included as the departments only contributed data on 
reactions being positive, or negative, i.e., no reaction grades. N(pat.), number of patients 
oligo-/polysensitised; N(rea.), total number of reactions of any grade, i.e. multiple 
occurrences possible (up to 2 identical or differing reaction grades in oligosensitised, up 
to the observed maximum of 15, and minimum 3, in polysensitised).
Oligosensitisation Polysensitisation
Country N(pat.) N(rea.) % + % ++ % +++ N(pat.) N(rea.) % + % ++ % +++
 Austria 625 860 79 20.5 0.6 213 824 81.6 16 2.4
Switzerland 2842 3760 57.8 31.1 11.1 711 2648 57.6 28 14.4
Germany 3696 4824 67 25.9 7.1 762 2860 62.4 26.8 10.7
Spain 2512 3357 21.7 60.6 17.6 429 1555 21 57.9 21.2
Finland 513 671 25.6 68.3 6.1 115 404 40.1 54.2 5.7
Italy 4840 6142 53.2 37.8 9 570 1919 54.9 34.7 10.4
Lithuania 554 728 48.1 36.8 15.1 86 317 51.4 33.1 15.5
Netherlands 2848 3866 81.6 16.4 2 885 3442 81.2 16.1 2.7
Poland 2265 3153 41.5 38.9 19.6 576 2103 40.8 38.1 21.2
United 
Kingdom
7677 9968 60.1 36.6 3.4 1280 4536 60.6 35.6 3.8
Total 28372 37329 56.4 35.3 8.3 5627 20608 58.7 31.6 9.8
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The distribution of grades of positive reactions, per number of positive reactions, for 
the total population is shown as a stacked bar plot in Fig. 1. A clear positive correlation 
can be seen between the number of positive reactions and the percentage of extreme 
positive (+++) reactions.
Figure 1.
The distribution of reaction grades according to the number of positive reactions to allergens 
of the departmental baseline series, each summed up to 100%. The number of patients 
having one, two and more positive reactions is indicated on the top x-axis. One patient each 
with 15 and 12 positive reactions, 3 patients with 11 positive reactions and 6 patients with 10 
positive reactions are omitted for clarity.
Analysis of risk factors for polysensitization
To assess the influence of country, sex, occupational contact dermatitis (OCD), 
atopic dermatitis, age ≥ 40 years and primary site of dermatitis on the risk of being 
polysensitized, a log-binomial regression analysis was performed (Table 6). The same 
6
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regression analysis was performed on the oligosensitized group for comparison. For 
quantification of the risk of being either oligo- or polysensitised associated with the 
country an individual has been patch tested in, Switzerland was chosen as reference, 
because it is situated between the 2 chosen European regions. The association between 
country and being oligosensitized was minimal; it was lower in Germany and the 
United Kingdom (PR = 0.79 and PR = 0.82, respectively) than in the reference country, 
Switzerland. In contrast, the association between country and being polysensitized 
was more pronounced. The risk of being polysensitized appeared to be significantly 
lower for most countries than for Switzerland, and was especially low in Germany 
(PR = 0.64), Italy (PR = 0.59), and the United Kingdom (PR = 0.54). Conversely, this risk 
was significantly higher for Austria (PR = 1.71) and The Netherlands (PR = 1.27). 
Table 6. Log-binomial regression analysis with Oligosensitisation (left) and 
polysensitisation (right), respectively, as outcome. As Slovenian departments could not 
contribute information on anatomical site, these were omitted from the analysis. CI, 
confidence interval.
Oligosens. Polysens.
Factor %(total) PR 95% CI PR 95% CI
Switzerland 8.7 1.00 (reference) 1.00 (reference)
Austria 1.9 1.1 (0.99-1.22) 1.82 (1.44-2.27)
Germany 13 0.79 (0.74-0.83) 0.63 (0.54-0.74)
Spain 7.6 0.94 (0.89-1) 0.77 (0.66-0.91)
Finland 1.5 0.95 (0.88-1.03) 0.9 (0.73-1.12)
Italy 14.9 0.95 (0.9-1) 0.6 (0.51-0.7)
Lithuania 1.6 0.98 (0.9-1.06) 0.77 (0.59-0.99)
Netherlands 8.1 1.04 (0.98-1.1) 1.3 (1.12-1.51)
Poland 6.4 1 (0.93-1.06) 1.28 (1.09-1.52)
United Kingdom 26.3 0.82 (0.77-0.86) 0.55 (0.47-0.64)
Male Sex 33.2 0.69 (0.68-0.71) 0.58 (0.55-0.62)
Occupational 
Dermatitis
16.3 1.23 (1.19-1.27) 1.51 (1.4-1.64)
Atopic Dermatitis 25.7 0.92 (0.9-0.95) 1.08 (1.01-1.16)
Age 40+ 59.7 1.1 (1.08-1.12) 1.69 (1.59-1.81)
Site: Trunk 9.7 1.00 (reference) 1.00 (reference)
Site: Hand 29.2 1.02 (0.99-1.07) 1.12 (1-1.26)
Site: Leg 6.1 0.91 (0.86-0.96) 1 (0.86-1.16)
Site: Face 19.2 1.03 (0.99-1.07) 1.03 (0.92-1.15)
Site: Other 35.8 0.98 (0.95-1.02) 1.03 (0.92-1.14)
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Low PRs for male sex in both the oligosensitized and polysensitized groups (0.7 and 
0.59, respectively) indicated that females had a significantly increased risk of being 
sensitized overall, and of being polysensitized in particular. Also, OCD was significantly 
associated with both oligosensitization and polysensitization, and again this association 
was even stronger for polysensitization. For atopic dermatitis, a small, significant 
association was seen for polysensitization, but not for oligosensitization. The highest 
PR for polysensitization was observed for age ≥ 40 years (1.71). Of the primary sites of 
dermatitis, only hand dermatitis (PR = 1.15) was found to be significantly associated 
with polysensitization when compared with trunk dermatitis as the reference. Leg 
dermatitis was inversely significantly associated with oligosensitization (PR = 0.92).
DISCUSSION
Prevalences of polysensitization
For the first time, prevalences of polysensitization are presented for different countries 
across Europe. Overall, the standardized prevalence of polysensitization was 7.1%, 
and the standardized prevalence of oligosensitization was 36.3%. The ‘P’ measure 
in this dataset was 43.0%, ie., the same as the 43% seen in the ESSCA population 
patch tested in 2005–2006 (39). Note that the ‘P’ measure includes, by definition, both 
oligosensitized and polysensitized patients, so similarities in association patterns are to 
be expected. There is considerable variation in polysensitization and oligosensitization 
between countries; besides reflecting actual sensitization frequencies and the 
differences thereof between countries, it can also mainly be explained by the varying 
eligibility criteria for patch testing between departments. Differences between 
countries and departments in relation to selection processes and health systems have 
been discussed in a previous ESSCA publication (26). Another explanatory variable is 
the length of the baseline series tested in a department; ‘a bigger net catches more 
fish’. However, in the present analysis, this effect has a ceiling, in the sense that only 
allergens of the EBS as currently recommended were considered (25), together with 
possible substitutes or additions as detailed above, but not any length of departmental 
baseline series. Nevertheless, as some national groups or departments systematically 
omit haptens from the EBS, some adjustment for, basically, a lower number of allergens 
tested in patients (from one country and department, respectively) was necessary, and 
was employed in the regression analysis. However, the putatively lower sensitivity 
(and thus lower prevalence yielded) in those departments still using 100 ppm MCI/MI 
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and 1% formaldehyde, respectively, has not been separately addressed, as the effect 
is regarded as being relatively minor. 
The high prevalence of polysensitization in Austria and The Netherlands may be 
explained by more restrictive patch testing (i.e. more selective) and different patterns 
of referral, for example in The Netherlands. It seems unlikely that these countries 
actually have a higher prevalence of polysensitization, as it does not seem obvious 
that individuals in these countries have higher exposure to baseline allergens than, 
for example, individuals in Italy or the United Kingdom. Additional explanations for 
variation in polysensitization prevalences seen between countries are variations in 
the factors described in the MOAHLFA index, that is, variations in proportions of 
atopic dermatitis, site of dermatitis and OCD in the patch tested population between 
countries. Many of these factors are positively or inversely related to polysensitization, 
as discussed below. The effects of age and sex, which certainly have an influence 
on polysensitization, on differences in prevalences between countries have been 
eliminated by using age- and sex-standardized prevalences, and by adjusting for these 
factors in the multifactorial analysis, respectively.
Taking these findings together, it appears that differences in polysensitization 
prevalences between countries are most likely explained by differences in patch tested 
populations, possibly patch test methodology, and the length of the baseline series 
(within the limit of the actual EBS set by the present analysis; see above). Therefore, 
studies investigating this topic have to take into account these factors when comparing 
their results with those of studies performed in a different department.
Similarly to what has been found in previous studies, the polysensitized population 
has a higher proportion of elderly individuals and females than patients with negative 
patch test results (1, 40). This is further supported by the present regression analysis, 
which shows that being male is a significant risk-lowering factor for polysensitization, 
and being aged > 39 years is a significant risk-increasing factor, most likely because 
of the effect of cumulative lifetime exposure. Furthermore, the present analysis was 
based on allergens of the EBS for better comparison, and the EBS may include some 
allergens of old relevance (such as clioquinol, primin, and neomycin) and does not 
rapidly adopt new allergens. Because of this, the overall yield of the EBS may be higher 
in the older population than in the younger population, and so will the odds of being 
polysensitized. 




Occupational dermatitis is a known risk factor for polysensitization; this is most 
likely attributable to increased (work-related) exposure to multiple allergens (15, 
41). Another risk factor for occupational dermatitis is wet work, which increases the 
risk of acquiring contact allergy. After age, OCD was most strongly associated with 
polysensitization, with a PR of 1.57. Certain countries contributed a higher proportion 
of OCD than others, for example Germany, Finland, and Poland, all three of which have 
contributions from departments specialized in occupational dermatology (33). A higher 
percentage of occupational aetiology of dermatitis in the polysensitized population 
than in the total patch tested population can be seen in all countries, except for Finland, 
where only 34.8% of the polysensitized group had OCD, as compared with 47.6% of all 
tested individuals. It is unclear whether this is simply an anomaly, but, without further 
investigation, there appears to be no easy explanation. 
Atopic dermatitis
In a case–control questionnaire study focusing on polysensitization, 45.1% of 
polysensitized individuals had a history of atopic dermatitis, as compared with 31.0% 
of oligosensitized individuals (40). Another study, however, found similar proportions 
of atopic dermatitis in polysensitized and oligosensitized populations, which we also 
found (42). Atopic dermatitis has been reported to be a risk factor for polysensitization 
(15) Whether atopic dermatitis patients are at higher or lower risk of developing contact 
allergy has not been completely elucidated yet; because of immunological differences, 
atopic dermatitis patients are less easy to sensitize in an experimental setting; however, 
this appears to be mitigated by easier penetration of allergens, owing to an impaired 
skin barrier (43), and increased exposure, at least to those haptens encountered in 
the treatment of atopic eczema. Regarding geographical differences, both Italy and 
Spain (South Europe) have relatively low percentages of atopic dermatitis. Also of 
interest is that, in these countries, a lower percentage of atopic dermatitis is seen in 
the polysensitized population than in all individuals tested. The only other country with 
this observation is the United Kingdom; in all other countries, the opposite is found. 
Sites of dermatitis
Given the findings of previous studies investigating the relationship between primary 
site of dermatitis and polysensitization, it is perhaps surprising that only one of the 
sites analysed in the present study was related to polysensitization. One possible 
explanation might be that only five sites were analysed, as opposed to previous studies, 
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in which between 12 and 19 sites were investigated (15, 44). Some sites previously 
found to be associated with polysensitization might have been combined with other 
areas in the present analysis, averaging out the previously found associations. One site 
of dermatitis that is widely accepted to be a risk factor for polysensitization is the lower 
leg, because of increased exposure to topical medicaments in patients with leg stasis 
dermatitis and/or chronic leg ulcers (9). In the present analysis, however, the site ‘legs’ 
also included the upper legs, knees, and popliteal fold. Another reason for the lack of 
association between the legs and polysensitization might be the decline in frequency 
of contact allergy in patients suffering from chronic leg ulcer/stasis dermatitis (45). 
Alternatively, or additionally, it might be that polysensitized patients suffer from more 
generalized dermatitis, as suggested by one study, but not confirmed by later studies 
(44, 46). Dermatitis of the hands is a well-known risk factor for polysensitization, and 
this was once again confirmed in the present analysis (15, 30, 44). More interesting, 
perhaps, are the country-specific differences; especially in Finland and Lithuania, the 
proportion of patients with hand dermatitis was lower in the polysensitized group than 
in all patch tested patients in those countries. This might be related to the difference 
in the proportion of OCD between the polysensitized and oligosensitized patients in 
Finland (discussed above), as hand dermatitis often has an occupational cause (41). 
Concomitant reactions in polysensitized individuals
Concomitant patch test reactions can be explained by various mechanisms; co-
sensitization, resulting from concomitant exposure to unrelated allergens, or cross-
reactivity, resulting from structural similarities between allergens. Several studies 
have investigated associations between allergens, most recently in a publication 
by the IVDK (16, 18, 30, 36). Most pairs can be explained by either co-sensitization 
through simultaneous exposure (for example, at least historically, cobalt and 
potassium dichromate in cement), or by cross-reactivity [p-phenylenediamine 
(PPD)–N-isopropyl-N′-phenyl-4-phenylenediamine and PPD–benzocaine], or both 
(8, 47). Co-sensitization can result from either exposure to a product containing 
different non-related allergens (e.g. topicals containing fragrances or preservatives), 
or concomitant exposure to different products, for example in specific occupations. 
The two most common pairs in our analysis, in both North/Central and South Europe, 
were quaternium-15–formaldehyde and carba mix–thiuram mix, both with high ORs, 
providing further justification for counting positive reactions to these pairs as one in 
the analysis of polysensitization. In a previous study, 73% of patients with contact 
allergy to formaldehyde also reacted to quaternium-15, and, conversely, 59% of 
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quaternium-15-positive patients also reacted to formaldehyde (48). Concomitant 
reactions between dithiocarbamates and thiurams is a common finding; the OR of 
reactions to zinc diethyldithiocarbamate being coupled with reactions to thiuram mix 
was 166.43 (i.e., extremely high) in a previous study (16). 
Ingredients of topical medicaments were often seen in the top 10 of both regions. One 
study showed that a larger proportion of polysensitized patients than of oligosensitized 
patients suffer from dermatitis, and that the dermatitis is of longer duration (for the 
group without atopic dermatitis) (1. Therefore, this group might have more intense 
and longer exposure to several topical medicaments than oligosensitized patients. 
An interesting observation is that three pairs contain primin, twice together with a 
topical medicament, and once with mercaptobenzothiazole–mercapto mix. Primin is 
the main allergen of Primula obconica H., and primin allergy occurs mainly in florists 
and gardeners (49). The relationships with clioquinol, an antiseptic agent used in both 
topicals and eye drops, and with tixocortol-21-pivalate, a corticosteroid, are not easily 
explained. The two might both be present together in topicals, or used concomitantly/
successively to treat dermatitis. Its relationship with mercaptobenzothiazole–
mercapto mix is most likely explained by the use of rubber gloves in florists and 
gardeners, or by the presence of mercapto compounds in fungicides. 
There are no large differences between North/Central and South Europe, and five 
pairs are present in the top 10 of both regions; quaternium-15–formaldehyde, carba 
mix–thiuram mix, tixocortol-21-pivalate–budesonide, fragrance mix I–fragrance 
mix II (together with HICC), and thiuram mix–mercapto mix (together with 
mercaptobenzothiazole). Some of the variation between the two regions might be 
explained by the fact that some departments do not test certain allergens in the EBS; 
for example, clioquinol is only tested in Spain, Lithuania, The Netherlands, Poland, 
and Slovenia.
It is important to note, however, that although the allergen pairs presented here 
are often diagnosed together in 1 patient, this does not reflect actual sensitization 
prevalences of the different allergens. For this, the reader is referred to previous 
ESSCA publications. For example, the sensitization prevalence of primin in Europe has 
considerably decreased in the last decade, most likely as a result of the introduction of 
primin-free cultivars of P. obconica H. in 2000 (33, 50). The same is true for clioquinol, 
with stable low prevalences in the last decade (< 0.5%), so its inclusion in the EBS seems 
no longer warranted (33, 35, 51). 
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Strengths of patch test reactions
In the present analysis, a positive correlation was seen between the number of positive 
patch test reactions and the proportion of extreme positive reactions. Similarly, one 
study found that individuals with strong or extreme positive patch test reactions were 
more likely to have additional positive reactions than individuals with weak positive 
reactions (52). Another study found that an extreme patch test reaction to fragrance 
mix I was associated with additional positive reactions (16). A possible explanation 
for our findings could be the often mentioned ‘angry back syndrome’, or ‘excited skin 
syndrome’, although the actual existence of these phenomena has been disputed, 
and the occurrence is thought to be rare at best (53, 54). The best explanation for 
more strong/extreme positive reactions in polysensitized individuals would be that 
polysensitization is a sign of heightened susceptibility, which is also expressed by 
increased reactivity. Differences between countries in the distribution of grades of 
positive reactions are not easily explained. As the distribution within each country 
was more or less comparable for oligosenitization and polysensitization, a possible 
explanation could be differences in how reactions were read, or differences in the patch 
test populations, or differences in the degree of contact sensitization, for example 
because of varying exposure conditions, as noted before concerning PPD (31). 
LIMITATIONS
The present analysis is based on only the EBS. As the chance of observing 
polysensitization increases with the number of allergens tested, the oligosensitized 
subgroup might include polysensitized individuals, if these had been tested with a 
more extended baseline series. Comparison of prevalences between countries is 
also made more difficult by variations in the length of the tested baseline series, as 
discussed above, particularly in terms of omissions. For instance, the Austrian, German 
and Swiss departments mostly use a baseline series that does not include, for example, 
the two corticosteroid markers budesonide and tixocortol-21-pivalate, as well as 
benzocaine and neomycin, but includes other allergens considered to be important, 
although these have been disregarded in the present analysis. In addition, the EBS 
is prone to contain old allergens, and is in need for an update. The present analysis 
also does not include D7 readings, possibly leading to an underestimation of single 
contact allergies (particularly to corticosteroids) (55), and thereby of polysensitization. 
Another limitation of this study is that inherent differences between departments 
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and countries, for example the mode of reading a patch test and different patterns of 
referral, make interpretation of the results difficult. 
CONCLUSION
Differences in polysensitization prevalences are seen between different countries in 
Europe, and while many reasons can be discussed, these differences are not easy to 
explain. Along with the variation in contact allergy prevalences between countries or 
even departments, polysensitization varies with the setting, and cannot be regarded as 
a fixed characteristic of patch tested patients. Known risk factors for polysensitization, 
such high age and occupational aetiology of dermatitis, were confirmed. Concomitant 
reactions to allergen pairs were evaluated for both South and North/Central Europe, 
showing no evidence of strong differences.
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Online supplemental table S1: The most commonly positive EBS allergens in polysensitised 
(n=6383) versus oligosensitised (n=31403) patients. CI, confidence interval; stand., age- 
and sex-standardised.
Oligosens. Polysens.
Allergen % pos. (95% CI) % stand. pos (95% CI) % pos. (95% CI) % stand. pos (95% CI)
 Nickel 42.6 (42–43.1) 40.9 (40.4–41.4) 52.6 (51.3–53.8) 52 (50.6–53.3)
Cobalt 10.1 (9.8–10.4) 10.7 (10.3–11.1) 35.4 (34.3–36.6) 37.4 (36.1–38.8)
Chromium 5.6 (5.3–5.8) 6 (5.7–6.3) 23.5 (22.4–24.5) 24.7 (23.4–25.9)
FM I 11 (10.7–11.4) 10.7 (10.3–11) 43.1 (41.9–44.3) 40.8 (39.5–42.2)
FM II 5 (4.7–5.2) 5 (4.7–5.2) 23.4 (22.4–24.4) 22.1 (21–23.2)
HICC 2.3 (2.1–2.4) 2.2 (2.1–2.4) 10.7 (10–11.5) 10.2 (9.4–11)
M. pereirae 9 (8.7–9.3) 8.7 (8.4–9) 33.1 (32–34.3) 31.3 (30–32.5)
Colophonium 4.1 (3.9–4.3) 4.2 (3.9–4.4) 16.3 (15.4–17.3) 15.7 (14.7–16.7)
Formaldehyde 2.7 (2.5–2.9) 2.8 (2.6–3) 9.3 (8.6–10.1) 9.3 (8.5–10.1)
Paraben Mix 0.8 (0.7–0.9) 0.9 (0.8–1) 4.4 (4–5) 4.9 (4.3–5.5)
Quaternium 15 1 (0.9–1.1) 1 (0.9–1.1) 3.2 (2.7–3.6) 3.1 (2.7–3.6)
MCI/MI 9.9 (9.6–10.2) 10.1 (9.7–10.4) 23.1 (22.1–24.2) 22.5 (21.4–23.6)
MI 4.6 (4.3–4.8) 4.5 (4.2–4.7) 9.6 (8.9–10.3) 9.3 (8.5–10)
MDBGN 3.1 (2.9–3.3) 3.1 (2.9–3.3) 13.4 (12.6–14.3) 13 (12.1–13.9)
PPD 5.7 (5.4–5.9) 5.5 (5.3–5.8) 11.2 (10.5–12) 11.2 (10.3–12)
Benzocaine 0.4 (0.3–0.5) 0.4 (0.3–0.5) 1.8 (1.5–2.2) 1.7 (1.4–2.1)
Clioquinol 0.1 (0.1–0.1) 0.1 (0.1–0.1) 0.7 (0.5–1) 0.7 (0.5–0.9)
Budesonide 0.8 (0.7–0.9) 0.8 (0.7–1) 2.4 (2–2.8) 2.5 (2–2.9)
Tixocortol 
pivalate
0.8 (0.7–0.9) 0.8 (0.7–0.9) 3.6 (3.2–4.1) 3.6 (3.1–4.1)
Neomycin 
sulfate
1.7 (1.6–1.9) 1.7 (1.6–1.9) 5.2 (4.7–5.8) 5.3 (4.7–6)
Thiuram mix 2.9 (2.7–3.1) 3 (2.8–3.2) 11.5 (10.8–12.3) 12.1 (11.2–13.1)
2-MBT 0.9 (0.8–1) 1.1 (0.9–1.2) 3.7 (3.3–4.2) 4.2 (3.6–4.8)
Mercapto mix 0.8 (0.7–1) 1 (0.9–1.1) 3.9 (3.5–4.4) 4.3 (3.7–4.9)
IPPD 0.8 (0.7–0.9) 0.9 (0.8–1) 3.5 (3.1–4) 3.9 (3.3–4.5)
Lanolin alcohol 2.5 (2.3–2.7) 2.6 (2.4–2.8) 10.6 (9.8–11.4) 10.7 (9.8–11.6)
SL mix 0.7 (0.7–0.8) 0.7 (0.6–0.8) 3 (2.6–3.4) 2.7 (2.3–3.2)
Primin 0.4 (0.3–0.4) 0.3 (0.3–0.4) 1.3 (1.1–1.7) 1.4 (1–1.7)
Epoxy resin 2 (1.9–2.2) 2.2 (2–2.4) 5.5 (5–6.1) 5.7 (5–6.3)
ptBFR 1.1 (0.9–1.2) 1.1 (1–1.2) 4.2 (3.7–4.7) 4.1 (3.6–4.7)
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Hydroperoxides of limonene and linalool are potent sensitizers.
Objectives
To investigate the prevalence of contact allergy to both hydroperoxides of limonene 
and hydroperoxides of linalool, to report clinical relevance, and to investigate patient 
demographics.
Methods
A total of 821 patients (35.6% male, mean age 42.4 years ± 17.8 years) were 
consecutively patch tested with our departmental baseline series and our fragrance 
series, including hydroperoxides of limonene 0.3% pet. and hydroperoxides of linalool 
1.0% pet. The clinical relevance was assessed for all positive reactions.
Results
Positive patch test reactions to hydroperoxides of limonene and to hydroperoxides of 
linalool were observed in 77 patients (9.4%, 95% confidence interval [CI]: 7.4%-11.4%) 
and in 96 patients (11.7%, 95%CI: 9.5%-13.9%), respectively; 38 of these patients 
(4.6%, 95%CI: 3.2%-6.0%) reacted to both. Most reactions were considered to 
be possibly or probably clinically relevant (66.3% and 68.8%, respectively), and a 
small proportion were deemed to be of certain clinical relevance (18.2% and 19.8%, 
respectively).
Conclusion
As compared with previous studies, high numbers of positive reactions to both 
hydroperoxides of limonene and hydroperoxides of linalool were observed, the 
majority of which were clinically relevant, supporting their inclusion in the European 
baseline series.
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INTRODUCTION
Limonene (d-limonene) is the main ingredient of pressed oil from the peel of citrus 
fruits, and linalool is present in many herbs, flowers, woods, etc.(1, 2) Both are 
common ingredients in household products and cosmetics, such as hygiene products, 
perfumes, and detergents, as well as industrial products.(3, 4) Limonene and linalool 
are ubiquitous fragrance terpenes with low sensitizing potential.(1, 2, 5) However, 
upon air exposure, oxidation occurs, during which different oxidation products are 
formed. Of these oxidation products, the hydroperoxides are potent sensitizers. High 
prevalences of contact allergy to these hydroperoxides of limonene and linalool have 
been reported.(6-9) The aim of the current study was to investigate the prevalences 
of contact allergy to hydroperoxides of limonene and hydroperoxides of linalool, and 
to characterize patients allergic to either or both hydroperoxides of limonene and 
hydroperoxides of linalool, with respect to patient characteristics and concomitant 
fragrance contact allergies.
METHODS
A database study was performed on all patients who were at least patch tested with 
both hydroperoxides of limonene 0.3% pet. and hydroperoxides of linalool 1.0% pet. 
All patients referred to our tertiary referral centre with suspected allergic contact 
dermatitis (ACD) are consecutively patch tested with our departmental extended 
European baseline series (EBS), TRUE Test® panels 1 and 2 (SmartPractice Europe, 
Reinbek, Germany) supplemented with additional investigator-loaded allergens, and 
a fragrance series. When specific contact allergies are suspected, additional series are 
patch tested. All investigator-loaded allergens were tested in Van der Bend square 
chambers (Van der Bend, Brielle, The Netherlands), and all patch tests were attached 
to the back with Fixomull stretch (BSN Medical, Hamburg, Germany) for 2 days. 
Both hydroperoxides of limonene 0.3% pet. and hydroperoxides of linalool 1.0% pet. 
(Chemotechnique Diagnostics, Vellinge, Sweden) were included in our fragrance series 
from December 1, 2015.
Consecutively patch tested dermatitis patients from December 1, 2015 to December 
15, 2017 were included in the current analysis. All patch tests were read and interpreted 
by the same dermatologist, with potential back-up from a dermatologist also trained 
in reading and interpreting patch test results, according to ICDRG/ESCD criteria, with 
7
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the possible outcomes being: negative, irritant, doubtful (?+), weak positive (+), strong 
positive (++), and extreme positive (+++) reactions.(10) Reactions were considered to 
be irritant if margins were sharply demarcated and the surface of the test area showed 
a silk paper structure or a shiny skin. Reactions were considered to be doubtful if 
erythema and infiltration did not cover the whole test area. Readings were performed 
on day (D) 3 and D7. For the present analysis, the maximum patch test reactions of 
these 2 readings were aggregated as the patch test outcome. The distribution of the 
strength of positive patch test reactions to the hydroperoxides are presented for 
different groups of patients: patients with positive reactions to either hydroperoxides 
of limonene or hydroperoxides of linalool but not to any other fragrance; patients with 
positive reactions to both hydroperoxides of limonene and hydroperoxides of linalool 
but not to any other fragrance; patients with positive reactions to hydroperoxides of 
limonene or hydroperoxides of linalool and to ≥1 other fragrances; and patients with 
positive reactions to both hydroperoxides of limonene and hydroperoxides of linalool 
and to ≥1 other fragrances.
Clinical relevance and additional contact allergies
For all positive patch test reactions, the current and/or past clinical relevance was 
determined based on patient history and exposure, with possible outcomes being 
unlikely/not, possible, probable, and certain. “Unlikely/not” suggested that there was 
no suspected ACD, “possible” suggested that there was some suspicion of a relationship 
between the allergen and the dermatitis (between 1% and 49% convinced), “probable” 
suggested that this suspicion was stronger (between 50% and 99% convinced), and 
“certain” meant that the relationship was proven (100% convinced) by the presence 
of allergen in a product to which there was exposure at the body site where there 
was dermatitis, with a clear temporal relationship. For hydroperoxides of limonene 
and hydroperoxides of linalool, patients were instructed to review the labelling of 
their products for either limonene (or d-limonene, also known as R-limonene, and its 
enantiomer S-limonene), or linalool, respectively, as ingredients in their products. Their 
findings were subsequently discussed at our outpatient clinic; if patients were unsure 
or unable to review their products, they were instructed to bring all of their suspected 
products for review by the dermatologist. Clinical relevance is presented for the same 
groups as described above for strength of patch test reaction. The types of product 
for which exposure caused ACD in patients with a contact allergy to hydroperoxides of 
limonene and/or hydroperoxides of linalool of certain clinical relevance are presented.
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To evaluate concomitant reactions in patients with contact allergy to hydroperoxides of 
limonene, hydroperoxides of linalool, or both, the proportion of patients with at least 
≥1 additional contact allergies apart from allergy to either hydroperoxides of limonene 
or hydroperoxides of linalool, and the proportion of patients with at least ≥1 additional 
non-fragrance allergies (excluding colophonium), are presented. Additional contact 
allergies were not limited to EBS allergens; that is, any contact allergy was considered.
Data analysis
For data analysis, different groups of patients were defined (Figure 1). Group A 
comprised all patients with at least positive patch test reactions to hydroperoxides of 
linonene and/or hydroperoxides of linalool. Group B and group C comprised all patients 
with positive patch test reactions to hydroperoxides of limonene and hydroperoxides 
of linalool, respectively. Group D comprised all patients with positive patch test 
reactions to both hydroperoxides of limonene and hydroperoxides of linalool. In other 
words, groups B-D are subsets of group A. Group E comprised all patients with at 
least 1 positive patch test reaction to a patch tested fragrance allergen but not to 
hydroperoxides of limonene/linalool, and group F comprised all other patch tested 
patients. Table S1 provides an overview of all fragrance allergens tested, including 
the tested concentration and vehicle, in the current cohort of patients. Patient 
demographics for these groups were described according to the MOAHLFA index.(11)
Figure 1.
Venn diagram illustrating the different groups of patients based on their patch test outcomes
7




Statistical analyses were performed according to pertinent guidelines.(12) Prevalences 
are provided in percentages together with 95% confidence intervals (CIs). The reaction 
index (RI) (showing the proportion of doubtful/irritant reactions relative to positive 
reactions, calculated with the formula [positive reactions – (doubtful reactions + irritant 
reactions)]/[positive + doubtful + irritant reactions], giving a value between −1 and 1) 
and positivity ratio (PR) (proportion of weak positive [+] reactions among all positive 
reactions) were calculated for both hydroperoxides of limonene and hydroperoxides of 
linalool.(13, 14) For variables with a normal distribution, the mean and SD are given; for 
non-normally distributed variables, median and interquartile range are given. Logistic 
regression analysis was performed to assess the risk factors for being in 1 of the above-
mentioned groups as compared with not being in that specific group. Both univariable 
and multivariable regression analyses were performed; for the multivariable regression 
analysis, all variables which reached a P-value of <0.1 in the univariable analysis were 
included. Variables analysed were: sex, age ≥ 40 years, (a history of) atopic dermatitis, 
occupational dermatitis, and primary site of dermatitis (generalized, trunk, hand, face, 
leg, and other). All P-values of <0.05 were regarded as being statistically significant. 
Statistical analyses were performed with spss v.23 (IBM) and Excel 2013 (Microsoft).
RESULTS
Hydroperoxides of limonene and linalool
A total of 821 patients (35.6% male, mean age 42.4 years ± 17.8 years) were tested 
with at least our departmental baseline series and our fragrance series including 
hydroperoxides of limonene and hydroperoxides of linalool. Altogether 77 patients 
(9.4%, 95%CI: 7.4%-11.4%) had positive patch test reactions to hydroperoxides 
of limonene, and 96 patients (11.7%, 95%CI: 9.5%-13.9%) had positive patch test 
reactions to hydroperoxides of linalool. The overlap between these 2 groups was 38 
patients (4.6%, 95%CI: 3.2%-6.0%) who had positive reactions to both hydroperoxides 
of limonene and hydroperoxides of linalool. An overview of the patch test reactions to 
both hydroperoxides of limonene and hydroperoxides of linalool is shown in Table 1. 
A total of 141 doubtful (?+) reactions (17.2%, 95%CI: 14.6%-19.7%) and 7 irritant 
reactions (0.9%, 95%CI: 0.2%-1.5%) to hydroperoxides of limonene were observed, 
and 180 doubtful reactions (21.9% 95%CI: 19.1%-24.8%) and 16 irritant reactions 
(1.9%, 95%CI: 1.1%-2.8%) to hydroperoxides of linalool were observed. The RI and 
PR for hydroperoxides of limonene were −0.32 (95%CI: −0.41 to −0.24) and 85.7% 
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(95%CI: 77.9%-93.5%), respectively, and the RI and PR for hydroperoxides of linalool 
were − 0.34 (95%CI: −0.42 to −0.26) and 88.5% (95%CI: 79.2%-94.9%), respectively. Of 
all positive reactions to hydroperoxides of limonene, 6 (7.8%) were either negative or 
doubtful on the D3 reading, and became positive on D7; for hydroperoxides of linalool, 
this was seen in 4 cases (4.2%). For both d-limonene 2.0% pet. and linalool 10.0% pet., 
1 positive reaction per allergen was observed in 2 different patients, both of whom 
were also allergic to both hydroperoxides of limonene and hydroperoxides of linalool.
Table 1. Cross table of all patch test reactions (n=821) to hydroperoxides of limonene 0.3% 
pet. and hydroperoxides of linalool 1.0% pet.
Hydroperoxides of linalool
Negative Irritant ?+ + ++ +++ Total
Hydroperoxides of 
limonene
Negative 479 10 70 37 0 0 596
Irritant 2 4 1 0 0 0 7
?+ 37 2 81 19 2 0 141
+ 9 0 26 26 5 0 66
++ 2 0 2 3 3 1 11
+++ 0 0 0 0 0 0 0
Total 529 16 180 85 10 1 821
Strength of reactions
As can be deduced from the calculated PRs shown above, the majority of positive 
reactions to both hydroperoxides of limonene and hydroperoxides of linalool were 
weak (+) positive. Only 1 extreme (+++) positive reaction to hydroperoxides of linalool 
was observed. Table 2 shows the distribution of the strength of reactions for the 
different groups of patients. It can be observed that patients who reacted to only 
hydroperoxides of limonene or hydroperoxides of linalool had only weak (+) positive 
reactions, whereas patients who reacted to both hydroperoxides of limonene and 
hydroperoxides of linalool and at least 1 additional fragrance had a higher proportion 
of strong (++) positive reactions to hydroperoxides of limonene and/or hydroperoxides 
of linalool.
7
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Table 2. The distribution of the varying degrees of positive reactions for both hydroperoxides 
of limonene and hydroperoxides of linalool, presented for different groups of patients; 
patients with only a positive reaction to one or the other hydroperoxides but not to any 
other fragrance; patients with a positive reaction to both hydroperoxides but not to any 
other fragrance; patients with a positive reaction to one or the other hydroperoxides and 
one or more other fragrances; and patients with a positive reaction to both hydroperoxides 
and one or more other fragrances.
Reaction profile Strength of patch test reaction, n (%)






Limonene 26 26 (100.0) 0 0
Only hydroperoxides 
of linalool
Linalool 42 42 (100.0) 0 0
Both hydroperoxides 
of limolene/linalool
Limonene 16 15 (93.8) 1 (6.3) 0
Linalool 16 13 (81.3) 3 (18.8) 0
Hydroperoxides of 
limonene + other 
fragrance
Limonene 13 9 (69.2) 4 (30.8) 0
Hydroperoxides 
of linalool + other 
fragrance
Linalool 16 14 (87.5) 2 (12.5) 0
Both hydroperoxides 
of limonene/linalool + 
other fragrance
Limonene 22 16 (72.7) 6 (27.3) 0
Linalool 22 16 (72.2) 5 (22.7) 1 (4.5)
Total hydroperoxides 
of limonene
Limonene 77 66 (85.7) 11 (14.3) 0
Total hydroperoxides 
of linalool
Linalool 96 85 (88.5) 10 (10.4) 1 (1.0)
Clinical relevance
The clinical relevance of the positive reactions to both hydroperoxides of limonene and 
hydroperoxides of linalool were evaluated according to the groups described above 
(Table 3). Positive reactions to hydroperoxides of limonene/hydroperoxides of linalool 
in patients who were allergic to both, with or without additional fragrance allergies, 
were more frequently of certain clinical relevance (ranging from 27.3% to 37.5%, not 
statistically significant). The majority of reactions were evaluated as being of possible 
or probable clinical relevance. For patients with “certainly relevant” positive patch test 
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reactions, the product type responsible for the allergic contact dermatitis are shown 
in Table S2. In the majority of patients (15/21, 71.4%), the responsible product types 
were rinse-off products such as soap and shampoo, followed by leave-on products 
such as cosmetics and creams (9/21, 42.9%). Other product types included cleaning 
agents (detergents), deodorants, and perfumes.
Table 3. Clinical relevance for each positive reaction to hydroperoxides of limonene and 
hydroperoxides of linalool, presented for different groups of patients; patients with only 
a positive reaction to one or the other hydroperoxides but not to any other fragrance; 
patients with a positive reaction to both hydroperoxides but not to any other fragrance; 
patients with a positive reaction to one or the other hydroperoxides and one or more other 
fragrances; and patients with a positive reaction to both hydroperoxides and one or more 
other fragrances.
Reaction profile Relevance, n (%)




Limonene 26 5 (19.2) 14 
(53.8)




Linalool 42 7 (16.7) 19 
(45.2)




Limonene 16 1 (6.3) 6 (37.5) 4 (25.0) 5 (31.3)
Linalool 16 0 6 (37.5) 4 (25.0) 6 (37.5)
Hydroperoxides of 
limonene + other 
fragrance
Limonene 13 3 (23.1) 7 (53.8) 3 (23.1) 0
Hydroperoxides 
of linalool + other 
fragrance





Limonene 22 3 (13.6) 7 (31.8) 6 (27.3) 6 (27.3)




Limonene 77 12 (15.6) 34 
(44.2)





Linalool 96 11 (11.5) 40 
(41.7)
26 (27.1) 19 
(19.8)
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The patient characteristics according to the MOAHLFA index are shown in 
Table 4 for each of the defined groups (Figure 1). When group A (positive reactions to 
hydroperoxides of limonene and/or hydroperoxides of linalool) was compared with 
group F (no positive reactions to any fragrance), patients in group A were significantly 
less often male (24.4% vs 39.3%, P = 0.001), significantly older (age >40 years; 67.4% 
vs 53.1%, P = 0.002), suffer(ed) significantly less from atopic dermatitis (40.0% vs 
50.7%, P = 0.028), and less often had the face as the primary site of dermatitis (17.0% vs 
21.8%, P = 0.24). No notable differences were observed between patients in groups B, 
C, and D, except that patients in group D were almost exclusively female (10.5% males).
A regression analysis was performed for each of these groups (except for group F, all 
members of which were not allergic to a fragrance); the results are shown in Table 5. 
Data from group A showed that being female was a significant risk factor for contact 
allergy to hydroperoxides of limonene and/or hydroperoxides of linalool (odds ratio 
[OR] 1.91, 95%CI: 1.25-2.91). In group A, another significant association was found for 
patients aged ≥40 years (OR 1.86, 95%CI: 1.26-2.75). A decreased risk was found in 
patients with a current or past history of atopic dermatitis (OR 0.64, 95%CI: 0.44-0.93). 
In the multivariable analysis, atopic dermatitis was no longer a significant risk factor 
(OR 0.71, 95%CI: 0.48-1.06), whereas female sex became an even larger risk factor (OR 
2.05, 95%CI: 1.33-3.13). In group A, females had significantly more atopic dermatitis 
than males (52.2% vs 43.8%, P = 0.019), which might explain this finding. When group 
B (positive reactions to hydroperoxides of limonene) was compared with group C 
(positive reactions to hydroperoxides of linalool), the main difference was that age 
≥40 years was a risk factor for patients in group C (OR 2.28, 95%CI: 1.43-3.65), but not 
significantly so in group B (OR 1.39, 95%CI: 0.86-2.26). Conversely, although female 
sex was a significant risk factor in both groups, it was a stronger risk factor in group B 
(OR 2.73) than in group C (OR 1.91). In the multivariable analysis, atopic dermatitis was 
significantly associated with being in group B (OR 0.59, 95%CI: 0.36-0.95), suggesting 
that the importance of atopic dermatitis in group A was mainly driven by the subset 
of patients allergic to hydroperoxides of limonene, whereas a larger proportion of 
the subset of patients allergic to hydroperoxides of linalool were aged ≥40 years. 
Occupational dermatitis and primary site of dermatitis were not significant risk factors 
for any of the groups.
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Concomitant contact allergies
The proportions of patients with contact allergies other than to either hydroperoxides 
of limonene or hydroperoxides of linalool were 75.6% (95%CI: 68.4%-82.8%) for group 
A (patients allergic to hydroperoxides of limonene and/or hydroperoxides of linalool), 
and 84.2% (95%CI: 72.6%-95.8%) for group D (allergic to both hydroperoxides) 
(Table 6). The proportion of patients with additional contact allergies but not to 
fragrances and/or colophonium was 72.6% (95%CI: 65.1%-80.1%) for group A.
Including both hydroperoxides of limonene and hydroperoxides of linalool, a total 
of 233 patients (28.4%, 95%CI: 25.3%-31.4%) had at least 1 positive reaction to a 
fragrance. Of these 233 patients, 98 (11.9%, 9.7%-14.1%) had a positive reaction 
to a fragrance but not to either hydroperoxides of limonene or hydroperoxides of 
linalool, 53 patients (6.5%, 95%CI: 4.8%-8.2%) reacted to both at least 1 fragrance 
and hydroperoxides of limonene and/or hydroperoxides of linalool, and the remaining 
82 patients (10.0%, 95%CI: 7.9%-12.0%) reacted only to hydroperoxides of limonene 
and/or hydroperoxides of linalool, but not to any other fragrance. Table 7 shows the 
numbers of concomitant fragrance reactions per patch tested fragrance. An important 
observation is that, regarding patients with contact allergy to hydroperoxides of 
limonene and/or hydroperoxides of linalool, a significantly larger proportion had a 
concomitant contact allergy to a fragrance and/or colophonium (39.3%, 95%CI: 
31.3%-47.5%) than patients who were not allergic to hydroperoxides of limonene and/
or hydroperoxides of linalool (14.3%, 95%CI: 11.7%-16.9%). On analysis of group A, 
patients who were allergic to both hydroperoxides of limonene and hydroperoxides 
of linalool more frequently reacted positively to additional fragrance allergens and/
or colophonium (63.2%, 95%CI: 47.9%-78.5%) than patients who were allergic to 
hydroperoxides of limonene (33.3%, 95%CI: 18.5%-48.1%) and significantly more 
frequently than patients who were allergic to hydroperoxides of linalool alone (27.6%, 
95%CI: 16.1%-39.1%).
7
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DISCUSSION
In our cohort of consecutively patch tested dermatitis patients, 9.4% and 11.7% showed 
positive patch test reactions to hydroperoxides of limonene and hydroperoxides of 
linalool, respectively, supporting the recent proposal to include them in the EBS.
(15) This is a higher number than found in recent studies, in which prevalences of 
contact allergy to hydroperoxides of limonene ranged from 2.5% to 5.4%, and 
prevalences of contact allergy to hydroperoxides of linalool ranged from 3.9% to 
7.7%.(6, 8, 9) However, in multicentre studies, a large variation in positive patch test 
reactions between centres was observed; for example, in one study, prevalences of 
contact allergy to hydroperoxides of limonene ranged from 0% to 24.8%.(8) A possible 
explanation for the large number of positive reactions to the hydroperoxides could 
be that our centre is a tertiary referral centre, so more patients with severe and/
or persistent dermatitis are seen than in other centres. This could also explain the 
large proportion of additional positive reactions observed for patients with positive 
reactions to hydroperoxides of limonene and/or hydroperoxides of linalool, and the 
large number of fragrance-positive patients overall. Concerning doubtful and irritant 
reactions to both hydroperoxides of limonene and hydroperoxides of linalool—in our 
cohort, there were many doubtful (17.2% and 21.9%, respectively) and few irritant 
(0.9% and 1.9%, respectively) reactions—large variations in the numbers of doubtful 
and irritant reactions have been observed in different studies. For instance, Deza et 
al observed 0.4% doubtful and 1.5% irritant reactions to hydroperoxides of limonene 
0.3% pet., whereas Bennike et al observed 13.7% doubtful and 5.8% irritant reactions.
(6, 8) An even larger variation in the percentages of doubtful and irritant reactions has 
been reported for hydroperoxides of linalool. Our observation that the majority of 
positive reactions to either hydroperoxides of limonene or hydroperoxides of linalool 
were weak positive (+) is in line with the literature.(7, 16-18)
On the basis of our results, a low RI (<0) and a high PR (>80%) for both hydroperoxides 
of limonene and hydroperoxides of linalool were calculated, indicative of a problematic 
patch test concentration.(13, 14) Considering that the low RIs for both allergens are 
mostly caused by a high number of doubtful reactions, and only a small number of 
irritant reactions, a reasonable assumption would be that patch testing with higher 
concentrations might improve the diagnostic performance. Differentiation between 
doubtful reactions and irritant reactions can be difficult, as can be deduced from the 
variation in doubtful and irritant reactions in previous studies. It can therefore not 
7
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be excluded that, even though all visual readings were performed by an experienced 
dermatologist, some of the doubtful reactions were irritant. If this was the case, it 
might be prudent to test both allergens in a lower concentration. An additional concern 
regarding testing at higher concentrations is the higher risk of active sensitization, 
as studies have shown that an irritant effect can increase this risk.(19) Christensson 
et al patch tested dermatitis patients and healthy controls with sequentially diluted 
concentrations of oxidized limonene and oxidized linalool; for both, an increasing 
concentration led to more irritant reactions, although this effect was stronger for 
oxidized limonene than for oxidized linalool.(20) The highest tested concentration 
of oxidized linalool (20%, most likely containing 3.34% hydroperoxides of linalool, on 
the basis of the presence of 1.0% hydroperoxides of linalool in 6.0% oxidized linalool)
(17) showed a mean irritation score of 1.63 points, and a maximum of 4 points, based 
on a scoring system ranging from 0 to 9 developed by Basketter et al,(21) in which an 
irritant reaction would be noted from 2 to 3 points.(20) Studies have been performed 
with lower patch test concentrations of hydroperoxides of limonene (0.1% and 0.2%) 
and hydroperoxides of linalool (0.25% and 0.5%), and have concluded that the current 
patch test concentrations are preferred over lower concentrations, as too many positive 
reactions might be missed.(8, 9) The observed high PR further supports the argument 
that the current patch test concentrations might be too low. Future studies should be 
performed to investigate the ideal patch test concentrations for hydroperoxides of 
limonene and hydroperoxides of linalool.
Clinical relevance is generally difficult to ascertain, as it depends on how well and 
how diligent a patient reads product labels and identifies the presence of contact 
allergens in the product. For hydroperoxides of limonene and hydroperoxides of 
linalool, an additional limitation is that these are not mentioned as such on labels. 
Therefore, patients have to look for limonene and/or linalool, as these are among the 
26 fragrances for which labelling is required on cosmetic and detergent products in the 
EU.(22) Studies have shown that fine fragrances and essential oils, which often contain 
limonene and/or linalool, also contain hydroperoxides as a result of autoxidation.
(23, 24) In the current study, the designation “certain” clinical relevance was reserved 
for patients who showed a clear temporal relationship between body site-specific 
exposure to a product containing limonene and/or linalool and dermatitis at that body 
site, even though the presence of actual hydroperoxides was not confirmed by analysis 
of the products, and no open use test or repeated open application test was performed. 
Notwithstanding these limitations, almost 20% of the reactions were evaluated as 
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being of “certain” clinical relevance, and at least another 20% were of “probable” 
clinical relevance.
Patients who are allergic to hydroperoxides of limonene and/or hydroperoxides of 
linalool were mostly female, were aged 40 years, and less frequently had (a history 
of) atopic dermatitis, in line with previous literature. The lower prevalence of atopic 
dermatitis in this patient group might explain the low number of irritant reactions to 
the hydroperoxides, as (a history of) atopic dermatitis is associated with increased 
susceptibility to irritants.(25) A recent study, however, did not find any differences 
in the prevalences of atopic dermatitis between patients with positive reactions to 
hydroperoxides of limonene and/or hydroperoxides of linalool, and patients with 
irritant reactions.(9) A strength of the current investigation is that D7 readings 
were performed, as, without this late reading, approximately 8% and 4% of positive 
reactions to hydroperoxides of limonene and hydroperoxides of linalool, respectively, 
would have been missed.
In conclusion, high prevalences of contact allergy to hydroperoxides of limonene and 
hydroperoxides of linalool have once again been observed, supporting the proposed 
inclusion in the EBS. Furthermore, 40% of all reactions to hydroperoxides of limonene 
and hydroperoxides of linalool were of either “probable” or “certain” clinical relevance. 
Although varying proportions of doubtful and irritant reactions have been reported in 
the literature, the low RIs and high PRs calculated for both hydroperoxides of limonene 
and hydroperoxides of linalool indicate that the ideal patch test concentration might 
be higher than the currently tested concentrations, although the risk of active 
sensitization must be kept in mind. A large number of patients who are allergic to 
hydroperoxides of limonene and/or hydroperoxides of linalool have additional contact 
allergies, both to fragrances and to other non-fragrance contact allergens.
7
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Table S1. Overview of all fragrance allergens (and colophonium) patch tested in each 
consecutive patient at our patch test clinic. Fragrance mix I, myroxylon pereirae, and 
colophonium are tested with the TRUE Test®, all other fragrance allergens are tested in 
petrolatum in Van der Bend chambers.
Fragrance Concentration and vehicle
European Baseline series
Fragrance mix I 430 μg/cm² (TRUE Test®)
Fragrance mix II 14.0% pet.
Hydroxyisohexyl 3-cyclohexenecarboxyaldehyde (Lyral) 5.0% pet.
Myroxylon Pereirae (Balsam of peru) 800 μg/cm² (TRUE Test®)
Colophonium (resin) 850 μg/cm² (TRUE Test®)
Fragrance series
Amyl cinnamyl alcohol 5.0% pet.
Anisyl alcohol (Anise Alcohol) 1.0% pet.
Benzyl alcohol 10.0% pet.
Benzyl benzoate 1.0% pet
Benzyl cinnamate 5.0% pet.
Benzyl salicylate 1.0% pet.
Cinnamic alcohol 2.0% pet






Hexyl cinnamic aldehyde (Hexyl Cinnamal) 10.0%
Hydroxycitronellal 2.0% pet
Isoeugenol 2.0% pet
Butylphenyl Methylpropional (Lilial) 10.0% pet.
D-Limonene 2.0% pet
Linalool 10.0% pet.
Methyl 2-Octynoate (Methyl heptene carbonate) 1.0% pet.
Alpha-isomethyl Ionone (gamma-Methylionone) 1.0% pet.
Evernia Prunastri (Oakmoss absolute) 2.0% pet
Evernia Furfuracea (Treemoss) 1.0% pet.
Amyl Cinnamal (alpha amyl Cinnamic aldehyde) 1.0% pet.
Eugenol 2.0% pet
Hydroperoxides of Linalool 1.0% pet.
Hydroperoxides of Limonene 0.3% pet.
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Table S2. The product category which caused allergic contact dermatitis in subjects with 
a contact allergy of certain clinical relevance to either/both hydroperoxides of limonene 
and/or linalool. Presence of either or both limonene and/or linalool in the product was 
ascertained by the patients themselves, and by the dermatologist in case a patient brought 




















3 limonene x x







11 both x x
12 both x x
13 both x
14 both x x x x
15 both x
16 both x x x
17 both x x
18 both x x x x
19 both x
20 both x x
21 both x x
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Transcutaneous electrical nervous stimulation (TENS) is an effective therapy for 
chronic lower back pain, and has few side effects as compared with pharmacological 
treatment (1, 2). Electrodes are patched onto the skin, and an electrical current running 
between these inhibits the neural conduction of pain stimulation. The electrodes are 
self-adhesive and stay on the skin for up to several days, and can therefore cause both 
irritant and allergic contact dermatitis.
CASE REPORT
An 81-year-old man was referred to us with erythema, superficial erosions, 
haemorrhagic crusts and some petechiae on the lower back at the site where TENS 
had been applied continuously for the last 3 years to treat his chronic lower back pain 
(Fig. 1a). The symptoms first appeared 14 months after the start of treatment. Since 
then, a total of six different TENS electrodes have been prescribed, all of them causing 
the same symptoms. The TENS device was switched on continuously during the day 
but not at night, although the electrodes stayed on the skin. The TENS electrodes 
prescribed were: Flexibele Elektroden (Klinerva, Ankeveen, The Netherlands), Klinerva 
Silver Electrode, Klinerva Stimtrode (Model ST50505) (Klinerva), Dura-stick® plus (Ref. 
42198), Dura-stick® (Ref. 42191), and Dura-stick® premium (Ref. 42209) (DJO Global, 
Guildford, UK). The patient was patch tested with our extended European baseline 
series (TRUE Test® panels 1 and 2; SmartPractice Europe, Barsbüttel, Germany), 
supplemented with additional chamber-loaded allergens and a (meth)acrylates series 
(Chemotechnique Diagnostics, Vellinge, Sweden), tested in Van der Bend chambers 
(Van der Bend, Brielle, The Netherlands) attached to the back with Fixomull stretch® 
(BSN Medical, Hamburg, Germany). Additionally, five of the six electrodes were patch 
tested ‘as is’, without an electrical current. One of the six, Klinerva Silver Electrode, 
was no longer in production, and could therefore not be patch tested. A ‘use test’ 
(with electrical current) was performed with four of the five electrodes on the lower 
back. The TENS devices were turned off during the night to reflect real-life conditions. 
The patch tests and electrodes were applied on the back for 2 days under occlusion, 
and readings were performed on day (D) 3 and D7, according to the guidelines of the 
ICDRG/ESCD (3). The results are shown in Table 1 and Figure S1. The patient had weak 
positive reactions to several (meth)acrylates, and strong positive reactions to four of 
the five tested TENS electrodes, but not to Flexibele Elektroden.
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Figure 1.
(a) Itchy rash on the lower back with erythema, superficial erosions, haemorrhagic crusts, 
and some petechiae. (b) Skin lesions on the lower back disappeared after switching to the 
Dura-stick premium Blue transcutaneous electrical nervous stimulation electrodes.
Table 1: Patch test results of electrodes ‘as is’, electrodes ‘use test’ (with current), the 
positive reactions to the (meth)acrylates series, to the acetone extracts, the thin layer 
chromatograms (TLCs), and to glycerine (10.0% aq.) and acrylic acid (0.1% pet.), as assessed 
according to the guidelines of the ICDRG.
Day 2 Day 3 Day 7
Electrodes ‘as is’
Flexibele Elektroden NR - -
Klinerva Stimtrode NR +++ +++
Dura-stick plus NR ++ ++
Dura-stick NR +++ +++
Dura-stick premium NR ++ ++
Electrodes ‘use test’
Flexibele Elektroden NR - -
Klinerva Stimtrode NR +++ +++
Dura-stick plus NR +++ +++
Dura-stick NR +++ +++
(Meth)acrylates series (positive reactions)
2-Hydroxyethyl acrylate 0.1% pet. NR ++ +
2-Hydroxypropyl acrylate 0.1% pet. NR + +
2-Hydroxyethyl methacrylate (2-HEMA) 2.0% pet. NR + +
Ethyleneglycol dimethacrylate (EGDMA) 2.0% pet. NR + +
1,4-butanediol diacrylate 0.1% pet. NR + +
8a




Day 2 Day 3 Day 7
Diethyleneglycol diacrylate 0.1% pet. NR + +
Acetone extracts, TLCs, and ingredients
1. Dura-stick plus extract - - -
2. Stimtrode extract - - -
3. Dura-stick extract - - -
4. Dura-stick premium extract - - -
Mix electrodes 1-4, acetone extract, non-evaporated ? ++ +
Mix electrodes 1-4, acetone extract, evaporated ++ +++ ++
TLC strip non-evaporated - - -
TLC strip evaporated - - -
Glycerine 10.0% aq. - - -
Acrylic Acid 0.1% pet. ? ++ +++
NR = no reading performed; ‘-‘ = negative; ‘?’ = doubtful reaction
Material data safety sheets (MSDSs) of all electrodes were retrieved, and showed that 
the same adhesive gel was used in Klinerva Stimtrode, Dura-stick®, Dura-stick® plus 
and Dura-stick® Premium: Multistick® Hydrogel. The composition was as follows: 
glycerol (glycerin) (non-tallow), water, and poly(acrylate) copolymer (CAS no. 28062-
44-4; acrylic acid-N-vinylpyrrolidone copolymer). The data sheet did not mention 
the presence of any of the (meth)acrylates to which our patient was sensitized. Our 
hypothesis was that, despite this fact, there could still be traces of (meth)acrylates 
present in the adhesive layer. The MSDS for Flexibele Elektroden showed that no 
(meth)acrylates were present, and we postulated that the patient most likely had 
developed irritant contact dermatitis initially. Another TENS electrode without (meth)
acrylates was prescribed: Dura-stick premium Blue (PALS® Platinum Blue Electrode 
with Blue Hydrogel). The ingredients according to the MSDS were: polyethylene glycol, 
water, magnesium acetate, and polyvinylpyrrolidone (CAS no. 9003-39-8). The skin 
lesions disappeared completely (Fig. 1b).
To ascertain whether there were any (meth)acrylates present in Multistick® Hydrogel, 
and to identify the true culprit allergen, additional patch testing was performed 
with acetone extracts of the electrodes, thin-layer chromatograms (TLCs), and the 
ingredients according to the MSDS. Non-evaporated extracts of each electrode 
containing Multistick® Hydrogel on its own and combined as a mix were prepared in 
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acetone, and an evaporated extract of all electrodes combined (mix) in acetone was 
also prepared. Extraction was performed with an ultrasonic bath, and the supernatant 
was concentrated with a vacuum evaporator (4). Two TLCs were prepared, one by 
application of 100 μl of the non-evaporated mix, and the other by application of 60 
μl of the evaporated mix, and then separated on silica gel (5). The mobile phase was 
50:50 heptane/ethyl acetate. Of the ingredients, acrylic acid (CAS no. 79-10-7) was 
patch tested 0.1% pet., and glycerol (CAS no. 56-81-5) was patch tested 10% aq. The 
extracts, acrylic acid, glycerol and TLCs were applied for 48 h, and read on D2, D3, 
and D7 (Table 1). Both extracts of the mixes and acrylic acid 0.1% pet. (Fig. 2) gave 
positive results, but the TLCs gave negative results. Subsequently, one Dura-stick® 
premium electrode was analysed for the presence of acrylic acid by the use of high-
performance liquid chromatography coupled with ultraviolet detection (HPLC-UV). 
The electrode was extracted in the mobile phase used for the analysis of acrylic acid 
(20:80 acetronitrile/water with 0.1% phosphoric acid). HPLC-UV of this extract showed 
an undisturbed spectrum of acrylic acid, and quantification showed that there was ∼57 
μg of acrylic acid per gram of electrode. When calculated for the electrode when it was 
attached to the back, the release of acrylic acid from the electrode was ∼7.6 μg/cm2 
(the patch test preparation of 0.1% acrylic acid corresponds to a dose of ∼39 μg/cm²). 
Figure 2.
Patch test reactions to acrylic acid 0.1% pet. on day 2 (a), day 3 (b), and day 7 (c), showing a 
clear crescendo pattern.
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Previously, 4 cases of contact allergy to (meth)acrylates used in TENS have been 
reported (6–8). Prior to that, there were reported cases of allergic contact dermatitis 
caused by propylene glycol in a conductive gel used for TENS application (9, 10), 1 
case report of contact allergy to nickel in a TENS electrode (11), and 1 case report of 
TENS contact dermatitis in which the allergen was not identified (12). When (meth)
acrylates were identified as the causative allergens, this was based on information 
from the MSDS or from the producer. 
In the present case report, the initial patch test showed (weak) positive reactions to 
(meth)acrylates. Although the MSDS only showed the presence of a poly(acrylate) 
copolymer, it has been shown through analysis of products containing acrylate 
polymers that the MSDS often provides incomplete information regarding the acrylate 
monomers present in the product (13). Our initial hypothesis was that traces of (meth)
acrylate monomers were the likely cause of the skin symptoms; however, further 
testing with acetone extracts and the ingredients according to the MSDS provided 
new information. The patient developed a +++ reaction to acrylic acid, showing a 
clear crescendo pattern. Positive reactions were also seen to the extracts of multiple 
electrodes combined, but not to extracts of the individual electrodes. This can be 
explained by the differences in concentrations of substances between the different 
extracts. It is interesting to note that the TLCs did not give positive reactions, even 
though they were prepared from the extracts that did give positive reactions. This 
might be explained by the volatile nature of (meth)acrylates (14). Another explanation 
might be a too low surface concentration of acrylic acid on the TLC plate, as it showed 
poor resolution on TLCs, without a well-defined spot for this substance. 
HPLC-UV of a sample of the Dura-stick® premium electrode (containing Multistick® 
Hydrogel) showed that acrylic acid was indeed present in the adhesive, and we 
therefore believe that acrylic acid was the culprit allergen. The MSDS of Dura-stick® 
premium Blue, which the patient tolerated, showed that it did not contain any acrylic 
acid. Acrylic acid was also shown to be the culprit allergen in a recent case report 
of allergic contact dermatitis caused by the adhesive layer of electrocardiogram 
electrodes (15).
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The release per cm2 of acrylic acid in the electrode was lower than that of the 
concentration in pet. With which the patient was patch tested (7.6 μg/cm2 as compared 
with 39 μg/cm2). However, given the fact that 0.1% acrylic acid gave a +++ reaction, it 
is not unlikely that the elicitation threshold might even be <7.6 μg/cm2. Furthermore, 
the electrodes were attached to the lower back continuously, whereas the patch test 
is applied for only 48 h. The positive reactions to the various (meth)acrylates might 
be explained as cross-reactions, although a recent patch test study did not show any 
cross-reactions between acrylic acid and (meth)acrylates (16). Another explanation 
might be previous sensitization, even though a detailed history of the patient did not 
show exposure to products containing (meth)acrylates.
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Following submission of the case report, two more patients were referred to our 
outpatient clinic presenting with contact dermatitis to their TENS electrodes. A 
short overview is provided below in table S1.
Table S1: Patch test results to TENS electrodes, acrylic acid 0.1% pet., and positive 
reactions to the (meth)acrylates series (Chemotechnique Diagnostics, Vellinge, 
Sweden) in two additional cases presenting with allergic contact dermatitis to their 
TENS electrodes; a 81 year old, non-atopic, female who developed contact dermatitis 
after 6 months of TENS application, and a 70 year old, non-atopic, male who developed 
contact dermatitis to his TENS electrodes shortly after start of TENS application. 
TENS electrodes that were used by the patients were: Uni-Patch S Series (REF 696SS, 
Covidien, Dublin, Ireland)(cases 2 and 3), Dura-stick premium (REF 42209, DJO Global 
inc., Guildford Surrey, England)(cases 2 and 3), ValuTrode (Model CFF153, Axelgaard 
Manufacturing CO, Ltd. Falbrook, USA) (case 2), Flexibele elektroden (Eurocept 
Homecare, Houten, the Netherlands, previously known as Klinerva BV, Ankeveen, 
The Netherlands)(case 3), and Elektroden rechthoekig (Eurocept Homecare, Houten, 
the Netherlands)(case 3).
Patch testing and readings were performed as described in the case report. Both 
cases developed a positive patch test reaction (strong positive and extreme positive, 
respectively) to acrylic acid, present in Multi-stick Hydrogel, used in the following 
TENS electrodes: Dura-stick, Dura-stick premium, ValuTrode. Covidien was contacted 
to provide the material data safety sheet for the Uni-Patch S series TENS electrode, 
but none were provided.
Case 2 (81-year old female) Case 3 (70 year 
old male)
Day 3 Day 7 Day 11 Day 3 Day 7
Electrodes ‘as is’ + acrylic acid
Uni-Patch S Series - - - - -
Uni-Patch S Series* Re-test - (D4 reading)
Dura-stick premium ? +++ ++ +++ ++
ValuTrode - ++ + NT NT
Flexibele elektroden NT NT NT - -
Zelfklevende elektroden rechthoekig NT NT NT ++ +
Dura-stick NT NT NT +++ ++
8a




Case 2 (81-year old female) Case 3 (70 year 
old male)
Day 3 Day 7 Day 11 Day 3 Day 7
Acrylic Acid 0.1% pet. ++ + + +++ ++
(Meth)acrylates series (positive 
reactions)
Ethyl acrylate 0.1% pet. +++ + NR ++ ++
Butyl acrylate 0.1% pet. ++ + NR ++ ++
2-hydroxyethyl acrylate 0.1% pet. ++ ++ NR +++ ++
2-hydroxypropyl acrylate 0.1% pet. ++ ++ NR +++ +++
Methyl methacrylate 2.0% pet. - - NR + +
2-hydroxyethyl methacrylate (HEMA) 
2% pet.
++ + NR ++ ++
2-hydroxypropyl methacrylate 
(HPMA)2% pet.
++ + NR ++ ++
ethyleneglycol dimethacrylate 
(EGDMA) 2% pet.
++ + NR ++ ++
Triethylene glycol dimethacrylate 
(TEGDMA) 2% pet.
- ? NR ? +
1,4-Butanediol dimethacrylate 2.0% 
pet.
- - NR + ++
1,4-butanediol diacrylate 0.1% pet. + ++ NR +++ ++
1,6 hexanediol diacrylate 0.1% pet. + ++ NR +++ ++
diethyleneglycol diacrylate 0.1% pet. +++ +++ NR +++ +++
tripropylene glycol diacrylate 0.1% 
pet.
- + NR +++ ++
trimethylolpropane triacrylate 0.1% 
pet.
- ? NR ++ ++
pentaerthritol triacrylate 0.1% pet. - + NR ++ ++
Oligotriacrylate 0.1% pet. - + NR + +
Urethane diacrylate (aliphatic) 0.1% 
pet.
- - NR ? -
Urethane diacrylate (aromatic) 0.05% 
pet.
- - NR + +
Epoxy acrylate 0.5% pet. - + NR ++ ++
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Table S1. Continued
Case 2 (81-year old female) Case 3 (70 year 
old male)
Day 3 Day 7 Day 11 Day 3 Day 7
triethylene glycol diacrylate 0.1% pet. + +++ NR +++ +++
‘-‘, negative patch test reaction; NR, not read; NT, not tested (because patient did not use 
the TENS electrodes).
* During application of the patch test material, case 2 revealed she had been using clobetasol 
ointment once per day on the whole back. For this reason, the Uni-Patch S Series TENS 
electrode was re-tested on the day 7 (D7) reading to confirm the negative reaction seen on 
the D3 and D7 reading, and subsequently read on D4, providing an opportunity for a D11 
reading for the other TENS electrodes.
Figure S1. 
Patch test results of the electrodes at day 3. The top row shows the patch test results of 
the electrodes ‘as is’. The bottom row shows the patch test results of the ‘use test’; i.e., 
electrodes exposed with electrical current. A1/2, Flexibele Elektroden; B1/2, Klinerva 
Stimtrode; C1/2, Durastick ® plus; D1/2, Dura-stick®; E, Dura-stick® premium.
8a
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Ethylenediamine [EDA, C2H4(NH2)2, CAS no. 107-15-3] is an aliphatic amine with 
a broad range of applications in rubber, dyes, insecticides, and synthetic waxes. 
Historically, the most common reason for allergic contact dermatitis caused by 
EDA was its use as a stabilizer in topical medicaments (e.g. Mycolog® cream) (1, 
2). This application of EDA has been discontinued. In 1995, EDA was removed from 
the European baseline series because of the low incidence of EDA sensitization (3). 
However, it is still present in the bronchodilator aminophylline, and is often found 
in occupational settings (4). In this article, we present two process operators with 




A 55-year-old, healthy, non-atopic male was referred to our centre with complaints of 
periocular oedema, erythema, and pruritus for over 1 year (Fig. 1). In addition to skin 
complaints, he suffered from nocturnal nasal obstruction and sneezing. Both skin and 
nasal symptoms subsided during weekends and holidays, suggesting a relationship 
with work. The patient had been working for the company for ∼5 years, and worked 
with safety goggles. The severity of his symptoms was apparently related to the 
presence and direction of the wind, and increased after he had been dealing with 
equipment malfunction or leakage.
136610_Daan_Dittmar_BNW-def.indd   182 30-7-2019   10:17:09
183
Allergic contact dermatitis in two employees of an ethylene amine-producing factory
Figure 1.
Case 1: oedema and erythema in the periocular region. Picture printed with full consent of 
the patient.
Case 2
A 27-year-old, healthy, non-atopic male was referred with pruritic hyperkeratosis, 
fissures and occasional vesicles of the hands (predominantly thumb and index fingers; 
Fig. 2). He had been working for the company for 8 months, and the first symptoms 
started 6 months ago. The symptoms persisted during weekends and holidays. 
During a previous internship at the same company ∼7 years ago, he also experienced 
complaints of  ‘dry red hands’ with pruritus. These symptoms resolved 4 months after 
the end of the internship. 
Both patients denied previous use of EDA-containing (topical) medicaments or 
aminophylline. The production facility of this company is completely outdoors. The 
patients’ work activities included controlling, connecting, and cleaning distillation 
columns; residual water from the distillation process is used for cleaning. Cleaning 
is performed with hoses, during which vapour of the processed water is in the air. 
Documentation from the factory showed that the residual water used for cleaning 
8b
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contained traces of EDA, diethylenetriamine (DETA), and triethylenetetramine (TETA), 
among other substances. 
Figure 2. 
Case 2: hyperkeratosis, fissures and lichenification of predominantly the thumb and index 
finger of the left hand. The right hand showed hyperkeratosis and fissures on the palm 
(photograph not shown).
Patch testing was performed in both cases with the European baseline series, partly 
with the TRUE Test® (Mekos, Hillerød, Denmark), which included ethylenediamine 
dihydrochloride 50 μg/cm2 in a hydrophilic matrix. Additional patch testing was 
performed with DETA 1.0% pet. and TETA 0.5% pet. (Chemotechnique Vellinge, 
Sweden) in Van der Bend® square chambers (van der Bend, Brielle, The Netherlands). 
In addition, all products of the distillation process were provided by the company as 
1.0% aq., and subsequently patch tested. The tests were read according to ICDRG 
guidelines on day (D) 3 and D7 (Table 1). Both patients had positive patch test reactions 
to EDA included in the TRUE Test® and 1.0% aq., to DETA 1.0% pet. and 1.0% aq., and 
to TETA 0.5% pet., but not to TETA 1.0% aq. Both workers had to change jobs because 
exposure to EDA could not be avoided while they were working as process operators 
at the ethylene amine-producing factory. Cessation of exposure to ethylene amines 
led to resolution of all symptoms.
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Table 1. Patch test results
Case 1 Case 2
Patch tests D3 D7 D3 D7
Departmental baseline seriesa
 Ethylenediamine (EDA) dihydrochloride 50 µg/cm² ++ + ++ +
Additional patch tests
 Diethylenetriamine (DETA) 1.0% pet. + - ++ +
 Triethylenetetramine (TETA) 0.5% pet. ? + ++ +
Distillation products
 Ethylenediamine (EDA) 1.0% aq. - ++ ++ +
 Diethylenetriamine (DETA) 1.0% aq. - + ++ +
 Triethylenetetramine (TETA) 1.0% aq. - - - -
 Tetraethylenepentamine (TEPA) 1.0% aq. - - - -
 Pentaethylenehexamine (PEHA) 1.0% aq. - - - -
 N-aminoethylpiperazine (n-AEP) 1.0% aq. - - - -
 Higher ethylene polyamines (HEPA) 1.0% aq. - - - -
 Higher ethylene polyamines (HEPA) s140 1.0% aq. - - - -
 Piperazine anhydrous (PIP) 1.0% aq. - - - -
 Aminoethylethanolamine (AEEA) 1.0% aq. - - - -
 Ethylene dichloride (EDC) 1.0% aq. - - - -
 Process water, undiluted - - - -
a Only relevant patch tests results are shown.
DISCUSSION
Occupational allergic contact dermatitis caused by EDA has been described, with the 
cause being exposure to aminophylline, lubricants, metal polishers, detergents, floor 
polish removers, and epoxy resin hardeners, among other substances (5–13). One 
study investigated a cohort of employees of an ethylene amine-producing factory 
exposed to EDA over the course of 36 years, and found that many had developed 
skin and/or respiratory complaints (14). In this case report, we describe 2 patients 
with allergic contact dermatitis working at the same factory, the first of whom also 
suffered from rhinitis. Another process operator from the same company was also seen 
at our outpatient clinic, but with respiratory complaints only. The ethylene amines 
are manufactured by a process in which ammonia reacts with ethylene dichloride 
8b
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under high pressure. Soda is added to the process, and multiple end-products (Table 
1, distillation products) are subsequently isolated by distillation. Heated residual water 
remains and is used, among other purposes, for cleaning. This water contains small 
amounts of ethylene amines, including, and most prominently, EDA. Both workers 
were sensitized to EDA, DETA, and TETA, and, because those were present in varying 
concentrations in the water and in the air at the factory, most likely all three were 
responsible for their allergic contact dermatitis. 
Case 1 presented with periocular airborne allergic contact dermatitis related to the 
direction of the wind, in spite of using safety goggles. He had positive patch test 
reactions to EDA, DETA, and TETA, although TETA only gave a positive reaction 
as 0.5% pet. and not as 1.0% aq. taken from the distillation process. This might be 
because pet. is a more appropriate vehicle for patch testing with TETA. Another 
explanation might be that the TETA aq. solution provided by the company actually 
contained <1.0% TETA. The localization of the patient’s skin symptoms could be 
explained by trapping of the airborne ethylene amines behind his safety goggles. 
His rhinitis could be explained by either a type IV hypersensitivity reaction or an 
irritant reaction, although a type I hypersensitivity reaction cannot be excluded. 
An assay for specific IgE for EDA has not been developed yet, and could therefore 
not be utilized. Occupational rhinitis caused by ethylene amines has been described 
previously, although the exact mechanism remains unclear (15). Case 2 presented with 
hand eczema, with positive patch test reactions to the same substances as case 1. His 
nitrile gloves are impermeable to liquids, but we hypothesize that either the residual 
water might have entered at the edge of the glove and become trapped inside, or that 
contamination occurred during the taking off and putting on of already used gloves, or 
a combination of both. The resulting hand dermatitis was diagnosed as allergic contact 
dermatitis with an irritant component.
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The focus of this thesis is on three different aspects of contact allergy: immunology, 
patch testing, and epidemiology, aspects that do not exist in a vacuum but inform 
one another. For example, in order to understand how patch testing works and how 
to correctly interpret its findings, some understanding is needed of immunology of 
contact allergy. In order to place epidemiological findings in the correct context, 
understanding is needed of how certain factors such as for example inter-individual 
variability and even meteorological conditions can influence patch test results. 
First, a short overview of the main findings of this thesis will be presented, after 
which two themes will be explored; whether polysensitisation represents a valid 
phenotype for increased susceptibility to develop contact allergy, and quantitative 
risk assessment, a toxicological method that serves as primary prevention to prevent 
induction of contact allergy to occur.
Chapter 2 presents a review of the role of TNF in both the induction and elicitation 
phase of contact allergy, the role of genetic variants in the promoter region of TNF in 
increased susceptibility to become sensitised to contact allergens, and how best to 
perform future investigations into the association between specific genetic variations 
and susceptibility to contact allergy. By reviewing the role of TNF in contact allergy 
induction the role of the innate immune system is highlighted, indicating that irritancy 
of a chemical can facilitate induction of contact allergy by producing reactive oxygen 
species, eventually leading to activation of dendritic cells needed to transport the 
hapten to draining lymph nodes where it can be presented to naïve T cells, followed by 
a cascade of events resulting in a hapten-specific delayed type hypersensitivity. It has 
been hypothesized that specific single nucleotide variants in the promoter region of 
TNF, specifically TNF -308 G->A, leads to increased TNF production, possible providing 
a clue to why some individuals are more susceptible, or, have a lower threshold, to 
develop contact allergy. Based on all available genetic association studies performed 
on this specific SNV and contact allergy, no evidence for such a relationship has been 
shown so far. An explanation for this is the small sample sizes. Moreover, future studies 
should focus on using an appropriate phenotype to represent susceptible individuals. 
Our suggestion that polysensitization might function as thus is explored below.
 
Cross-elicitation responses to the newly developed hair dye molecule 2-methylethoxy-
para-phenylenediamine (ME-PPD) were investigated in 25 subjects with contact allergy 
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to para-phenylenediamine (PPD) in chapter 3. Quantitative risk assessments (see 
below) have indicated that although ME-PPD is a moderate sensitizer according to 
the LNNA, it is not expected to induce contact allergy for hair dye consumers at the 
concentration used in hair dye conditions. Our study showed that ME-PPD is not a 
safe alternative for individuals already sensitised to PPD, as 48% showed an elicitation 
response to an open use test with a hair dye preparation containing 2.0% ME-PPD and 
an exposure time of 45 minutes. In PPD-sensitised individuals, 84% showed a positive 
patch test response to ME-PPD 2.0% pet, the difference with the open use test being 
an exposure time of 48 hours and under occlusion. A dose-response relationship shows 
that higher doses of ME-PPD are needed to elicit an allergic contact dermatitis reaction 
compared to PPD. Another finding was that the dose of ME-PPD needed to elicit a 
reaction depends on the strength of PPD patch test reactions; individuals with an 
extreme (+++) positive PPD patch test reaction showed a positive patch test reaction 
to lower concentrations of ME-PPD on average compared to individuals with a weak 
(+) or strong (++) PPD patch test reaction. 
A retrospective database study investigating the persistence of positive patch test 
reactions upon re-testing is performed in chapter 4, showing that 33.2% of all 
positive reactions were negative at a second patch test procedure. As expected, the 
vast majority of non-persistent reactions were initially weak (+) positive, although 
there were two reactions that had changed from extreme (+++) positive to negative. 
The only factors found to be associated with a more consistent level of persistence 
were allergens tested in the TRUE Test and strength of initial patch test reactions; 
no influence of patient specific factors was observed nor of time passed between 
two patch tests. Although retrospective and with a relatively small sample size, 
the findings do shed some light on the validity of patch test results and should be 
considered when drawing conclusions from epidemiological studies. The possibility of 
a sensitised individual to become tolerant is something that could be explored more 
in future studies. A possible explanation for non-persistence of a positive patch test 
is a decreased function of the immune system with increasing age, although evidence 
exists that this most likely is not relevant until 80 years and older.(1) Other explanations 
are that the first positive patch test reaction was a false positive or an irritant reaction 
wrongly interpreted as positive, or that the consequent negative patch test reaction 
was false negative. 
9
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Another aspect of patch testing – the concentration and vehicle in which a 
hapten is tested – is explored in chapter 5 in which the diagnostic performance of 
methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) tested in 0.01% aq. 
(corresponding to 3 mg/cm2) Is compared to MCI/MI 4 mg/cm2 as tested in the TRUE 
Test. In total, 14.4% of the patch tested population showed a positive reaction to one 
or both patch test preparations, indicating once again the extent of the MI contact 
allergy epidemic.(2, 3) A higher number of positive reactions were observed to the 
TRUE test preparation, almost twice as many, despite the concentration that is tested 
in the TRUE Test is only a 4:3 ratio higher. A steep dose-response relationship for MCI/
MI could explain this finding, as well as the different vehicle. A major limitation of this 
study is that the current recommended patch test concentration for MCI/MI of 0.02% 
aq. was not included.(4) 
Chapter 6 presents a large European multicenter study investigating polysensitization, 
defined as sensitizations to three or more non-related allergens of the European 
baseline series. An age- and sex-standardized prevalence of about 7% was observed, 
but with some variability observed between countries. Although it is tempting to 
assume this variability might be explained by differences in exposures between 
countries, a more likely explanation is the difference in patch tested populations 
between centers, especially eligibility criteria for patch testing. Previously described 
risk factors for polysensitization is confirmed in a larger population, namely female 
sex and age older than 40. An interesting observation was the increased proportions 
of strong and extreme positive reactions in polysensitised individuals compared to 
oligosensitised (1 or 2 positive reactions) individuals. The study presents a more refined 
definition of polysensitization as well by listing combinations of contact allergens that 
should be counted as one based on cross-reactivity and co-sensitization. One example 
of this is when a person has positive patch test reactions to both PPD and benzocaine; 
as these cross-react it is likely that this person is only sensitised to one of both, and 
therefore these should not be counted as two separate reactions when assessing 
polysensitization. 
Recently the European baseline series with recommended additions 2019 were 
published (Wilkinson et al.).(5) Hydroperoxides of limonene and hydroperoxides of 
linalool were recommended to be included in the additional baseline series, while 
further information is needed to confirm or refute their importance. 
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The importance of this possible inclusion is underscored in Chapter 7 because 9.4% 
and 11.7% positive reactions to hydroperoxides of limonene and hydroperoxides of 
linalool, respectively, were observed. An important observation was that the majority 
were weakly positive, and a relatively high proportion of doubtful and low proportion 
of irritant reactions were observed, supporting the argument for higher patch test 
concentrations. This study attempts to characterize patients allergic to either or 
both hydroperoxides and how they differ from patients allergic to other fragrances, 
patients allergic to other allergens, and patients without any positive patch test 
reactions, indicating the majority are female. Clinical relevance is also presented, 
indicating that 40.3% and 46.3% of positive reactions to hydroperoxides of limonene 
and hydroperoxides of linalool, respectively, were of probable to certain clinical 
relevance. A limitation of the clinical relevance assessment was that hydroperoxides 
are not labelled, only the unoxidized forms of limonene and linalool. Therefore clinical 
relevance was evaluated by the presence of limonene and linalool in the products and 
improvement of the symptoms after stopping exposure to these allergens.
Chapter 8 presents two case reports. The first is a case report of an elderly man 
who developed allergic contact dermatitis to his Transcutaneous Electric Nervous 
Stimulation (TENS) electrodes which he used to treat lower back pain. The search 
for the culprit allergen is presented and the use of thin layer chromatography is 
highlighted, resulting in the identification of acrylic acid being the responsible hapten. 
The second presents two patients with allergic contact dermatitis to ethylenediamine, 
both working at the same factory that produces this chemical. The first suffered from 
peri-ocular airborne allergic contact dermatitis, most likely caused by trapping of 
ethylene diamine behind his safety goggles, and concomitant rhinitis. The second 
patient suffered from hand dermatitis despite handling products with protective 
gloves, most likely as result of some excess ethylene diamine containing water getting 
inside the gloves. 
POLYSENSITISATION AS A PHENOTYPE FOR INCREASED 
SUSCEPTIBILITY
When patch testing a dermatitis population it is not uncommon to find positive 
reactions to more than one sensitising chemical. Previous literature termed two or 
more such positive reactions polysensitization,(6) in more recent publications the term 
was defined as three or more positive reactions to contact allergens in the European 
9
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Baseline Series.(7) In our multicenter study (chapter 6), we formulated the additional 
requirement of counting concomitant sensitisations caused by either cross-reactions 
or co-sensitization as one positive reaction. However, different definitions are still 
used within the scientific community. A recent study investigating allergic contact 
dermatitis in atopic dermatitis patients also defined polysensitization as reacting 
to at least three different unrelated contact allergens, however these also included 
contact allergens tested in additional series other than the European Baseline series.
(8) Examining the literature investigating polysensitization to food- and aeroallergens 
provides a similar pattern of varying definitions.(9, 10) 
The importance of using one definition agreed upon by the scientific community as 
opposed to many different ones is the opportunity it presents for comparing data and 
performing meta-analyses. There are some challenges in finding the correct definition 
for polysensitization, mostly because it is not yet understood whether polysensitization 
represents true increased susceptibility or is simply the result of increased exposure.(6) 
Should positive reactions detected by additionally tested series be counted or not, and 
if yes, should the number of positive reactions required for polysensitisation increase 
with the amount of allergens tested? 
There is some evidence that polysensitization is the result of increased susceptibility. 
A landmark study by Moss and Friedmann showed that polysensitised individuals, 
defined by three or more contact allergies to unrelated allergens, were more easily 
sensitised to 2,4-dinitrochlorobenzene (DNCB) at lower concentrations.(11) They 
further investigated monosensitised individuals and found they were also slightly easier 
to sensitize compared to non-sensitised individuals, but not significantly so.(11) This 
implies that susceptibility to develop contact allergies might a graded phenomenon 
rather than a binary one. Our own results (chapter 6) show a positive correlation 
between number of positive reactions and proportion of extreme (+++) positive 
reactions, indicating increased reactivity and therefore increased susceptibility. 
As mentioned above and in the introduction of this thesis, there are many factors 
influencing the outcome of a particular patch test; external influences, personal 
factors, and patch testing related factors. These factors can influence the probability 
of a false positive or a false negative reactions. An example of external influences are 
meteorological conditions.; one study found that for certain allergens the probability 
of doubtful positive and irritant patch test reactions increased during cold and arid 
weather.(12) Personal factors can include hormonal influences as discussed in the 
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introduction of the current thesis.(13-15) Another example is atopic dermatitis, which 
is a topic of some controversy in whether it increases or decreases the susceptibility to 
developing contact sensitization. In our large European multicenter study (chapter 6), 
atopic dermatitis was a small but significant risk factor for polysensitisation. This could 
however be because of increased exposure (e.g. to topicals) as opposed to increased 
susceptibility. 
An example of a patch test related factor is the ‘spill-over’ effect; patch testing with a 
marginally irritating concentration of sodium lauryl sulfate at varying distances from 
an positive patch test reaction (to example nickel, epoxy resin, PPD, etc) results in to 
enhanced irritant reactions the closer the proximity.(16)
Another factor that should be considered is that an increasing number of positive 
reactions might enhance the probability of a false positive reaction. For example, 
one study showed that thiuram mix was significantly more likely to be positive with 
increasing concomitant positive reactions to allergens unrelated to thiuram mix.(17) 
Furthermore, our own results of chapter 4 suggest that a significant number of mostly 
weak positive patch test reactions are non-persistent upon re-testing. These studies 
provide some evidence for the existence and extent of false positive reactions, which 
should be taken into account when defining polysensitization. Another important 
confounding factor is of course the difference in exposure and exposure in general as 
the most logical explanation for becoming polysensitised. 
These considerations lead us to a discussion on how polysensitization should be best 
defined when the aim is to use it as a phenotype for increased susceptibility. The 
possibility of false positives and the ‘spill-over’ effect indicate that choosing three 
or more positive patch test reactions as the cut-off is on the conservative side. A way 
to decrease the effect of these confounders is to only count strong (++) and extreme 
(+++) positive reactions, perhaps scoring weak (+) positive reactions as half a positive 
reactions, i.e. two weak positive reactions to be counted as one. If following this line 
of thought, another question is whether doubtful (?) patch test reactions should be 
considered as well, as these might well become positive at higher concentrations. 
It should however be noted that evaluation and interpretation of these type of 
questionable reactions might be too dependent on the experience of the investigator, 
notwithstanding inter-investigator variability. Deciding to use a more strict definition 
for polysensitization (more positive reactions, not counting weak positive reactions) 
can aid in the search for genetic variants associated with increased susceptibility 
to become sensitised. The other side of this argument is that choosing such a strict 
9
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definition makes it more difficult to find individuals meeting these criteria. To reiterate, 
the most important thing is that the scientific community should settle on one 
definitive definition taking the above in consideration.
RISK OF ALLERGY INDUCTION AND ATTEMPTS AT PRIMARY 
PREVENTION
Our skin is exposed to many chemicals in daily life that are potential sensitisers, both 
at home and in occupational settings. As explored in the current thesis, this leads 
to adverse health effects such as allergic contact dermatitis. In order to determine 
whether a chemical is a sensitizer different in vivo investigations have been developed 
throughout the decades. The Local Lymph Node Assay (LLNA), a murine assay in which 
proliferative responses of lymphocytes in local lymph nodes are following repeated 
topical exposure, has provided a sensitive method for this.(18) Besides identification 
of sensitizing potential, the LLNA provides the additional value of being able to 
estimate sensitizing potency. The LLNA of a chemical results in an EC3 value, from 
which sensitizing potency can be extrapolated.(19, 20) The EC3 represents the effective 
concentration required to obtain a three-fold increase in lymph node cell proliferative 
activity compared to vehicle tested controls. It is used to categorize a chemical into 
being a weak, moderate, strong, or extreme sensitisers.(1) Currently, the use of 
the LLNA cannot be used for cosmetic ingredients due to a ban on animal testing, 
necessitating in vitro alternatives to assess the sensitization potential of chemicals.(21) 
Quantitative risk assessment
The reason for evaluating not just the ability to sensitize (hazard) but also the potency 
of how sensitizing a chemical is, is that this allows for determining the risk it poses in 
real life context. One of the main tenets of toxicology is that risk equals hazard times 
exposure, where in the case of induction of skin sensitization hazard is the intrinsic 
property of a chemical to cause harm. Risk is driven by exposure and translates to the 
probability of an adverse event or in this scenario induction of contact allergy with 
possible subsequent allergic contact dermatitis. 
The Research Institute for Fragrance Materials (RIFM) introduced quantitative risk 
assessment (QRA) for fragrance ingredients following discussions on the burden of 
fragrance contact allergy.(22) One publication that followed from this discussion 
was the 7th amendment of the Cosmetic Directive in 2003 which introduced the 
requirement that of 26 fragrance substances their presence cannot exceed 10 ppm 
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(or, mg/L) for leave-on products and 100 ppm for rinse off products.(23) Dermal 
sensitization quantitative risk assessment was developed as a model to determine safe 
concentrations of fragrance ingredients in consumer products, i.e., concentrations that 
would not induce skin sensitization.(24) The three pillars of QRA are i) identification 
and quantification of hazard, ii) assessing both acceptable and actual exposure and 
iii) comparing actual to acceptable exposure to characterize the risk of induction of 
sensitization. 
It is assumed that there is a threshold below which the dose of a sensitiser is unlikely to 
induce sensitisation. For hazard identification and quantification this threshold, termed 
the no expected sensitization induction level (NESIL), needs to be determined. The 
NESIL is derived from both animal studies (LLNA) and human data (human repeated 
insult patch test, see (25) for more detail). As the sensitising potency increases, the 
amount of the chemical needed to induce sensitization decreases, so it follows that 
the NESIL will also decrease. The NESIL is then adjusted using appropriate safety 
factors (termed sensitization assessment factors (SAF)). Examples of SAFs are inter-
individual variability, differing exposure matrices, and possible exposure conditions or 
characteristics not included in the actual exposure assessment. Adjusting the NESIL 
by applying SAFs results in the acceptable exposure level (AEL), expressed in dose/
unit daily. The AEL is derived by dividing the NESIL by the SAF, which are often in the 
range of a factor 10 to 300. Characterizing the real life risk is performed by comparing 
the resulting AEL to the consumer exposure level (CEL), where the AEL has to be equal 
or larger than CEL to avoid induction of sensitization.(24, 26) 
Hair dye ingredients: does QRA address risk in consumers who experi-
ence an adverse reaction after hair dying
Although QRA was developed for fragrance ingredients, it has been used for other 
product groups and chemicals as well, such as PPD in hair dye, classified as a strong 
sensitizer based on LLNA data. (27, 28) After ME-PPD was developed by the industry 
as a less sensitizing hair dye ingredient (categorized as a moderate sensitizer) than the 
extreme sensitisers PPD and toluene-diamine (TDA), QRA was performed indicating 
a much lower allergy induction risk under consumer hair dye usage conditions.(27)  
ME-PPD was developed as a means of primary prevention of hair dye induced allergic 
contact dermatitis, and therefore its primary focus was not on consumers with a pre-
existing contact allergy to important hair dye ingredients. QRA also does not address 
this as it only assesses induction risk and not risk of (cross-)elicitation. Different studies 
have investigated cross-elicitation responses to ME-PPD in PPD allergic individuals, 
9
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the latest of which is part of this thesis. An important conclusion is that while ME-PPD 
might fulfill its role as a hair dye ingredient with good hair dying performance with 
negligible risk of allergy induction, it does pose a risk of eliciting allergic contact 
dermatitis under hair dye use conditions in individuals previously sensitised to PDD, 
indicating cross-reactivity. A dose-response curve showing proportion of PPD allergic 
individuals responding to increasing ME-PPD patch test doses showed that while a 
higher concentration of ME-PPD is needed to elicit a similar proportion of elicitation 
reactions than to PPD, virtually all PPD allergic individuals are able to respond to 
ME-PPD as long as the exposure dose is high enough. This study is based on single 
exposure open use test to a hair dye preparation containing 2.0% ME-PPD for 45 
minutes, not on multiple exposures as might occur in a real life context. A study by 
Kock et al. revealed that a proportion of PPD allergic individuals initially showing no 
reaction to an ME-PPD open use test, might still develop allergic contact dermatitis 
following repeated hair dyeing.(29) 
This example of QRA in action in regards to the newly developed hair dye ingredient 
ME-PPD shows that although it can indicate the risk of induction of contact allergy, 
it cannot completely address the risk for adverse skin events in consumers as it does 
not consider cross-reactivity between chemicals. 
Other concerns about QRA
The lack of focus on prevention of elicitation, and other concerns about QRA, were 
addressed in an opinion published by the European Commission Scientific Committee 
on Consumer Products (SCCP) in 2008. (30) Further criticism was focused on the lack 
of consideration of aggregated exposure (concomitant exposure to multiple fragrance 
ingredients in one product, and frequency of exposure). Many products containing 
fragrance ingredients contain multiple fragrance ingredients, and other potential skin 
sensitisers such as preservatives. This is supported by a recent study which found that 
of cosmetic products containing at least one of the 26 fragrance ingredients identified 
by the Cosmetic Directive, 85.5% and 73.9% contained at least more than two or more 
than three fragrance ingredients, respectively.(31) Occupational exposure was another 
area which deserved more attention. Other points of concern were the low estimated 
exposure levels in consumers, and the conservative use of SAF. 
However, the main concern was that despite the introduction of QRA no reduction 
in sensitization trends to fragrances had been observed so far in epidemiological 
data. This was true in 2008 and is, unfortunately, still true.(32) Our investigation 
on polysensitization in patch tested patients in Europe between 2009 and 2014 
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showed that in this subgroup, 40.8% (sex- and age-standardized) had a positive 
patch test to fragrance mix I (containing eight fragrance allergens), as well as 10.7% 
of oligosensitised patients. Complicating interpretation of such epidemiological data 
is that an unknown proportion of patients were most likely sensitised prior to the 
introduction and implementation of QRA.
In response to this criticism, the fragrance industry set up International Dialogue on the 
Evaluation of Allergens (IDEA), developing QRA2.(32) A recent example of a fragrance 
allergen dermal sensitization QRA taking into account aggregated exposure is hand 
exposure to geraniol in personal care products and household cleaning agents. It 
indicated that aggregated exposure exceeded the AEL, thereby seemingly confirming 
the validity of this criticism.(33) Another recent dermal sensitization QRA focused on 
occupational exposure to hair dye ingredients in hair dressers, addressing another of 
the criticisms of the SCCP that QRA was focused solely on protecting consumers and 
not employees. In this specific QRA, other risk factors for induction of contact allergy 
in the setting of hair dressers were considered, for example wet work, an irritant factor 
decreasing the barrier function of the skin. (34) 
Hydroperoxides of limonene and linalool: challenges of QRA and primary 
prevention
Two fragrance allergens that show especially high prevalences of contact allergy in 
patch tested populations are hydroperoxides of both limonene and linalool, as shown 
again in this thesis. Another observation of concern was that of all patients allergic to 
either or both hydroperoxides of limonene and hydroperoxides of linalool, 39.3% had 
at least one additional fragrance contact allergy. This increased to 63.2% of patients 
with a contact allergy to both hydroperoxides of limonene and hydroperoxides of 
linalool. A potential explanation for this high rate of additional fragrance allergies 
is concomitant exposure to multiple fragrances, as cosmetic products that contact 
either limonene or linalool also often contain other fragrances. Furthermore, terpenes 
(including limonene and linalool) function as skin penetration enhancers, possibly 
facilitating induction of contact allergy to other concomitantly present sensitisers.
(35) Sensitisation rates to either hydroperoxides in the general population have not 
been investigated yet. Considering relatively high rates of fragrance contact allergy in 
the general population, it is not unlikely that a considerable proportion of the general 
population has a contact allergy to either hydroperoxide of limonene or linalool.(36, 
9
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37) Pending further epidemiological investigations, the need for primary prevention 
for these contact allergens is apparent. 
In recent years, this need has been voiced. For example, the oxidized forms of limonene 
and linalool were identified as allergens of high concern in the European Commission 
Scientific Committee on Consumer Safety (SCCS) opinion on fragrance allergens in 
cosmetics in 2012.(38) These oxidized forms of limonene and linalool contain different 
oxidation products including multiple different hydroperoxides. It was proposed 
that content of the oxidized fraction represented by the (hydro)peroxide content 
(so not including secondary oxidation products such as aldehydes and epoxides) in 
cosmetics should not exceed 10 ppm, or, that the total oxidized fraction should not 
exceed 100 ppm. As limonene and linalool are pre-haptens (auto-oxidation has to take 
place in order for hydroperoxides, identified as the main contact allergens in oxidized 
limonene and linalool, to be formed), prevention of activation into haptens can help 
as a prevention measure, for example by preventing air exposure during handling and 
the addition of suitable antioxidants. 
In 2015, the RIFM published a risk assessment of linalool which states that linalool itself 
does not present a concern for skin sensitization, acknowledging that the oxidation 
products are known sensitisers.(39) It recommended, in line with International 
Fragrance Association (IFRA) standards, to limit the peroxide levels to 20 mmol/l, and 
to add an antioxidant during production. LLNA investigation of oxidized limonene and 
linalool, and specific hydroperoxides, concluded that oxidized limonene and oxidized 
linalool were moderate sensitisers, and hydroperoxides more potent sensitisers.(40, 
41) A complicating factor is that although the hydroperoxides have been identified as 
the most important sensitisers in oxidized limonene, other oxidation products have 
also been shown to be potential sensitisers, for example carvone and limonene-l,2-
oxide.(42) Karlberg et al. found that a certain proportion of guinae pigs sensitised to 
limonene-l,2-oxide,did not show elicitation responses to hydroperoxides of limonene, 
and vice versa, confirming that hydroperoxides are not the sole allergen in oxidized 
limonene.(40) 
Therefore, if primary prevention is to be implanted, itis necessary to perform QRA’s on 
all potential sensitisers in oxidized limonene and oxidized linalool. However, in order to 
be able to do this, the exposure levels to each potential sensitiser in consumers would 
have to be known. It is currently unknown what proportion of limonene and linalool 
auto-oxidizes in consumer products, in particularthe proportion of hydroperoxides and 
other oxidation products. This is most likely different per product category, and also 
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depends on how it is handled by consumers. Reasonable assumptions can be made as 
to which product categories pose an increased risk for sensitization to hydroperoxides 
of limonene and linalool and should therefore be of particular concern; any product for 
which auto-oxidation is able to take place, for example products which are frequently 
opened (or left open by accident) and products that are present on the skin for 
longer durations of time. In our investigation into contact allergy to hydroperoxides 
of limonene and linalool we assessed which product categories were the cause of 
allergic contact dermatitis in patients with a certain clinically relevant positive patch 
test reaction: rinse of products (soap, shampoo), stay on products (cosmetics creams), 
cleaning agents, deodorants, and perfumes. Whether these patients were sensitised 
by the same products that caused their allergic contact dermatitis cannot be said 
with complete certainty. A recent case study did identify hydroperoxides of linalool 
in shampoo as the most likely culprit of allergic contact dermatitis of the eyelids in a 
young girl.(43)
Ultimately, although many challenges are still to be overcome in implementing a 
truly effective QRA and primary prevention, the importance of such work cannot 
be overstated. The prevalence of contact allergy is and remains high, with many 
implications for health, occupational consequences, and an impaired quality of life. 
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This thesis presents studies investigating different aspects of contact allergy: 
immunology, patch test methodology, and epidemiology. Contact allergy is a type 
IV hypersensitivity reaction that is frequent and impairs quality of life; it can lead to 
itchy and painful skin rashes, can cause problems in occupational settings, and can 
limit someone’s use of products such as cosmetics. Sensitized individuals develop 
allergic contact dermatitis upon re-exposure of the skin to the responsible contact 
allergen. Patch testing diagnoses specific contact allergies by exposing individuals 
to a large range of contact allergens and forms the basis of epidemiological data. 
Epidemiological studies help identify groups at risk for developing contact allergy 
overall and to specific contact allergens. Chapter 1 introduces these topics in detail 
and serves as a general framework within which the subsequent chapters can be 
understood.
In chapter 2 we reviewed the role of tumor necrosis factor (TNF) in contact allergy and 
allergic contact dermatitis, and whether genetic variants in the TNF gene increases 
susceptibility to develop a contact allergy. 
TNF is a pro-inflammatory cytokine and plays a role in many inflammatory diseases, 
including contact allergy. During the sensitization phase, TNF is produced by 
keratinocytes because of the innate immune system reaction caused by skin contact 
with a hapten. It helps the maturation of dendritic cells, which subsequently carry the 
hapten to local lymph nodes to present it to immature T lymphocytes. During the 
elicitation phase, TNF is produced by the hapten-specific T lymphocytes who, following 
sensitisation, reside in the skin. It helps produce dermatitis because of its cytotoxic 
effect and production of adhesion molecules that recruit circulating T lymphocytes.
Although exposure is the main factor in sensitization – theoretically anyone can 
become sensitized as long as exposure is of high enough dose or long enough duration 
– inter-individual differences in susceptibility exist. Genetic differences might account 
for part of this variation. The most extensively researched genetic variant in the TNF 
gene is TNF -308 G->A, a single nucleotide variant in the promoter region of TNF. 
In vitro data suggests that this variant increases TNF production, possibly making 
carriers of this variant more susceptible to develop contact allergy. However, genetic 
association studies performed so far have failed to support this hypothesis. We propose 
two possibilities: or this variant is not functional to such an extent that it increases 
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susceptibility, or these genetic association studies lack power and suffer from other 
methodological flaws.
Para-phenylenediamine (PPD) is a hair dye ingredient with strong coloring properties 
and is a potent sensitizer responsible for the majority of hair-dye related contact 
allergies.  2-methoxyethoxy-para-phenylenediamine (ME-PPD) is a new hair dye 
ingredient with a weaker sensitising potential. Contrary to PPD, which is classified 
as a strong sensitizer, ME-PPD is a moderate sensitiser. In chapter 3 we looked at 
whether ME-PPD is also safe to use for PPD allergic individuals. We investigated 
cross-elicitations responses in 25 PPD-allergic subjects with a history of hair dye 
related allergic contact dermatitis. We performed both open use testing with hair 
dye preparations containing either 2.0% PPD or ME-PPD and patch testing with 
increasing doses of ME-PPD in petrolatum. 48% of study participants showed an 
elicitation reaction to open use testing with ME-PPD, and 84% showed a positive patch 
test reaction to 2.0% ME-PPD. Dose-response curves indicated a lower reactivity of 
ME-PPD compared to PPD; higher doses of ME-PPD are needed to elicit a comparable 
response to PPD.  We also found that the proportions of positive reactions to ME-PPD 
was correlated with the strength of the original PPD patch test response; 20% of 
individuals with a weak positive PPD patch test reaction reacted to ME-PPD as well, 
while 62.5% of individuals with an extreme positive PPD patch test reaction reacted 
to ME-PPD.
Chapter 4 investigates the persistence of positive patch test reactions. We found that 
33.2% of all positive patch test reactions had turned negative upon re-testing. The 
majority of these non-persistent reactions were weak positive; strong and extreme 
positive patch test reactions showed a persistence of 82.1% and 89.5%, respectively. 
Patient characteristics did not influence persistence rates. 
Considering the immunology of contact allergies it is unlikely that they can be transient. 
Other explanations are that the initial positive reaction was a false positive, or the 
consequent negative reaction a false negative. Possibilities of becoming tolerant to a 
contact allergy should be explored, including predictive factors. 
Chapter 5 explores the impact of the concentration and vehicle in which an allergen is 
patch tested by comparing methylchloroisothiazolinone/methylisothiazolinone (MCI/
MI) in 0.01% aq. (corresponding to 3 µg/cm2) to 4 µg/cm2 in the TRUE Test, a ready-
made patch test with povidone as its vehicle. Almost twice as many patients tested 
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positive to the higher concentration of 4 µg/cm2 in the TRUE Test compared to 3 µg/cm2 
in water, which can be explained by the steep dose-response relationship of MCI/MI, 
or by the different vehicles. For the latter to be investigated, the same concentration 
should be compared in both vehicles. 
 
Polysensitisation, defined as three or more contact allergies to non-related 
allergens of the European baseline series, is a phenotype used, among other 
purposes, to investigate susceptibility to acquiring contact allergies. It also serves 
as an epidemiological measurement that provides additional information over just 
a prevalence. We have improved this definition by indicating which contact allergen 
couples should be counted as one sensitisation, for example because of cross-reactivity 
or because of concomitant testing of a mix and one of its ingredients. Chapter 6 
found that about 7% of patients from patch testing centres across Europe and were 
polysensitised. Previously suggested risk factors – female sex and age over 40 years 
old – were confirmed. A new finding was that polysensitized patients showed a 
higher proportion of strong and extreme positive patch test reactions compared to 
oligosensitised patients (one or two unrelated positive patch test reactions). 
Limonene and linalool are common fragrance terpenes present in many household 
products. They transform into allergenic hydroperoxides after adequate air exposure. 
In chapter 7 we found that 9.4% and 11.7% of our patch tested population had 
a contact allergy to hydroperoxides of limonene and hydroperoxides of linalool, 
respectively. Clinical relevance is difficult to assess for both hydroperoxides as they 
are not mentioned on labels; only the presence of limonene or linalool is mentioned. 
Clinical relevance was therefore determined based on their presence in the product and 
improvement of symptoms following cessation of exposure. Because a high amount 
was clinically relevant, we can assume that most reactions were true positives. 
The optimal patch test concentration for hydroperoxides of limonene and 
hydroperoxides of linalool is a contested subject. We propose a higher concentration 
based on a high amount of weak positive and doubtful reactions and a low amount 
of irritant reactions.
In chapter 8 we present two case reports and highlight the at times complex journey 
to discover the allergen causing the allergic contact dermatitis. The first case report 
shows how using thin layer chromatography aided in identifying the culprit allergen in 
a case of allergic contact dermatitis to Transcutaneous Electric Nervous Stimulation 
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(TENS) electrodes. The second case report reports two employees from the same 
ethylene amine producing factory with occupational dermatitis and other complaints. 
Exposure to many by-products in the manufacturing of ethylenediamine required patch 
testing with a range of chemicals in order to diagnose allergic contact dermatitis. The 
challenge in testing with work-related substances is to find a patch test concentration 
that does not give irritant reactions but is high enough to diagnose a contact allergy.




Dit proefschrift beschrijft studies die verschillende aspecten van contactallergie 
onderzoeken: immunologie, de methodologie van plakproeven, en epidemiologie. 
Contactallergie is een type IV overgevoeligheidsreactie welke frequent voorkomt en de 
kwaliteit van leven verminderd; het kan leiden tot een jeukende en pijnlijke huiduitslag, 
het kan problemen veroorzaken in de werkomgeving en kan het gebruik van producten 
zoals cosmetica beperken. Gesensibiliseerde individuen ontwikkelen allergisch 
contacteczeem bij hernieuwde blootstelling van de huid aan het verantwoordelijke 
contactallergeen. Plakproeven diagnosticeren specifieke contactallergieën door 
individuen bloot te stellen aan een groot aantal contactallergenen en vormt de basis 
voor epidemiologische data. Epidemiologische studies helpen bij het identificeren van 
risicogroepen voor het ontwikkelen van een contactallergie in het algemeen en voor 
specifieke contactallergenen. Hoofdstuk 1 introduceert deze onderwerpen in detail en 
functioneert als een algemeen referentiekader waarbinnen de volgende hoofdstukken 
kunnen worden begrepen.
 
In hoofdstuk 2 wordt de rol van tumornecrosefactor (TNF) in contactallergie en 
allergisch contacteczeem besproken, en wordt besproken of genetische varianten in 
het TNF-gen de gevoeligheid voor het ontwikkelen van een contactallergie verhogen. 
TNF is een pro-inflammatoire cytokine en speelt een rol in vele inflammatoire 
aandoeningen, waaronder contactallergie. Tijdens de sensibilisatie fase wordt 
TNF geproduceerd door keratinocyten nadat het aangeboren immuunsysteem is 
geactiveerd door huidcontact met een contactallergeen. Het helpt de rijping van 
dendritische cellen, die vervolgens het contactallergeen aan onrijpe T-lymfocyten 
presenteren in lokale lymfeklieren. Tijdens de elicitatie-fase wordt TNF geproduceerd 
door de contact-allergeen-specifieke T-lymfocyten, die zich na de sensibilisatie fase in 
de huid bevinden. TNF draagt bij aan de ontstaan van eczeem door een cytotoxische 
effect en door de productie van adhesiemoleculen die circulerende T-lymfocyten 
aantrekken. 
Hoewel blootstelling de belangrijkste factor is bij sensibilisatie - theoretisch kan 
iedereen worden gesensibiliseerd zolang de blootstelling lang genoeg duurt en de 
concentratie hoog genoeg is – bestaan er interindividuele verschillen in gevoeligheid 
voor het ontwikkelen van contactallergie. Genetische verschillen kunnen een deel 
van deze variatie verklaren. De meest uitgebreid onderzochte genetische variant in 
het TNF-gen is TNF-308 G-> A, een enkel-nucleotide variant in het promoter gebied 
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van TNF. In-vitro gegevens suggereren dat deze variant de TNF-productie verhoogt, 
waardoor het mogelijk zou kunnen zijn dat dragers van deze variant vatbaarder zijn 
voor het ontwikkelen van contactallergie. Genetische associatiestudies die tot nu toe 
zijn uitgevoerd, hebben deze hypothese echter niet ondersteund. Dat kan worden op 
verschillende manieren worden verklaard: of deze variant is niet zodanig functioneel 
dat het de gevoeligheid verhoogd, of de steekproefgrootte van deze genetische 
associatie studies waren te klein, naast andere methodologische tekortkomingen.
 
Para-phenylenediamine (PPD) is een kleurstof in haarverf en is een potent 
allergeen dat verantwoordelijk is voor veel haarverf gerelateerde contactallergieën. 
2-Methoxyethoxy-para-phenylenediamine (ME-PPD) is een nieuwe grondstof voor 
haarverf met minder sensibiliserend vermogen. In tegenstelling tot PPD, wat een sterk 
sensibiliserend vermogen heeft, heeft deze grondstof matige potentie tot sensibilisatie. 
In hoofdstuk 3 hebben we gekeken of ME-PPD ook veilig te gebruiken is door PPD-
allergische personen. Om dit te onderzoeken heb we gekeken naar kruisreactiviteit 
in 25 PPD-allergische personen met een voorgeschiedenis van haarverf-gerelateerde 
allergisch contacteczeem. We voerden zowel open use test uit met haarverf die óf 2,0% 
PPD óf 2,0% ME-PPD bevatte en plakproeven met toenemende concentraties ME-
PPD. 48% van de PPD-allergische deelnemers toonde een reactie op de ME-PPD open 
use test en 84% toonde een positieve plakproefreactie op 2,0% ME-PPD. Dosis-respons 
curven toonden dat voor ME-PPD hogere doses nodig zijn om een vergelijkbaar 
percentage mensen te laten reageren in vergelijking met PPD. De resultaten lieten 
verder zien dat de proportie van positieve reacties op ME-PPD geassocieerd was met 
de sterkte van de oorspronkelijke PPD plakproefreactie; 20% van individuen met een 
zwak positieve PPD plakproefreactie reageerde ook op ME-PPD, terwijl 62.5% van 
individuen met een extreem positieve PPD plakproefreactie op ME-PPD reageerde.
In hoofdstuk 4 wordt de reproduceerbaarheid van positieve plakproefreacties 
onderzocht. Wij vonden dat 33,2% van alle positieve plakproefreacties negatief waren 
geworden bij een tweede keer testen. De meerderheid van deze niet-persistente 
reacties waren zwak positief; sterke en extreem sterke positieve plakproefreacties 
toonden een reproduceerbaarheid van respectievelijk 82,1% en 89,5%. De 
reproduceerbaarheid van positieve plakproefreacties werd niet beïnvloed door 
patiëntkaraksteristieken.
Het is immunologisch gezien onwaarschijnlijk dat contactallergieën van voorbijgaande 
aard zijn. Andere verklaringen zijn dat de aanvankelijk positieve reactie fout positief 
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was, of de daaruit voortvloeiende negatieve reactie fout negatief. Mogelijkheden 
om tolerant te worden voor een contactallergie moeten verder worden onderzocht, 
inclusief voorspellende factoren.
Hoofdstuk 5 onderzoekt de invloed van de plakproefconcentratie en het vehikel 
waarin een allergeen getest wordt door 0,01% methylchloroisothiazolinone/
methylisothiazolinone (MCI/MI) in aqua (overeenkomend met 3 μg/cm2) te vergelijken 
met 4 μg/cm2 in de TRUE-test, een kant-en-klare plakproeftest met povidon als vehikel. 
Bijna twee keer zoveel patiënten reageerden positief op de hogere concentratie van 4 
μg/cm2 in de TRUE-test vergeleken met 3 μg/cm2 in aqua, wat kan worden verklaard 
door de steile dosis-responsrelatie van MCI/MI, of door de verschillende vehikels. 
Om dit laatste te onderzoeken, moet dezelfde concentratie in beide vehikels worden 
vergeleken.
Polysensibilisatie, gedefinieerd als drie of meer contactallergieën voor niet-
gerelateerde allergenen van de Europese standardreeks, is een fenotype dat onder 
andere wordt gebruikt om de gevoeligheid voor het verwerven van contactallergieën 
te onderzoeken. Epidemiologisch gezien geeft het aanvullende informatie naast 
enkel een prevalentie. We hebben deze definitie verbeterd door aan te geven welke 
contactallergeenkoppels als één sensibilisatie moeten worden geteld, bijvoorbeeld 
vanwege kruisreactiviteit of  omdat zowel een mix van allergenen als een van de 
bestanddelen van de mix wordt getest. In hoofdstuk 6 vonden wij dat bij ongeveer 
7% van de patiënten van plakproefcentra in Europa sprake was van polysensibilisatie. 
Eerder aangetoonde risicofactoren - vrouwelijk geslacht en leeftijd ouder dan 40 jaar - 
werden bevestigd. Een nieuwe bevinding was dat patiënten met polysensibilisatie een 
hoger percentage sterke en extreem sterke positieve plakproefreacties vertoonden 
in vergelijking met patiënten met oligosensibilisatie (één of twee niet-gerelateerde 
positieve plakproefreacties).
 
Limonene en linalool zijn veel voorkomende terpenen met een karakteristieke geur 
die in veel huishoudelijke producten aanwezig zijn. Ze transformeren in allergene 
hydroperoxiden na voldoende luchtblootstelling. In hoofdstuk 7 vonden we dat 9,4% 
en 11,7% van onze plakproef populatie een contactallergie hadden voor hydroperoxiden 
van limonene en hydroperoxiden van linalool. Voor beide hydroperoxiden is de klinische 
relevantie moeilijk vast te stellen omdat hydroperoxiden niet op labels worden 
aangegeven; enkel de aanwezigheid van limonene en/of linalool. De klinische relevantie 
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werd daarom bepaald op de aanwezigheid van limonene of linalool, en het verbeteren 
van het klinische beeld nadat blootstelling werd vermeden. Aangezien  een aanzienlijk 
percentage klinisch relevant was, kunnen we veronderstellen dat de meeste reacties 
niet fout positief waren. De optimale plakproef concentratie voor hydroperoxiden 
van limoneen en hydroperoxiden van linalool is een veel besproken onderwerp. Wij 
beargumenteren voor een hogere concentratie op basis van een grote hoeveelheid 
zwak positieve en twijfelachtige reacties en een lage hoeveelheid irritatieve reacties.
In hoofdstuk 8 presenteren we twee casuistieken en benadrukken we de soms 
complexe reis om het allergeen te achterhalen dat het allergisch contacteczeem 
veroorzaakt. De eerste casus laat zien hoe het gebruik van dunnelaagchromatografie 
(thin layer chromotography (TLC)) geholpen heeft bij het identificeren van het 
verantwoordelijke allergeen bij allergisch contacteczeem op Transcutane Electrische 
Neurostimulatie (TENS) elektroden. In het tweede artikel worden twee medewerkers 
beschreven met werk gerelateerde klachten van dezelfde ethyleen amine producerende 
fabriek. Blootstelling aan vele bijproducten bij de productie van ethyleendiamine 
vereiste plakproeven met een reeks van chemicaliën waarna de diagnose allergisch 
contacteczeem gesteld kon worden. De uitdaging bij het testen met werk gerelateerde 
producten is om te testen met een concentratie die geen irritatieve reactie geeft maar 
wel hoog genoeg is om een contactallergie te kunnen aantonen.
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